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BSTRACT 
 
Genomic DNA is continuously damaged by various endogenous 
and exogenous physicochemical agents. Specifically,             
bis-electrophiles produced endogenously as a result of normal 
cellular metabolism, environmental carcinogens, and chemotherapeutic agents can 
alkylate multiple sites on biomolecules to form a wide array of damaged DNA called 
DNA lesions (DNA adducts). Among these are small DNA monoadducts and exocyclic 
lesions as well as helix distorting DNA-DNA cross-links and bulky DNA-protein cross-
links. The resulting lesions, if not repaired, can elicit adverse biological effects including 
cytotoxicity and mutations due to their ability to interfere with key cellular DNA 
transactions such as DNA repair, replication and transcription. Unless recognized by 
cellular repair mechanisms to restore normal DNA, DNA adducts can be replicated in an 
error-prone manner. Despite the eminent threat of DNA damage by bis-electrophiles to 
cell viability and genomic integrity, the biological consequences of the resulting complex 
DNA adducts are not fully understood. In the present work, we investigated the 
mechanisms of repair and replication of complex DNA lesions formed by reactive 
metabolites of a known human carcinogen, 1,3-butadiene (BD) and antitumor nitrogen 
mustards. 
BD is an industrial chemical and environmental pollutant that has a widespread 
occurrence in the urban environment and high potential for human exposure. BD is 
metabolized by cytochrome P450 enzymes in cells to generate highly reactive epoxides, 
3,4-epoxy-1-butene (EB), 3,4-epoxy-1,2-butanediol (EBD) and 1,2,3,4-diepoxybutane 
(DEB) that can form covalent DNA adducts. In the first part of this thesis, we 
investigated the repair mechanisms responsible for the removal of three potentially 
mutagenic BD-induced 2'-deoxyadenosine lesions recently discovered in our laboratory: 
N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine (N6-HB-dA), N6,N6-(2,3-dihydroxy-
butan-1,4-diyl)-2'-deoxyadenosine (N6,N6-DHB-dA) and 1,N6-(2-hydroxy-3-hydroxy-
  v 
methylpropan-1,3-diyl)-2'-deoxyadenosine (1,N6-HMHP-dA). Synthetic oligodeoxy-
nucleotides containing site- and stereospecific BD-dA adducts were prepared by a post-
oligomerization strategy. In vitro repair assays using human fibrosarcoma nuclear 
extracts revealed that all three BD-dA adducts were repaired by base excision repair 
(BER) pathway. 
Covalent entrapment of cellular proteins on genomic DNA mediated by various 
endogenous and exogenous physicochemical species results in the formation of highly 
heterogeneous and unusually bulky DNA adducts called DNA-protein cross-links 
(DPCs). The structural complexity and diversity of DPCs and the difficulty of generating 
site-specific DNA-protein conjugates represent a special challenge, hindering the 
previous studies of their biological outcomes. In the second part of the thesis, we 
developed novel synthetic methods to generate hydrolytically stable model DPCs and 
examined their effects on DNA replication. 
In our first approach, we employed post-synthetic reductive amination between  
7-(2-oxoethyl)-7-deazaguanine containing DNA and amino side chains of lysine/arginine 
residues on proteins to generate hydrolytically stable DPCs to the C7 position of 
deazaguanine in DNA. The resulting model lesions are structural analogs of the major 
DPCs formed in cells mediated by bis-electrophiles such as chlorooxirane and antitumor 
nitrogen mustards. In our second approach, copper-catalyzed [3+2] Huisgen 
cycloaddition between alkyne containing DNA and polypeptides engineered to contain an 
azide functionality was used to generate DPCs to the C5 of thymidine on DNA.  
The resulting site-specifically modified DNA was subjected to in vitro replication 
bypass assays using recombinant human translesion synthesis (TLS) polymerases, hPol η, 
κ and . These experiments have revealed that large proteins and peptides cross-linked to 
either 7-deaza-G or C5-T completely blocked replication, while a decapeptide cross-link 
was bypassed with varying efficiencies, suggesting that the protein component of DPCs 
undergoes proteolytic processing prior to in vivo replication. Steady-state kinetic studies 
provided evidence for the highly error-prone lesion bypass of peptides cross-linked to 
C5-T and high fidelity bypass of the corresponding 7-deaza-G conjugates. Although hPol 
  vi 
η showed a higher catalytic efficiency in bypassing these lesions, hPol κ was more 
accurate in lesion bypass. Further, HPLC-ESI--HRMS and MS/MS quantitation and 
sequencing of replication products of decapeptide cross-linked to C5-T revealed a large 
number of deletion and substitution mutations. Taken together, our data suggest that 
efficiency and fidelity of replication bypass of DNA polypeptide cross-links are 
dependent on the lesion size, the cross-linking site within DNA, and the identity of the 
polymerase. 
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LITERATURE REVIEW 
1 LITERATURE REVIEW 
1.1 DNA DAMAGE AND HUMAN DISEASES 
1.1.1 DNA Modification and Its Consequences in Cells 
The integrity and stability of genomic DNA are essential for life since DNA is the 
repository of hereditary information in cells.1-3 DNA is not chemically inert, but 
possesses multiple reactive sites.1-3 Genomic DNA is continuously modified by various 
endogenous and exogenous sources to form structurally altered nucleobases (DNA 
adducts).1,4,5 In addition to damage caused by various chemical and physical agents,1,3,6,7 
DNA replication, the process by which genetic code is inherited to new generations of 
cells, can itself introduce errors compromising the cell viability.1,3,7 DNA adducts can be 
recognized by cellular repair mechanisms to restore normal DNA.8,9 Alternatively, they 
can be replicated via cellular replication machinery or DNA damage tolerance 
pathways.8,9 Some DNA adducts can escape cellular repair mechanisms and persist in 
cells, and replication of such modified DNA can be error-prone, ultimately leading to 
mutations.1,8,9 
1.1.2 Causative Agents and Types of DNA Damage 
There are many causative agents that induce DNA adducts including endogenous 
chemicals produced inside the body by metabolic pathways, exogenous chemicals from 
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environmental and food sources, ionizing radiation and UV light (Figure 1-1).8,10-14 DNA 
damaging agents can be broadly categorized into three classes: spontaneous chemical 
reactions occurring in cells, endogenous species generated from cellular metabolism and 
exogenous physicochemical agents.8,14 
Spontaneous hydrolysis and deamination lead to DNA damage in cells.15-17   
Acid-catalyzed hydrolysis of N-glycosidic bond between the nucleobase and deoxyribose 
sugar generates apurinic/apyrimidinic (AP) or abasic sites.15 AP sites are prone to          
-elimination, resulting in single-strand DNA breaks (SSBs).16 Deamination reactions of 
exocyclic amine bearing nucleosides can generate abnormal DNA bases.15,17 For 
example, cytosine gets deaminated to form uracil.15 Deamination of adenine and guanine 
forms hypoxanthine and xanthine, although at lower rates compared to cytosine 
deamination.15 
DNA modification also occurs through endogenous reactive chemical species 
naturally formed in cells such as reactive oxygen species (ROS),18-20 reactive nitrogen 
species (RNS)21 and electrophilic species15 generated during cellular metabolism. ROS 
like O2-, H2O2 and OH are known to generate a large number of oxidative lesions, single- 
and double-strand breaks (DSBs) and DNA-protein cross-links (DPCs).18,19 Nitric oxide 
(NO) and its byproducts can also induce oxidative DNA damage.21 Nitrosated amines and 
radicals generated by lipid peroxidation mediate alkylation of heteroatoms in DNA 
bases.15 
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Figure 1-1 DNA damage and repair. Types of DNA damage caused by common DNA 
damaging agents and mechanisms responsible for the repair of damaged DNA. 
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Genomic DNA undergoes constant attack from exogenous damaging agents. 
Ultraviolet (UV) light produce cyclobutane pyrimidine dimers (CPD) and 6-4 pyrimidone 
photoproducts ([6-4]PP).22 Ionizing radiation like X-rays and -rays, directly or indirectly 
via ROS generation, can cause multiple types of damage including single-strand breaks 
(SSBs), double-strand breaks (DSBs), base modifications, DNA-DNA cross-links and 
DNA-protein cross-links (DPCs).4  
Hundreds of chemical agents are also known to form DNA adducts. These include 
industrial and household chemicals, environmental pollutants, agrochemicals, chemicals 
from dietary sources, and chemotherapeutics (Chart 1-1 and Table 1-1).23,24 These 
chemical agents can alkylate multiple sites on DNA forming a variety of DNA 
monoadducts, exocyclic lesions, DNA-DNA cross-links, DSBs and DPCs. Highly toxic 
DNA adducts, such as DNA-DNA cross-links and DPCs, formed by some exogenous 
chemicals trigger apoptosis or programmed cell death.25,26 This is the mechanism of 
action of most anticancer drugs including cisplatin,27 mitomycin C,28 1-haloalkyl-          
1-nitrosoureas and nitrogen mustards.29 Therefore, better understanding of mechanisms 
of DNA damage can be beneficial in preventing adverse effects of damaged DNA as well 
as in the development of novel therapeutics against lethal disease conditions. 
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Chart 1-1 Structures of some known chemical carcinogens. 
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Table 1-1 Known chemical carcinogens and their carcinogenic properties.23,24 
Carcinogen class 
Carcinogenicity 
Examples 
Cocarcinogen Mutagen Promoter 
Aldehydes    formaldehyde, acetaldehyde, acrolein 
Aromatic amines    2-toluidine, 2-naphthylamine, 4-aminobiphenyl 
N-heterocyclic amines    2-amino-9H-pyrido[2,3-b]indole, 2-amino-3-methylimidazo[4,5-b]quinoline 
Compounds of mineral origin    Asbestos 
Polycyclic aromatic hydrocarbons 
(PAHs) and derivatives    
benzo[a]pyrene, benzofluoranthenes, dibenzopyrenes, 
dibenz[a,h]anthracene, 
5-methylchrysene, indeno[1,2,3-cd]pyrene 
Diphenylmethanes and bisphenols    bisphenol A 
Miscellaneous organic compounds    1,3-butadiene, isoprene, furan, ethylene oxide 
Phthalates    di(2-ethylhexyl) phthalate, butyl benzyl phthalate 
Dioxins    1,2-dioxin, 1,4-dioxin 
Hormonal residues    prolactin, estrogens, androgens 
Metals and metalloids    nickel, chromium, cadmium, lead, arsenic 
N-nitroso compounds    N-nitrosodiethylamine, N-nitrosopyrrolidine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
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Table 1-1 (continued from page 6) 
Carcinogen class 
Carcinogenicity 
Examples 
Cocarcinogen Mutagen Promoter 
Polychorobiphenyls (PCBs)    2,2',4,4',5,5'-hexachlorobiphenyl, 2,4,4'-trichlorobiphenyl, 2,4'-dichlorobiphenyl 
Pesticides    organochlorines, carbamates, pyrethroids 
Aza-arenes    dibenzacridines, quinoline, 7H-dibenzo[c,g]carbazole 
Anticancer drugs    
anti-estrogens such as tamoxifen, toremifen and 
fulvestrant, alkylating agents like nitrogen mustards, 
nitrosoureas, alkyl sulfonates and platinum drugs 
Pharmaceuticals    oral contraceptives, hormone replacement therapy 
Air fine particles    air carbonaceous particles 
Benzene and related compounds    benzene 
Organohalides    vinyl chloride, 1,2-dichloroethane 
Inorganic compounds    hydrazine 
Fluorene compounds    2-acetylaminofluorene 
Nitriles    acrylonitrile 
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1.1.3 Role of DNA Damage in Human Disease 
DNA adducts are implicated in various disease conditions including cancer,30-33 
cardiovascular diseases34-36 and age-related neurodegeneration.35-39 Mutations in genes 
associated with cell cycle checkpoints and chromosomal instability can lead to cancer. 
For example, mutations in oncogenes, like RAS and MYC, and in tumor suppressor genes, 
such as TP53 and CDKN2A, can disturb the balance of cell proliferation and apoptosis 
forming malignant cells.25,26 Chronic inflammation increases the risk of developing many 
human cancers.40 The inflammatory response generates a complex spectrum of reactive 
species that can damage biomolecules including DNA.41 
Genome maintenance is implicated in anti-aging.14 It has been found that aging is 
accelerated in patients with segmental progeroid syndrome, whose genome maintenance 
is compromised.14 Defects in several genes related to nucleotide excision repair (NER) 
enzymes (see section 1.3.1) cause rare hereditary diseases such as xeroderma 
pigmentosum, Cockayne’s syndrome and trichothiodystrophy. Xeroderma pigmentosum 
(XP) patients, who have defects in genes XPA–XPG, show sun-induced pigmentation 
abnormalities, increased risk of skin cancer and internal cancers, and accelerated 
neurodegeneration.14 Cockayne’s syndrome (CS) results from the mutated CSA and CSB 
genes, while defects in XPB and XPD genes cause trichothiodystrophy.14 These patients 
show, among other conditions, premature aging, growth and developmental arrest, and 
neurodysfunction.14 These effects are attributed to increased mutations caused by the 
inability to repair DNA adducts.14 Ataxia talengiectasia (AT) is characterized by 
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increased risk of leukemia and lymphoma, and neurologic abnormalities. AT is caused by 
a mutated ATM gene that code for a protein kinase involved in DSB repair.42 
Amyotrophic lateral sclerosis (ALS) is related to defects in APE gene, while Ataxia is 
related to defective APTX and TDP1 genes.37 Proteins transcribed from these genes are 
involved in base excision repair (BER) and SSB repair (see section 1.3.1).37  
Significant damage to DNA was observed in cell culture models of heart disease 
and samples obtained from patients with cardiovascular disease.43 Further, recent 
experimental and clinical studies suggest that oxidative DNA damage is enhanced in 
cardiovascular disease.44 Taken together, these experimental and clinical evidences 
strongly suggest that DNA damage play a direct or indirect role in many human diseases. 
Although the formation of DNA adducts by endogenous sources and genetic factors are 
beyond our control, such adverse effects induced by exogenous agents are preventable to 
a certain extent. 
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1.2 1,3-BUTADIENE-MEDIATED MUTAGENESIS AND 
CARCINOGENESIS 
1.2.1 1,3-Butadiene: A Potent Environmental Carcinogen 
1,3-Butadiene (BD) is an important industrial chemical widely used as a raw 
material in synthetic rubber and plastic industry,45 and manufacture of certain 
fungicides.46 It is a colorless, highly volatile gas, which is a byproduct of ethylene 
manufacturing process.45,47 Global production of BD was estimated to be ~9 million 
metric tons.45,47 Occupational BD exposure levels, in 8-hour time-weighted average 
concentration units, can be as high as 10 ppm, while average daily concentrations in 
ambient air near petrochemical facilities have been reported to exceed 100 ppb.46 BD is 
also an environmental pollutant found in automobile exhaust47,48 with average 
concentration in urban air estimated as 1–10 ppb.47 Further, high quantities of BD are 
present in cigarette smoke: 20–75 g/cigarette and 205–360 g/cigarette in mainstream 
and sidestream smoke, respectively.25,49,50 In retrospect, these amounts are 102–106-fold 
higher than those of more extensively studied polycyclic aromatic hydrocarbons    
(PAHs, 0.6–70 ng) and nitrosamines (0.1–80 ng).25 This widespread occurrence of BD in 
the environment in turn contributes to a high potential for human exposure. 
The adverse biological effects of BD have been well documented. Chronic 
exposure to BD has been implicated in various health conditions including respiratory 
disorders, cardiovascular disease, and various types of cancers in both humans51-60 and 
laboratory animals.61,62 According to toxicological risk analysis, BD has the highest 
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cancer risk index among all tobacco constituents.63 Further, based on epidemiological and 
toxicological studies in humans and inhalation studies in laboratory animals, BD has been 
classified as a human carcinogen.46,64,65 Nevertheless, the exact molecular mechanisms of 
BD-induced mutagenesis and carcinogenesis are yet to be fully understood. 
1.2.2 Metabolic Activation of 1,3-Butadiene and DNA Adduction 
BD required metabolic activation inside the body to cause any undesirable 
biological effects. Cytochrome P450 monooxygenases, CYP2E1 and CYP2A6, catalyze 
the epoxidation of a double bond of BD to form 3,4-epoxy-1-butene (EB),66,67 which is 
either hydrolyzed by epoxide hydrolase (EH) to 1-buten-3,4-diol (BED)68 or further 
oxidized by CYP2E1 and CYP3A4 to 1,2,3,4-diepoxybutane (DEB) (Scheme 1-1).67,69 
BED can be oxidized to 3,4-epoxybutan-1,2-diol (EBD) by CYP2E1, while DEB can be 
hydrolyzed to EBD.70 These epoxide metabolites can be detoxified by glutathione 
conjugation followed by mercapturic acid pathway, and excreted from the body as the 
corresponding N-acetylcysteine conjugates.71,72 If not deactivated, they can alkylate 
nucleophilic sites on cellular biomolecules to form covalent adducts.73-77 For example, 
bis-alkylation of DNA by DEB can produce exocyclic nucleobase adducts,78,79         
DNA-DNA cross-links80-84 and DNA-protein cross-links.85,86 These DNA lesions can 
have varying toxic and mutagenic effects depending on their size, shape, hydrogen-
bonding ability, and the extent of helix distortion. The generation of multiple reactive 
species upon BD metabolism, ability of those electrophiles to react at numerous sites 
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within DNA and formation of various stereo- and regioisomeric DNA lesions contribute 
to the BD-induced biological effects.  
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Scheme 1-1 Metabolic activation of 1,3-butadiene and formation of DNA adducts.* 
                                                 
*	 BD: 1,3-butadiene, BED: 1-buten-3,4-diol, CYP2E1, CYP2A6, CYP3A4: cytochrome P450 enzymes,                  
DEB: 1,2,3,4-diepoxybutane, EB: 3,4-epoxy-1-butene, EBD: 3,4-epoxybutan-1,2-diol, EH: epoxide hydrolase,         
HB: 2-hydroxy-3-buten-1-yl, HEB: 2-hydroxy-3,4-epoxybutan-1-yl, THB: 2,3,4-trihydroxybutan-1-yl.	
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1.2.3 Adverse Biological Effects of 1,3-Butadiene 
Acute and chronic exposure to BD can induce various adverse effects such as 
toxicity, mutagenicity, and carcinogenicity. Epidemiological studies suggest that long-
term occupational exposure to BD causes chromosomal abnormalities and is associated 
with an increased incidence of various types of malignancies including respiratory, 
gastrointestinal and lymphato-hematopoietic cancers, and cardiovascular conditions such 
as rheumatic and arteriosclerotic heart diseases.51-60,87 Inhalation exposure of laboratory 
animals to BD induces tumors at various tissues such as heart, lung, brain, liver, ovary, 
testis and pancreas, in addition to adverse effects on cardiovascular and respiratory 
systems.60-62,87-89 
BD shows tissue specific differences in mutation spectra. For example, when 
B6C3F1 laci transgenic mice were exposed to BD by inhalation, both bone marrow and 
spleen showed ATGC transitions and ATTA transversions, while GCAT 
transitions were only observed in the spleen.90 In addition, EB induced GCAT,       
ATTA and deletion mutations in the lung of mice.90 It is also known that DEB induces 
ATTA transversions and partial deletions at hprt in human TK6 lymphoblasts     
(Table 1-2).90 The less mutagenic EB induces substitutions at G:C and A:T base pairs, 
while EBD causes GT mutations.90,91 AT transversions and frameshift mutations 
were also observed in workers occupationally exposed to BD.92,93 
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Table 1-2 Hprt mutation spectra of 3,4-epoxy-1-butene (EB) and 1,2,3,4-diepoxybutane 
(DEB) in human TK6 lymphoblast cells after 24 h exposure.90 
Mutational class No. (%) of mutations  
Control 400 M EB 4 M DEB 
GC  AT 10 (23) 15 (30)† 3 (6) 
GC  CG 1 (2) 2 (4) 2 (4) 
GC  TA 3 (7) 2 (4) 2 (4) 
AT  GC 3 (7) 6 (12) 1 (2) 
AT  CG 3 (7) 2 (4) 1 (2) 
AT  TA 2 (5) 12 (24)† 9 (18)† 
Partial deletions 1 (2) 0 (<2) 7 (14)† 
Other alterations 22 (41) 12 (24) 40 (59) 
 
 
 
 
 
 
 
                                                 
†	significant increase compared to control.	
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According to experimental data on genotoxicity and mutagenicity of BD 
metabolites, DEB is 50- and 100-fold more genotoxic and mutagenic than EB and EBD, 
respectively.94-96 It induces sister chromatid exchanges and chromosomal 
aberrations.90,97,98 All three stereoisomers of DEB (S,S, R,R and meso) are formed           
in vivo,69 and they have varying levels of toxicities and mutagenicity (Chart 1-2). 
Among these, (S,S)-DEB is the most genotoxic followed by (R,R)- and meso-DEB.99-101 
This variability in toxicity is attributed to different DNA adducts formed. (S,S)-isomer 
produces the largest number of 1,3-interstrand DNA cross-links, which are highly toxic 
due to their ability to block DNA repair, replication and transcription, whereas meso-
DEB forms both 1,3-interstrand and 1,2-intrastrand cross-links (Chart 1-2).83,102 
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Chart 1-2 Stereoisomers of 1,2,3,4-diepoxybutane and their relative toxicities.83,102 
Stereoisomer 
Percentage of DNA-DNA cross-links 
Relative toxicity 
1,3-interstrand 1,2-interstrand 1,2-intrastrand 
O
O
 96 0 4 most toxic 
S,S-DEB 
O
O
 68 13 19 moderate 
R,R-DEB 
O
O
 49 0 51 least toxic 
meso-DEB 
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1.2.4 DNA Lesions of 1,3-Butadiene 
Upon activation in vivo, BD metabolites can form a range of DNA adducts, 
protein adducts103-107 and urinary metabolites.71,72,108 These can be used as biomarkers of 
exposure to BD. More importantly, covalent DNA adducts can be extremely useful in 
understanding the structures and mechanisms responsible for the adverse biological 
effects of BD. 
DNA Monoadducts 
A significant number of DNA lesions caused by epoxide metabolites of BD has 
been identified.109 Most of the observed adducts involve nucleophilic attack by BD 
metabolites at the N7 position of guanine, N3 of thymidine, and the N1, N3 and N6 of 
adenine (Chart 1-3).73,74,110 Amongst the DNA monoadducts observed are N3 and       
N7-(2,3,4-trihydroxybutan-1-yl)-2'-deoxyguanine (THB-dG), N6-(2,3,4-trihydroxybutan-
1-yl)-2'-deoxyadenine (N6-THB-dA), N7-(2-hydroxy-3-buten-1-yl)-2'-deoxyguanine  
(N7-HB-dG), N3-(2-hydroxy-3-buten-1-yl)-2'-deoxyuridine (N3-HB-dU), N6-(2-hydroxy- 
-3-buten-1-yl)-2'-deoxyadenine (N6-HB-dA) and their regio- and stereo-isomers     
(Chart 1-3).73-77 
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Chart 1-3 Structures of DNA monoadducts formed by epoxide metabolites of             
1,3-butadiene. 
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DNA Cross-Links of 1,2,3,4-Diepoxybutane 
The higher genotoxicity of DEB compared to other BD metabolites is attributed to 
its ability to form bifunctional lesions. Both interstrand and intrastrand DNA-DNA  
cross-links contribute heavily to the mutational spectra of the BD diepoxide. Although 
1,4-bis-(guan-7-yl)butan-2,3-diol (bis-N7G-BD) is the predominant DNA-DNA       
cross-link found in vivo and in vitro,80,81 many regioisomeric G-A cross-links are also 
observed (Chart 1-4). 1-(Aden-1-yl)-4-(guan-7-yl)butan-2,3-diol (N1A-N7G-BD) and its 
deaminated product, 1-(hypoxanth-1-yl)-4-(guan-7-yl)butan-2,3-diol (N1HX-N7G-BD), 
1-(aden-3-yl)-4-(guan-7-yl)butan-2,3-diol (N3A-N7G-BD), 1-(aden-N6-yl)-4-(guan-7-yl) 
butan-2,3-diol (N6A-N7G-BD) and 1-(aden-7-yl)-4-(guan-7-yl)butan-2,3-diol (N7A-N7G-
BD) are some examples (Chart 1-4).82-84 Further, mass spectrometry-based proteomics 
have revealed that DEB can form DNA-protein cross-links with numerous proteins 
having various cellular functions including DNA repair, replication, transcription and 
translation.85 These super bulky DNA-protein adducts may have significant toxic effects 
because of their ability to block DNA replication, transcription and repair (see        
section 1.5.5). 
 
 
 
 
 21 
Chart 1-4 Structures of DNA-DNA cross-links induced by 1,2,3,4-diepoxybutane. 
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DNA Exocycles 
As discussed above, DEB has the ability to alkylate two nucleophilic sites within 
the same nucleobase to form exocyclic lesions (Chart 1-5). DEB forms 1,N2 exocyclic 
lesions with guanine, (7-hydroxy-3-(2-deoxy--D-erythro-pentofuranosyl)-6-hydroxy-
methyl-5,6,7,8-tetrahydropyrimido[1,2-a]purin-10(10H)-one (P4-1) and 7,8-dihydroxy-3-
(2-deoxy--D-erythro-pentofuranosyl)-3,5,6,7,8,9-hexahydro-1,3-diazepino[1,2-a]purin-
11(11H)one (P6).79 However, these guanine exocycles have not been observed in vivo. If 
formed in cells, they can potentially be mutagenic due to their hydrolytic stability and 
disruption of normal Watson-Crick base pairing. In addition, Tretyakova and coworkers 
have observed that adenine forms 1,N6-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-
deoxyadenosine (1,N6--HMHP-dA), 1,N6-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl) 
-2'-deoxyadenosine (1,N6--HMHP-dA), and N6,N6-(2,3-dihydroxybutan-1,4-diyl)-2'-
deoxyadenosine (N6,N6-DHB-dA) (Chart 1-5).78 Both 1,N6-HMHP-dA regioisomers 
have been detected in tissues of rodents exposed to BD,111 and in vitro replication studies 
have provided evidence for the potential mutagenicity of 1,N6-HMHP-dA.112 
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Chart 1-5 Structures of 1,2,3,4-diepoxybutane-induced exocyclic DNA adducts. 
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1.3 REPAIR OF 1,3-BUTADIENE-INDUCED DNA ADDUCTS 
1.3.1 Cellular DNA Repair Mechanisms 
All living cells have hundreds of genes dedicated to DNA repair. These cellular 
repair mechanisms are in constant watch to restore normal DNA and to mitigate the 
effects of DNA damage.1 Multiple repair pathways have evolved to recognize damaged 
DNA in eukaryotic systems (Schemes 1-2 and 1-3), including direct repair,113,114 base 
excision repair (BER),13,113-115 nucleotide excision repair (NER),13,113-118 mismatch repair 
(MMR),7,113,114 homologous recombination (HR),13,114,119 and non-homologous end-
joining (NHEJ).13,114,117,120 One or more factors including size and shape of the DNA 
lesion, helix distorting nature and their thermodynamic instability can play a role to 
which repair pathways are involved in identifying the damaged DNA.1,121 
Direct Repair 
Direct repair is the reversal of an alkylated nucleobase to a normal base without 
cleaving the phosphate backbone (Scheme 1-2).113,114 For example, O6-alkylguanine 
DNA alkyltransferase (AGT, also known as O6-methylguanine DNA methyltransferase, 
MGMT) transfers the alkyl group from the O6-alkylguanine onto Cys145 in its active 
site.113,114 E. coli AlkB and its homologues can repair alkylated bases like N1-Me-dA and 
N3-Me-dC in an oxygen, ketoglutarate and Fe(II)-dependent oxidative mechanism.113,114 
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Scheme 1-2 Cellular repair mechanisms: direct repair, base excision repair and nucleotide excision repair. 
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Base Excision Repair 
BER is the principal mechanism responsible for the removal of alkylated or 
incorrect DNA bases and oxidative lesions, which can be recognized by specific enzymes 
called DNA glycosylases (Scheme 1-2).6,114,115 Type I/monofunctional glycosylases only 
possess the glycosylase activity, while type II/bifunctional glycosylases have both  
glycosylase and 3'-endonuclease activity.6 Uracil DNA glycosylases (UDGs), methyl 
purine glycosylase (MPG) and adenine-specific mismatch DNA glycosylase (MYH) are 
human type I/monofunctional enzymes, while oxoguanine glycosylase (OGG1), NTH1, 
NEIL1 and NEIL2 are examples of human type II glycosylases.6 Single-strand breaks 
(SSBs) and apurinic/apyrimidinic (AP) sites resulting from spontaneous hydrolysis are 
also processed by BER.8,117 In the case of base modifications, DNA glycosylases 
hydrolyze the N-glycosidic bond via a base-flipping mechanism to excise the damaged 
base.6,8,13,113-115 The resulting AP site is cleaved by AP endonuclease 1 (APE1) in the case 
of type I glycosylases or by 3'-endonuclease activity of type II enzymes to create a single-
strand break.6,8,13,113-115 In the case of SSBs, poly ADP-ribose polymerase 1 (PARP1) 
accumulation at the strand break promotes the binding of X-ray repair cross-
complementing protein 1 (XRCC1).8,117 XRCC1 recruits either of the repair factors, 
tyrosyl DNA phosphodiesterase 1 (TDP1) or Aprataxin (APTX), to modify the DNA 
ends for ligation.117 In short-patch BER, DNA polymerase  (Pol β) inserts a nucleotide 
to fill the gap and cleaves the 5'-deoxyribose phosphate.6,8,13,114,115 DNA ligase 3 (LIG3) 
then seals the remaining nick.6,8,13,114,115 Long-patch BER recruits Pol / and 
 27 
proliferating cell nuclear antigen (PCNA) to carry out repair synthesis by adding 2–10 
nucleotides, flap endonuclease 1 (FEN1) to remove the displaced DNA flap, and DNA 
ligase 1 (LIG1) to seal the nick.6,8,13,114,115  
Nucleotide Excision Repair 
A wide range of bulky, helix-distorting lesions such as UV-induced photolesions 
and intrastrand cross-links are removed by NER.114-116 NER consists of two sub-pathways 
that differ in the damage recognition step: global genomic repair (GG-NER) and 
transcription-coupled repair (TC-NER) (Scheme 1-2). GG-NER repairs helix-distorting 
DNA lesions located throughout the genome, while TC-NER eliminates lesions located 
on the coding strand of actively transcribed genes.114-117 In GG-NER, xeroderma 
pigmentosum complementation group C and Rad23 homolog B complex (XPC-HR23B) 
or XPE binds to the damage site.8,114-118 TC-NER is triggered, when RNA polymerase II 
(RNAPII) is stalled upon encountering the DNA damage. Cockayne syndrome A (CSA) 
and B (CSB) displaces the RNAPII to initiate TC-NER.8,114-117 Subsequent stages of both 
pathways are similar. Transcription factor IIH (TFIIH) is recruited at the damage  
site,8,114-118 while XPA confirms the presence of a damage by probing for abnormal 
backbone structure.8,116,118 DNA dependent ATPase, XPB and XPD helicase of TFIIH 
complex locally unwind DNA,13,114-118 and ssDNA binding replication protein A (RPA) 
binds to the undamaged strand, stabilizing the open intermediate.8,116,118 XPG cleaves 3' 
to the damage site, while ERCC1-XPF performs the 5' incision to remove a ~24–32 
nucleotide stretch containing the damage.8,13,113-118 Repair synthesis is then carried out by 
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Pol / with PCNA using the undamaged strand as a template, and LIG seals the 
nick.13,113-118 
Homologous Recombination 
HR is a high fidelity, template dependent repair mechanism involved in repairing 
DNA double-strand breaks (DSBs), DNA gaps, and interstrand DNA-DNA cross-links in 
proliferating cells (Scheme 1-3).13,114,119 5'3' Exonuclease activity of Mre11-Rad50-
Nbs1 (MRN) complex creates 3'-overhangs at the break site.8,13,114,119 RPA binds the 
single-stranded overhangs to remove disruptive secondary structures, and along with 
Rad52 facilitate the assembly of Rad51 nucleoprotein filament that includes mediator 
proteins such as Rad54, breast cancer associated 2 (BRCA2) and Rad51 
paralogs.8,13,114,119 Rad54 ATPase-mediated homology search follows the strand invasion 
by Rad51 recombinase.8,13,114,119 In this process, homologous strand from the sister 
chromatid is inserted into the damaged chromatid, which acts as an error-free template 
for DNA synthesis.8,13,114,119 Pol η replicates from the 3'-end of the invading strand, and 
subsequent ligation by LIG1 forms a four-way junction called a Holliday junction. The 
Holliday junction is resolved into crossover or non-crossover products by resolvases such 
as BLM DNA helicase and type 1 topoisomerase TOPOIII  complex.119 
Non-Homologous End-Joining 
NHEJ directly ligates two ends of DSBs without any sequence homology 
information (Scheme 1-3), and sometimes results in nucleotide loss, affecting genome 
integrity.8,114,120 DNA termini recognition and binding of Ku70/Ku80 heterodimer attracts 
 29 
the catalytic subunit of DNA-dependent protein kinase (DNA-PK) to Ku encircled DNA 
duplex.8,13,114,117,120 DNA-PK protects degradation and premature ligation of the DNA 
termini, and recruits either polymerases for gap filling or Artemis for resection of single-
stranded overhangs.120 Blunt ends are then ligated by LIG4/XRCC4.8,13,114,117,120 
Mismatch Repair 
MMR pathway is mainly responsible for eliminating misinsertions that have 
escaped proofreading mechanism during replication and fixes insertion/deletion loops 
resulting from polymerase slippage events (Scheme 1-3).7,114 It also repairs base 
mismatches caused by deamination, oxidation, and alkylation.114 Mutator S (MutS) 
complex recognizes the mismatch and recruits the MutL heterodimer to the damaged 
site.7,8,113,114 Diffusion of MutS-MutL leads to nicking of the unmethylated daughter 
strand either upstream or downstream of the mismatch followed by the removal of a 
fragment of DNA by exonuclease 1 (EXO1).7,8,113,114 Pol / with PCNA fills the gap by 
repair synthesis and subsequent nick sealing by LIG1.7,8,113,114 
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Scheme 1-3 Cellular repair mechanisms: homologous recombination, non-homologous end-joining and mismatch repair. 
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1.3.2 In Vivo and In Vitro Persistence and Repair Studies 
Information on repair and persistence of BD-DNA adducts are crucial for the 
assessment of lesions contributing to the adverse effects of BD in vivo. Wickliffe et al. 
investigated the role of GG-NER on repairing BD-induced DNA adducts.122,123 Xpc-null 
mice exposed to BD or its epoxide metabolite, EB showed ~2–3-fold higher Hprt 
mutation frequencies as compared to wild-type mice.122,123 In another study, human 
bronchial epithelial cells treated with an organic extract of BD soot revealed 
overexpression of  isoform of human 8-oxoguanine DNA glycosylase (-hOGG1) and 
human apurinic/apyrimidinic endonuclease (hAPE-1).124 These studies provide initial 
evidence for the repair of BD-DNA adducts by NER and BER pathways, although they 
suffer from the lack of information about the structures of actual DNA adducts. 
A limited number of studies is available on repair of specific BD-induced DNA 
adducts. Goggin et al. quantified 1,N6-HMHP-dA, bis-N7G-BD and N7G-N1A-BD in 
wild-type, Mpg-deficient and Xpa-deficient mice exposed to BD using isotope dilution 
liquid chromatography-tandem mass spectrometry.111 The half-life (t½) of bis-N7G-BD 
was 2.3–5.7 days, while t½ of N7G-N1A-BD and 1,N6-HMHP-dA were estimated to be 
36–42 days.111 No differences in number of exocyclic adducts or either of the cross-links 
were observed between the wild-type and Mpg-null or Xpa-null mice.111 Methyl purine 
glycosylase (MPG), also known as alkyl-N-purine DNA glycosylase (APNG) or 
alkyladenine DNA glycosylase (AAG), is a BER enzyme (see section 1.3.1) known to 
recognize alkylated purines including 1,N6-etheno-dA, which is structurally analogous to 
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1,N6-HMHP-dA.125,126 As discussed in section 1.3.1, XPA is a protein involved in lesion 
recognition/verification in NER pathway.116,118,127 In vitro repair assays using              
site-specifically adducted 50-mer DNA oligomers containing 1,4-bis-(2'-deoxyguanosin-
N2-yl)-2,3-butanediol (bis-N2G-BD) have revealed that this intrastrand cross-link is not 
recognized by E. coli uvrABC complex.128 These results provide evidence against the 
involvement of MPG-mediated BER or NER mechanisms for repair of these BD-DNA 
adducts. Nonetheless, the potential roles of other BER enzymes in BD adduct repair have 
not been investigated, and NER studies have not been conducted for the majority of the 
adducts. 
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1.4 REPLICATION OF 1,3-BUTADIENE-MEDIATED DNA 
ADDUCTS 
1.4.1 DNA Adducts and Translesion Synthesis 
Structural modifications of DNA nucleobases can alter their interactions with 
other biomolecules involved in cellular homeostasis. In some cases, adducted DNA can 
evade cellular repair mechanisms leading to adduct accumulation in tissues.129 Because of 
their altered size and shape as compared to native bases, these adducts may not be 
accommodated in the compact active site of the high fidelity human replicative 
polymerases like hPol δ and ε.130,131 So upon encountering the adduct, the replication fork 
stalls.131,132 During such instances, the replication machinery recruits a specialized group 
of low fidelity polymerases called translesion synthesis (TLS) polymerases to the blocked 
replication fork (Scheme 1-4).130,133,134 Ubiquitination of sliding clamp (PCNA in 
humans) increases the affinity of TLS polymerases for the replication fork, and the 
replicative polymerase is switched with a TLS polymerase.130,131,135 Nucleotide insertion 
opposite the adduct is followed by the extension past the lesion by the same or a different 
TLS polymerase (Scheme 1-4).131 The identity of TLS polymerase employed is 
dependent on the specific lesion, while the fidelity is determined by the nature of the 
lesion, as well as the polymerase employed.131 TLS polymerases have low processivity, 
leading to their dissociation from the replication fork, and the replicative polymerase 
takes over to complete DNA synthesis (Scheme 1-4).130,131,136 
 
 34 
Scheme 1-4 Polymerase switching model for translesion synthesis. 
 
 
 
 
 
 
 35 
Human Y family polymerases hPol η, κ, ι and Rev1, human B family polymerase 
ξ, and human A family polymerase ν are the main TLS polymerases known to be 
involved in replication bypass of a range of DNA adducts.131,136-142 E. coli Pol IV and   
Pol V, and S. solfataricus DPO4 are amongst the most-studied prokaryotic TLS 
polymerases, while S. cerevisiae Pol η, Rev1 and ξ belong to eukaryotic TLS 
polymerases.130,131,136,143,144 Processivity, fidelity, and efficiency of lesion bypass 
polymerases are extremely low. For example, the error rate for TLS polymerases is one 
misinsertion for every 101–104 bases, while that of replicative polymerases is one 
incorrect base for every 106–108 bases.139,145 These features are directly related to their 
structures. TLS polymerases have significantly smaller thumb and finger domains as 
compared to replicative polymerases, resulting in a more open and solvent accessible 
active site.131,142,144,146 These polymerases also have a unique wrist domain called as little 
finger (LF) or polymerase-associated domain (PAD) that extends from the finger 
domain.129,131,139,144,146-148 This large and flexible active site enables for the 
accommodation of bulky DNA adducts, while PAD domain makes additional contacts 
with DNA and is implicated in lesion specificity.129,131,139,144,146-148 The interactions 
between the DNA major groove and PAD, and the orientation of DNA and PAD relative 
to the active site can alter processivity and fidelity of a TLS polymerase.139,146,148 
The accuracy of nucleotide incorporation by replicative polymerases is further 
enhanced by an induced fit mode of replication and proof reading activity. Upon regular 
Watson-Crick base pairing of the incoming nucleotide and the template base, a 
conformational change in the finger domain of the replicative polymerases allows the 
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new base pair to be accommodated in a closed active site.144,146 However, induced fit 
conformation is not achieved when a DNA adduct is encountered, thus stalling the 
replication fork.144,146 In contrast, TLS polymerases have an open and preformed active 
site and as a result tolerate the non-Watson-Crick base pairing along with distorted 
primer-template complexes.143,144,146 In addition, bypass polymerases lack the intrinsic    
3'5' proof reading activity,129,130,139,143,149,150 reducing the replication fidelity by 2–3 
orders of magnitude.136,139 
1.4.2 In Vivo Replication and Mutagenesis Studies of 1,3-Butadiene DNA 
Adducts 
As discussed in sections 1.2.3 and 1.2.4, BD forms a vast array of DNA adducts 
and induces a range of mutations, including AT transversions and frameshift 
mutations. However, the structures and mechanisms responsible for these mutagenic 
effects are not fully understood. N7-G adducts are the most abundant form of BD-DNA 
lesions observed in vivo.80,111,151,152 However, due to the rapid hydrolysis of N7-G lesions 
and synthetic challenges in preparing hydrolytically stable N7-G adducted DNA, 
mutagenicity of these lesions has not been investigated. On the other hand, a limited 
number of studies has been reported on replication and mutagenicity of less abundant but 
hydrolytically stable BD-DNA adducts (Table 1-3).70,91,128,153,154 
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Table 1-3 Summary of in vivo mutagenicity of 1,3-butadiene-induced DNA 
lesions.70,91,128,153,154 
DNA adduct (X) Mutagenicity Total mutation yield‡ 
Mutations (%) 
XA XC XG XT 
R-N6-HB-dA II non-mutagenic N/A - - - - 
S-N6-HB-dA II non-mutagenic N/A - - - - 
R,R-N6-THB-dA very weak 0.1% - 0 100 0 
S,S-N6-THB-dA very weak 0.2% - 100 0 0 
R-N2-HB-dG strongly blocking 0.01% 50 50 - 0 
S-N2-HB-dG strongly blocking 0.2% 32 23 - 45 
R,R-N2-THB-dG strongly blocking 0.03% 30 30 - 40 
S,S-N2-THB-dG strongly blocking 0.07% 35 35 - 30 
N3-HB-dU extremely high 96.9% 34 - 11 55 
R-N1-HB-dI high 59% - 12 82 6 
S-N1-HB-dI extremely high 94.5% - 10 84 6 
R,R-bis-N6A-BD high 54% - 17 74 9 
S,S-bis-N6A-BD mutagenic 19.4% - 4 67 29 
R,R-bis-N2G-BD§ strongly blocking 0.1% 27 7 - 66 
S,S-bis-N2G-BD§ strongly blocking 0.6% 44 28 - 28 
 
 
 
                                                 
‡ total mutation yield = no. of mutagenic colonies/total no. of colonies×100.	
§ deletion mutations were observed.	
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In vivo replication studies of N6-adenine and N2-guanine adducts derived from EB 
and DEB have been conducted.70,91 Synthetic 11-mer oligodeoxynucleotides containing 
site-specific R and S-N6-(1-hydroxy-3-buten-2-yl)-2'-deoxyadenosine (N6-HB-dA II), or 
R,R and S,S-N6-(2,3,4-trihydroxybutan-1-yl)-2'-deoxyadenosine (N6-THB-dA) within the  
N-ras codon 61 were ligated into single-stranded (ss) M13mp7L2 plasmids.70 Repair-
deficient (uvrA-, recA-) E. coli were transfected with the adducted plasmids, and resulting 
plaques were screened for mutations. No effect on plaque forming ability was observed, 
suggesting these adducts do not significantly block in vivo replication.70 N6-HB-dA II 
isomers were non-mutagenic, whereas stereoisomer-specific mutation spectra were 
observed for N6-THB-dA adducts.70 R,R-N6-THB-dA induced AG transitions, while 
S,S-isomer induced AC transversions.70 Similar study conducted using site-specific     
R and S-N2-HB-dG, and R,R and S,S-N2-THB-dG within N-ras 12 codon revealed that all 
four adducts cause GA and GC mutations, while all but R-N2-HB-dG also induced 
GT mutations, although mutagenic frequencies were low.91 In contrast, replication of 
N3-(2-hydroxy-3-buten-1-yl)-2'-deoxyuridine (N3-HB-dU) and stereoisomeric             
N1-(1-hydroxy-3-buten-2-yl)-2'-deoxyinosine (N1-HB-dI) adducted ss-pMS2 vectors in 
COS-7 monkey fibroblasts was extremely error-prone.153,154 N3-HB-dU induced all 
possible types of base substitutions, with an overall mutation yield of ~97%.153 Similarly, 
R- and S-N1-HB-dI produced 59% and ~95% total mutations, respectively. The majority 
of mutations were AG transitions.154 Overall, these results provide evidence for highly 
mutagenic nature of BD-DNA adducts and suggest that factors such as site of adduction 
and carcinogen stereochemistry can affect the mutagenicity. 
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DNA-DNA cross-links are expected to hinder replication and to cause a 
significant amount of mutations. Indeed, 1,4-bis-(2'-deoxyadenosin-N6-yl)-2,3-butanediol 
(bis-N6A-BD) and 1,4-bis-(2'-deoxyguanosin-N2-yl)-2,3-butanediol (bis-N2G-BD) 
decreased plaque forming ability and increased mutagenic frequency.128,154 Mutation 
spectra from diastereomeric bis-N6A-BD containing ss-pMS2 plasmids transfected in 
mammalian cells revealed that these adducts cause primarily AG mutations, with 54% 
and 19% total mutations observed for R,R and S,S-isomers, respectively.154 Plaque 
forming ability of bis-N2G-BD adducted ss-M13mp7L2 vectors replicated in repair-
deficient E. coli was decreased by 4–5 orders of magnitude as comparrd to unmodified 
plasmids, suggesting these adducts strongly hinder replication.128 Mutation spectra have 
revealed both base substitutions and deletions, and S,S-bis-N2G-BD was more mutagenic 
of the two.128 However, it should be noted that these BD-DNA cross-links have not been 
detected in animals exposed to BD or BD-treated DNA. The mutagenic potency of many 
BD-DNA adducts formed in vivo remain to be established. 
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1.4.3 In Vitro Replication Bypass of 1,3-Butadiene-Induced DNA Adducts 
Lloyd and coworkers have investigated the in vitro replication of several         
BD-DNA monoadducts and intrastrand cross-links (Table 1-4). Synthetic DNA strands 
containing site-specific R and S-N6-HB-dA II, and R,R and S,S-N6-THB-dA annealed to  
(-2), (-5) or (+5)-primers were efficiently and fully extended by E. coli repair polymerase, 
Pol I, TLS polymerase, Pol II, and the replicative polymerase, Pol III.70 Single nucleotide 
insertion assays using Klenow fragment of Pol I (KF-) have revealed that correct base 
(dT) was preferentially incorporated, while mispair (dA) was inserted with much less 
efficiency.70 Although N6-THB-dA was predicted to mispair with dG from molecular 
modeling and NMR studies,155 no such transition mutation was observed.70 Bypass 
studies conducted using R and S-N2-HB-dG, and R,R and S,S-N2-THB-dG have revealed 
that E. coli DNA polymerases were completely blocked by all four N2-dG adducts under 
both running start and standing start conditions.91 Further, N3-HB-dU adducted templates 
presented a complete block to KF- and hPol , while calf thymus Pol  was able to bypass 
the adduct, but with extremely low efficiency.153 These results suggest the possibility for 
translesion synthesis of N2-dG and N3-HB-dU adducts, if formed in cells. Fernandes et 
al. have tested the ability of TLS polymerases to replicate N3-HB-dU adducted DNA.156 
In running start experiments, the adducted template significantly blocked hPol κ, ι, and 
yeast Pol ζ one nucleotide prior to the lesion.156 hPol η fully extended the adducted 
primer, with preferential incorporation of the correct base, dG or mismatch, dA as 
revealed by single nucleotide insertion assays.156 Further, both hPol η and Pol ζ were able 
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to extend primers with mismatched bases opposite the adduct in post-lesion synthesis 
assays with the extension of dA mismatch being the most efficient, and the hPol η and 
Pol ζ showed a synergy in primer extension.156 On the other hand, DNA-DNA cross-links 
are expected to strongly block replication. As expected, bis-N2G-BD completely blocked 
E. coli polymerases in vitro.128 
Tretyakova and coworkers have investigated the replication bypass of three     
BD-dA lesions (Table 1-4), R,S-1,N6-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-     
2'-deoxyadenosine (R,S-1,N6-HMHP-dA), R,R-N6,N6-(2,3-dihydroxybutan-1,4-diyl)-2'-
deoxyadenosine (R,R-N6,N6-DHB-dA) and N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenine 
(S-N6-HB-dA). These adducts were site- and stereo-specifically incorporated into 18-mer 
oligodeoxynucleotides, and replication bypass by human repair polymerase β,                 
S. solfataricus TLS polymerase DPO4, and human TLS polymerases η, κ and ι was 
studied.112,157 (R,S)-1,N6-HMHP-dA completely blocked hpol β, while hpol η and κ fully 
extended the adducted primer with η being the most efficient.112 DPO4 was inefficient in 
primer extension, while hpol ι catalyzed nucleotide insertion opposite the adduct, but 
showed no further extension.112 However, subsequent addition of η or κ showed full 
extension, suggesting co-operativity of TLS polymerases in replication bypass.112 While 
hPol η, κ and Dpo4 preferentially incorporated the correct nucleotide, dT, opposite the 
adduct, steady-state kinetic studies have revealed high misinsertion frequencies (f) for dA 
and dG.112 hPol ι exclusively inserted the correct base. Further, HPLC-MS/MS analyses 
of extension products of hPol η, κ and Dpo4 revealed significant amounts of dA and dG 
incorporation opposite the lesion site as well as base deletions.112 Among the three 
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enzymes, hpol η was the least mutagenic (19% of error-prone products), whereas κ 
showed 82% of erroneous products, hence the most mutagenic.112 These results suggest 
that replication bypass of (R,S)-1,N6-HMHP-dA is highly error-prone, causing AT and 
AC mutations. In contrast, polymerase bypass of (R,R)-N6,N6-DHB-dA was extremely 
inefficient, and hPol η and κ incorporated all four nucleotides opposite the modified base 
with almost similar frequencies.157 Hence, (R,R)-N6,N6-DHB-dA can cause AT, AC 
and AG mutations. HPLC-MS/MS data further confirmed the highly error-prone 
replication past this exocyclic lesion.157 On the other hand, (S)-N6-HB-dA was readily 
bypassed by all DNA polymerases examined including hPol β in a highly accurate 
fashion.157 Taken together, these results provide support for the mutagenic potential of 
BD-dA adducts, and confirm that structural features of the modified base can influence 
their biological effects. 
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Table 1-4 In vitro replication studies of 1,3-butadiene-induced DNA 
adducts.70,91,112,128,153,156,157 
DNA Adduct Polymerase 
Primer extension Misinsertion 
Efficiency Fidelity A C G T 
R- and S-N6-HB-dA II Pol I, II and III high error-prone    - 
R,R- and S,S-N6-THB-dA Pol I, II and III high error-prone    - 
R- and S-N2-HB-dG Pol I, II and III blocking N/A  -   
R,R- and S,S-N2-THB-dG Pol I, II and III blocking N/A  -   
N3-HB-dU 
KF- and hPol  blocking N/A   -  
CT Pol ** low -   -  
hPol κ, ι and 
yeast Pol ζ blocking N/A   -  
hPol η moderate error-prone   - 
R,R- and S,S-bis-N2G-BD Pol I, II and III blocking N/A  -   
R,S-1,N6-HMHP-dA 
hPol  blocking N/A    - 
hPol η and κ†† moderate error-prone    - 
Dpo4†† low error-prone    - 
hPol ι insertion only error-free    - 
R,R-N6,N6-DHB-dA 
hPol  low -    - 
hPol η and κ†† low error-prone    - 
hPol ι insertion only error-free    - 
S-N6-HB-dA 
hPol  moderate error-free    - 
hPol η and κ moderate high    - 
hPol ι moderate error-free    - 
                                                 
**		CT – calf thymus	
††	deletion mutations were observed.	
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1.5 DNA-PROTEIN CROSS-LINKING BY BIS-ELECTROPHILES 
1.5.1 DNA-Protein Cross-Links: A Ubiquitous Class of DNA Adducts 
DNA-protein cross-links (DPCs) are a class of structurally diverse, unusually 
bulky DNA lesions formed when cellular proteins become covalently trapped on DNA 
upon exposure to various endogenous and exogenous physicochemical agents.4,5 Cellular 
DPCs are highly complex and heterogeneous due to the involvement of a wide range of 
proteins of varying size, physicochemical properties, cellular distribution and 
functions.85,158-160 Participation of numerous sites on DNA and multiple amino acids on 
proteins in the cross-linking reactions further contributes to the heterogeneity of these 
super bulky lesions (Chart 1-6).4,85,158,161-168 DPCs can compromise genetic stability and 
cell viability by interfering crucial cellular processes such as DNA repair, replication and 
transcription due to their enormous size and disruption of key DNA-protein 
interactions.4,5  Despite implications of DPCs in cancer,30-33 cardiovascular disease34-36 
and age-related neurodegeneration35-39 and their eminent threat to cell viability, the 
structures and mechanisms responsible for such adverse effects are not well understood. 
Hence, elucidating the mechanisms of DPC formation, repair and replication is crucial to 
fully comprehend the biological consequences of these super bulky adducts in order to 
develop approaches to mitigate their lethal effects. 
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Chart 1-6 Chemical structures of DNA-protein cross-links. 
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1.5.2 Types of DNA-Protein Cross-Links 
DPCs are broadly categorized into four classes in literature.5,169 Three classes    
(A, B and C) result from regular DNA-protein transactions, while the fourth class of 
DPCs (D), the most common and most abundant types of DPCs under physiological 
conditions, is generated upon exposure to various physical and chemical agents. Class D 
has received the most attention amongst researchers, since this class of DPC lesions is the 
culprit responsible for preventable adverse biological effects of DPCs in cells. 
Class A DPCs occur when topoisomerase I (TOPO I) forms a covalent tyrosine 
phosphodiester bond at the 3' end of a DNA single strand break (SSB) during DNA 
unwinding,5,169,170 and when the complex is persistent due to damaged DNA in close 
proximity or treatment with topoisomerase inhibitors.170-173 These DPC lesions are 
repaired by tyrosyl-DNA phosphodiesterase 1 (Tdp1).169,170 
Covalent attachment of topoisomerase II (TOPO II) and meiotic recombination 
protein (SPO II) to the 5' ends of double strand breaks (DSB) on DNA, possibly via a 
similar mechanism to that of class A, leads to the formation of class B DPCs.174,175   
TOPO II DPCs are repaired by tyrosyl-DNA phosphodiesterase 2 (Tdp2) or             
MRN-catalyzed, CtIP-dependent endonucleolytic pathway,176 while SPOII adducts are 
endonucleolytically processed.177 
An amide linkage between a protein and an oxidized form of DNA generates class 
C DPCs. For example, human DNA polymerase  (Pol ) and endonuclease III        
(Endo III), two enzymes involved in base excision repair (BER) can form an amide bond 
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with the 2'-deoxyribonolactone generated upon cleavage of the oxidized abasic site by 
human apurinic/apyrimidinic endonuclease 1 (APE 1).178,179 An in vivo preventative 
mechanism for class C DPCs was revealed, where 2'-deoxyribonolactone is rapidly 
removed by  long-patch BER.180 
Class D DPCs are the most abundant and most interesting type of lesions, as they 
are formed upon exposure to a variety of physical agents and chemical species from both 
endogenous and exogenous sources (Chart 1-6). Endogenous species involved are 
reactive oxygen species (ROS),166,167,181-186 reactive nitrogen species (RNS),164,165,187,188 
oxidants and free radical inducing agents,181 and bis-electrophiles resulting from cellular 
metabolism.189,190 Environmental pollutants and industrial chemicals,85,86,191-210 heavy 
metals,211-215 and chemotherapeutic agents158,159,216-221 are examples of exogenous 
chemicals that mediate DPC formation. In addition, physical agents such as UV light and 
ionizing radiation can contribute to class D DPCs.160,168,222,223  
1.5.3 DNA-Protein Cross-Links Induced By Physicochemical Agents 
Reactive oxygen species (ROS) are mainly generated in cells as byproducts 
during cellular respiration in the mitochondria224 and lipid peroxidation within cell 
membranes.225 Exposure to ionizing radiation like infrared (IR) and X-rays can also 
generate ROS.4 These species can cause one electron oxidation of DNA or proteins to 
initiate free radical reactions. Such electron deficient species can ultimately form DPCs 
by covalent attachment of proteins that interact with DNA. For example, Gajewski et al. 
reported ROS-mediated DPCs between pyrimidines on DNA and several amino acid 
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residues on histones both in vivo and in vitro.182-185 In addition, theoretical studies have 
suggested that ROS can induce DPCs involving cytosine and tyrosine residues.186 
Further, Burrows and coworkers have reported that 8-oxoguanosine get cross-linked to 
lysine and tyrosine residues to mediate DPC formation (Chart 1-6).166,167,181 
Some reactive nitrogen species (RNS) function as important intracellular 
messengers, while some can have deleterious effects on cells.226 One of the major RNS 
formed in vivo, nitric oxide (NO) is known to induce DPCs via a mechanism initiated by 
oxidation of DNA bases or amino acid residues.227 In addition, Oxanine, a NO-induced 
deaminated product of guanine forms amide linkage to Lys and Ser residues of DNA 
binding proteins (Chart 1-6).164,165 Further, Makino and co-workers reported that 
cytosine diazoate, a product of the reactions of cytosine with nitrous acid (HNO2) and 
nitric oxide can form lysine adducts, providing evidence for DNA-nucleoprotein      
cross-linking by HNO2 and NO in cells.187,188 
Endogenous electrophilic species can also contribute to DNA-protein cross-
linking in cells. Glyoxal and methylglyoxal are endogenous aldehydes.4,228,229 Glyoxal is  
an -oxoaldehyde biosynthesized during lipid peroxidation, ascorbate autoxidation, 
oxidative degradation of glucose and degradation of glycated proteins.230 Methylglyoxal, 
an -ketoaldehyde, is a physiological metabolite formed during glycolytic bypass, 
acetone metabolism, and amino acid catabolism.231 These highly reactive aldehydes are 
known to cross-link guanine in DNA and lysine and arginine residues in proteins.189,190,232 
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Murata-Kamiya et al. reported that methylglyoxal mediate DNA-KF- cross-link 
formation.229 
Amongst the environmental pollutants and industrial chemicals that induce   
DNA-protein cross-linking, formaldehyde (FA) is the most extensively studied. FA is a 
highly reactive colorless gas classified as a human carcinogen. It is employed in the 
manufacture of thousands of household, medicinal, and industrial products, leading to a 
high potential for human exposure,194,233,234 and also found in cigarette smoke, 
automobile exhaust and photochemical smog.235 FA is also formed endogenously through 
various metabolic pathways including amino acid and methanol metabolism, lipid 
peroxidation and P450-dependent demethylation.236 While FA is known to induce several 
types of DNA adducts, the main type of lesions formed is attributed to DPCs.191-194,234 It 
is well characterized that FA reacts with N-terminal amino group and side chains of Lys, 
Arg, His and Cys237,238 forming methylols, Schiff bases, and methylene bridges.237 It can 
also modify exocyclic amines and endocyclic imines of all four nucleobases in DNA                 
(Chart 1-6).162,163,238 Based on the existing evidence for DPC formation by FA,239-243 
DNA-histone cross-links are considered the main contributors to its carcinogenicity, and 
all five major types of histones were found to be involved in DPC formation.244  
Acrolein, another carcinogenic chemical used in biocide and polymer industry 
and also present in cigarette smoke and automobile exhaust,195,245 is known to mediate 
DNA-protein cross-linking in cells.246 Acrolein is formed endogenously during lipid 
peroxidation.247 This ,-unsaturated aldehyde can mediate cross-linking via Michael 
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addition or Schiff base formation between exocyclic amines of purines in DNA and Cys, 
His and Lys residues of proteins (Chart 1-6).195-198  
1,2,3,4-Diepoxybutane (DEB), the ultimate carcinogenic metabolite of BD      
(see section 1.2), is yet another bis-electrophile known to facilitate DPC 
formation.85,86,199-201,248 Evidence for DEB mediated cross-linking of proteins to DNA    
ex vivo and in vivo was initially obtained using biophysical methods.199,200 Subsequent   
in vitro studies employed recombinant proteins and mass spectrometry as a tool to show 
that Cys residues in proteins and N7 of guanine in DNA are involved in DEB-mediated 
DPC formation (Chart 1-6).201,248,249 Over three dozens of proteins with various cellular 
functions formed covalent cross-links to DNA in DEB-treated cells as revealed by mass 
spectrometry-based proteomics.85 Other known environmental carcinogens such as        
N-methyl-N'-nitro-N-nitrosoguanidine, sulfur dioxide (SO2) and dihaloalkanes are also 
found to induce DPCs that elicit cytotoxic and mutagenic effects.202-210,250 
Numerous metallic compounds commonly found as environmental and 
occupational pollutants are another main class of DPC-inducing agents.4,169,251,252 A study 
conducted by Kuykendall et al. has shown that DPCs are a potential biomarker of 
exposure to transition metal cations.253 Metal ion-mediated DPC formation can occur via 
either of two mechanisms: a metal chelating mechanism213 or an oxidative mechanism 
involving free radicals.254,255 Arsenic (As) is an environmental pollutant present in the 
form of arsenite or arsenate in soil, water and air.32 In vitro studies using multiple human 
cell lines have revealed DPC formation in cells upon treatment of arsenite.211,212 
Chromium (Cr) compounds, industrial chemicals resulting from stainless steel and 
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pressure-treated wood manufacturing32 and water pollutants,253 were found to mediate 
DPC generation through a chelatable form of Cr.213,256 They are thought to first chelate 
Cys, His and Glu residues within proteins, followed by chelation with adenine, cytosine 
and guanine bases within DNA, forming bulky DPC adducts.213 In contrast, nickel (Ni), a 
component of alloys used to manufacture various consumer products such as coins and 
jewelry,257 is found to form DPCs via a ROS-mediated pathway.214,215  
UV light and ionizing radiation are two physical agents known to generate a range 
of DNA adducts including DPCs in vivo.4,160,258-260 DPC formation by ionizing radiation 
has been studied using biophysical and mass spectrometry-based methods.160,168,222,223 
The amounts of DPCs generated when cells exposed to IR is 3–5-fold higher than DNA 
double-strand breaks and DNA-DNA cross-links.160 Radiation-induced DPCs result from 
the radicals produced in cells upon irradiation, while radiation can form such radicals by 
direct oxidation of DNA and proteins or generating ROS.4 Cress et al. found that ionizing 
radiation induces DPC in dose dependent manner in Chinese hamster ovary (CHO) 
cells.223 Murray and coworkers has identified 29 proteins in CHO cells and human 
fibroblasts that become cross-linked to chromosomal DNA following exposure to 
ionizing radiation,160 while Gueranger et al. found that UVA/6-thioguanine treated 
CCRF-CEM leukemia cells cross-link proteins involved in DNA repair.259 Further, 
radiation-induced DPCs are known to involve tyrosine residues within proteins and 
thymine in DNA (Chart 1-6).168  
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1.5.4 DNA-Protein Cross-Linking by Antitumor Drugs 
Most antitumor drugs currently used in clinic elicit their therapeutic effects 
through their ability to modify genomic DNA, which ultimately leads to cell death.261 
The vast majority of these drugs are bis-alkylating agents, electrophilic species that have 
two reactive groups, and can form covalent bonds with two sites on biomolecules.262,263 
Antitumor drugs give rise to a variety of lesions including DNA monoadducts, single- 
and double-strand breaks, intra- and interstrand DNA-DNA cross-links, and DPCs.263-266 
Historically, the anti-cancer activity of these drugs has been attributed to DNA-DNA 
cross-linking.267 Interstrand DNA-DNA cross-links can prevent DNA strand separation 
and can obstruct DNA replication inducing apoptosis.262,267,268 However, these drugs also 
form unusually bulky DPC lesions.158,159,216-221 Alkyl sulfonates, 2-chloroethyl-
nitrosoureas, nitrogen mustards, and platinum-based drugs are important classes of 
antineoplastic agents known to induce DPCs (Chart 1-7).  
Busulfan (1,4-butanediol dimethanesulfonate) is an antitumor alkyl sulfonate 
currently used in clinic (Chart 1-7A), and is prescribed for leukemia.269 It is known to 
form a large number of DPCs (Scheme 1-5A),270 although the therapeutic benefits were 
attributed to intrastrand DNA-DNA cross-links between N7 of guanine and N7 of adenine 
within 5'-GA-3' sequence, and between N7 of two guanine bases within 5'-GG-3' 
sequence.271 
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Chart 1-7  Chemical structures of bis-alkylating antitumor drugs known to induce DNA-
protein cross-links. (A) alkyl sulfonates, (B) 2-chloroethylnitrosoureas, (C) nitrogen 
mustards and (D) platinum-based drugs. 
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Scheme 1-5 Mechanisms of DNA-protein cross-linking by alkyl sulfonates (A) and       
2-chloroethylnitrosoureas (B).272,273 
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1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) is one of the 2-chloroethyl-
nitrosoureas used in clinic for brain tumors (Chart 1-7B).274 Its therapeutic effect is due 
to the ability to form interstrand DNA-DNA cross-links between N1 of guanine and N3 of 
cytosine275 that will inhibit the biosynthesis of DNA and RNA similar to other alkylating 
agents.274 Seidenfeld et al. and Ewig et al. have reported that BCNU forms DPCs 
(Scheme 1-5B), in addition to DNA single strand breaks and interstrand DNA-DNA 
cross-links in human adenocarcinoma and mouse leukemia cell lines.216,276 
Nitrogen mustards belong to a diverse class of chemotherapeutic agents, whose 
DNA-protein cross-linking ability is well documented (Chart 1-7C). These are bis-      
(2-chloroethyl)amines that structurally differ by the substitution at the third valence of the 
nitrogen atom.262,277 Because of the high reactivity and off-target toxicity of the first 
nitrogen mustard drug, mechlorethamine, the N-methyl group was replaced with a variety 
of alkyl groups to reduce the reactivity and increase selectivity towards malignant 
cells.262,277 This class of drugs has been used in clinic since 1940s for the treatment of      
a variety of cancers including leukemia, lymphoma, carcinoma and myeloma.277,278 Their 
therapeutic effects are attributed to inter- and intrastrand cross-links involving primarily 
the N7 of guanine, but also N1, N3, N6 and N7 of adenine.279-284 Kohn et al. and Bonner 
and colleagues provided the initial evidence for DPC formation mediated by nitrogen 
mustards.217,218,281,285 Tretyakova and coworkers have employed mass spectrometry-based 
methods to identify cellular proteins that get cross-linked to DNA in the presence of 
nitrogen mustards and to characterize structures of DPCs mediated by nitrogen 
mustards.158,159,161 Structural elucidation was conducted using O6-alkylguanine DNA 
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alkyltransferase (AGT) as a model protein. It was found that the Cys residues within the 
protein and N7 of guanine in DNA were involved in cross-linking reactions mediated by 
mechlorethamine and chlorambucil (Scheme 1-6A).161 Further, 15, 53 and 38 proteins, 
with varying cellular and biological functions including DNA repair, replication and 
transcription, were identified in mechlorethamine-treated Chinese hamster ovary (CHO), 
human cervical carcinoma (HeLa) and human fibrosarcoma (HT1080) cells, 
respectively.158,159 
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Scheme 1-6 Mechanisms of DNA-protein cross-linking by nitrogen mustards (A) and 
platinum drugs (B).272,273 
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Platinum-based drugs used in cancer treatment are coordination complexes of 
platinum (Chart 1-7D). Cisplatin (cis-diamminedichloroplatinum(II)) was the first 
generation antineoplastic in this class introduced to clinic in 1970s for testicular and 
ovarian cancers.286 Neurotoxicity and nephrotoxicity286,287 observed with cisplatin have 
led to the development of second generation platinum drugs: carboplatin (cis-diammine-
[1,1-cyclobutanedicarboxylato]platinum(II)) and oxaliplatin ([(1R,2R)-cyclohexane-1,2-
diamine](ethanedioato-O,O')platinum(II)).286,288 These compounds show biological 
activity against a wide range of cancers, especially solid tumors such as sarcoma, 
carcinoma, lymphoma, and brain, lung, colorectal, head and neck cancers.286,288,289 The 
biological activity of platinum drugs is also attributed to their ability to form DNA 
monoadducts and cross-links. For example, cisplatin is known to form 1,2-intrastrand 
cross-links at GpG and ApG sites, 1,3-intrastrand cross-links at GpXpG sites, GG 
interstrand cross-links and adenine, cytosine and guanine monoadducts.286,290 The N3 
position of cytosine, N1 and N7 of adenine, and N7 of guanine were the main alkylating 
sites within DNA,290 and the two amine groups remained bound to Pt.286 Nonetheless, 
cisplatin has been shown to form DPCs.221,291,292 For example, cisplatin formed DPCs 
with the Klenow fragment of DNA polymerase I (KF-), histone H1, and NF-κB,219 and 
DNA-protein cross-linking correlated with cell death.293 Tandem mass spectrometry-
based peptide mapping of AGT protein treated with cisplatin in the presence of                
a synthetic DNA has revealed that DPC occurs at N7 of guanine within DNA, and Arg, 
Cys, Glu, His and Lys residues within the protein (Scheme 1-6B).294 An affinity capture 
methodology coupled with mass spectrometry-based proteomics using HeLa nuclear 
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extracts has identified 131 proteins cross-linking to DNA via cisplatin in vitro.294 Further, 
bottom-up mass spectrometry-based proteomics employing HT1080 cells incubated with 
cisplatin have discovered 256 proteins participating in cisplatin-mediated DNA-protein 
cross-linking.294 The majority of proteins identified in these proteomics studies were 
localized in the nucleus, while their molecular and biological functions involved 
important cellular transactions such as DNA replication and damage response, RNA 
transcription and processing, and protein translation and transport.294 Taken together, 
these evidence warrant the importance of investigating the biological consequences of 
antitumor drug-induced DNA-protein cross-links. 
1.5.5 Biological Consequences of DNA-Protein Cross-Links 
The unusually bulky nature of DPC lesions and their ability to block DNA protein 
interactions can interfere with cell viability and genetic integrity.4,5 The high stability and 
long-term persistence of these lesions, except for the hydrolytically labile N7 adducts, can 
further enhance these effects. For example, DPCs formed under oxidative conditions and 
mediated by metal ions are stable for days to weeks,253,295,296 although some aldehyde-
induced DPCs are hydrolytically unstable and last only a few hours.199,297,298 Cytotoxic 
effects of many DNA damaging agents such as industrial and environmental 
carcinogens,39,234,299-301 antitumor drugs,132,216,220,302 metals,251 and ionizing radiation259,260 
are attributed to DPCs, and some of these effects result from inhibition of DNA 
transactions like repair,259 replication132,220,234,260,300,301 and transcription,260 ultimately 
leading to apoptosis.39,301 
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The genotoxic and mutagenic effects of DPC-inducing agents are also well 
documented.32,95,191,299,300,303 Tretyakova et al. recently reported direct evidence to 
support DPC-induced toxicity and mutagenicity in human cells using protein 
monoepoxides engineered to selectively form DPCs.304 Not only large proteins, but also 
smaller peptides cross-linked to DNA elicit mutagenic effects,198,305 and the ability to 
cause mutations is dependent on the site of cross-linking within DNA.198 Cytotoxicity 
and carcinogenicity observed in mice deficient in Fanconi Anemia DNA repair pathway 
is linked to DPCs formed by endogenous aldehydes.306,307 Further, studies employing 
human subjects occupationally exposed to DPC-inducing agents such as transition metals 
have implicated DPCs in the observed genotoxicity.308-310 For example, an increased 
incidence of chromosomal aberrations in lymphocytes was observed in workers 
occupationally exposed to Ni.309,310 
Because of their unusual size, DPCs may affect various biological functions via 
mechanisms different to those of smaller, conventional DNA lesions. As mentioned 
before, they can block DNA repair, replication and transcription. DPCs have been 
implicated in many diseases including cancer,30-33 cardiovascular disease34-36 and        
age-related neurodegeneration.35-39 DPCs have been observed in rat marrow cells exposed 
to FA, and it is hypothesized that DPC formation is the molecular mechanism responsible 
for FA-induced leukemia.30 A dose-dependent increase in DPCs with exposure to DPC-
inducing agents like SO2, CrVI and NiII was observed in white blood cells (WBCs) and 
several organs such as lung, liver and heart of rodents.250,251 Studies employing several 
strains of mice reported that the amounts of DPCs in numerous organs, including brain 
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and heart, increased significantly with age.36,311 Exposure to metals such as Ni, Cr and As 
is implicated in various cancers including respiratory, adrenal and liver cancers in both 
rodents and humans.213,312-314 
Despite their abundance in tissues, the biological effects of DPCs are poorly 
understood. The vast majority of DPC-inducing species can also produce other types of 
DNA adducts.262Hence, it is very difficult to isolate the deleterious effects of DPCs from 
those of other DNA adducts to fully comprehend biological consequences of DPCs. In 
this regard, novel methodologies are required to induce DPCs selectively in cells as well 
as synthetic approaches to generate site-specific DPCs for studies of their repair and 
replication. 
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1.6 REPAIR STUDIES OF DNA-PROTEIN CROSS-LINKS 
The unusually bulky nature of DPCs presents a unique challenge to cellular repair 
machinery in order to restore normal DNA, because the cross-linked protein (CLP) 
hinders the access of repair proteins to the lesion site. Also, the stability and persistence 
of DPCs play a key role in the mechanisms involved in removal of these bulky adducts in 
cells. The hydrolytically labile DPCs, such as those generated by aldehydes, can be 
rapidly eliminated from cells within a matter of hours.199,297,298 However, certain DPCs 
are hydrolytically stable and long-lived.253,295,296 There is evidence that DPCs induced by 
transition metals and oxidative stress can persist through several cycles of DNA 
replication,260,315,316 and are only partially repaired,317 thus resulting in downstream 
effects in vivo due to permanent damage to genomic DNA.4 Hence, such stable DPCs 
require the participation of active cellular repair. Several factors including the chemical 
nature of the DPC lesions and specific cellular system can dictate which damage 
tolerance mechanisms will be involved in recognizing a particular type of DPC lesions.4,5 
Direct reversal, nucleotide excision repair (NER) and homologous recombination (HR) 
are potential mechanisms by which these bulky adducts can be removed in vivo 
(Schemes 1-2 and 1-3). 
Direct reversal by chelation is possible, if DNA and protein is bound through 
complexation with a metal like Cr.4,318 FA-induced DPCs were found to be removed by 
hydrolysis.4,297 DPCs-induced by platinum compounds are known to release the CLP by 
“platination migration”.319-321 This phenomenon was observed in vitro with DNA-AGT 
cross-links induced by cisplatin.294 The AGT protein was released by the migration of the 
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Pt-S bond of a Cys residue within CLP to N7-G on DNA forming a DNA-DNA        
cross-link.294 This can be a possible mechanism by which Pt-induced DPCs are removed 
from cells. 
NER is known to have a broad substrate specificity and to remove bulky, helix 
distorting DNA adducts,115,322,323 hence can be potentially involved in DPC repair. Lloyd 
and coworkers reported that bacterial UvrABC nuclease incised site-specific DPCs 
between T4 pyrimidine dimer glycosylase/apurinic/apyrimidinic site lyase (T4-pdg) and 
an apurinic/apyrimidinic (AP) site within duplex DNA in vitro.324,325 Nakano et al. 
showed that in vitro excision of proteins cross-linked to DNA via an oxanine moiety by 
UvrABC is size-dependent, and NER only repairs DPCs smaller than 11–14 kDa.326 In 
contrast, upper size limit of DPCs for mammalian NER was found to be 8–10 kDa.327 
However, FA-induced chromosomal DPCs were not repaired by mammalian NER 
proteins,327 which contrasts a previous report that similar DPCs were removed by 
bacterial NER system.326 In addition, XPF-deficient CHO cells showed a marked 
decrease in IR-induced DPC repair under hypoxic conditions as compared to wild-type 
cells, suggesting the involvement of NER.328 In contrast, XPD- and XPB-deficient cells 
were not IR-sensitive under hypoxia, suggesting that NER is not involved in IR-induced 
DPC lesions, rather recombination repair is.329  
Several groups have proposed that DPC repair involves partial proteasomal 
degradation of the DPCs followed by NER. Lloyd and colleagues reported that tetra- and 
dodecylpeptides cross-linked to either an AP site or N2-G of DNA via a trimethylene 
linker were excised more efficiently by UvrABC complex as compared to T4-pdg     
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cross-linked to an AP site in DNA.325 Reardon et al. confirmed these observations using 
the same substrates in both mammalian and bacterial systems.330 Quievryn and 
Zhitkovich found that proteasome inhibitors hinder the repair of FA-induced DPCs in 
human HF/SV fibroblasts and NER-deficient XPA cells, while NER-deficient XPF cells 
showed higher sensitivity to FA, suggesting the involvement of XPF protein in the 
removal of DPCs.297 Baker et al. have investigated the repair of site-specifically       
cross-linked HhaI DNA methyltransferase (HDnmt) to C6 of 5-fluorocytosine containing 
oligodeoxynucleotides or plasmids.331 In vitro assays using mammalian cell free extracts 
have shown that protease-digested, but not the full length HDnmt-DPC was excised.331 
Further, their in vivo assays demonstrated that wild-type cells repaired the site-specific 
DPCs, while both Xpg-deficient cells and 26S proteasome inhibitor-treated cells were 
ineffective in repair.331 Based on these observations, Reardon et al. have proposed a 
replication coupled NER model for DPC repair:169 when the replication fork encounters 
DPCs, fork regression triggers the recruitment of proteolytic enzymes to degrade the CLP 
to a smaller peptide.169 Simultaneously, repair factors necessary to excise the resulting 
peptide cross-links are recruited at the lesion site to initiate NER.169 
Independent reports on hypersensitivity of bacterial uvrA and recA mutants to FA 
treatment, and hypersensitivity of recA, but not the uvrA mutant, to 5-azacytidine (azaC) 
suggest that multiple repair pathways are involved in DPC repair.326,332,333 These 
observations suggest that both FA and azaC-induced DPCs are repaired by HR, but only 
FA-induced DPCs are recognized by NER. Confirming this hypothesis, Nakano et al. 
observed that HR-deficient, but not HR-proficient bacterial and mammalian cells, were 
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hypersensitive to DPC-inducing agents.326,327 Further, bacterial cells repaired double 
strand breaks resulting from replication folk stalling upon encounter of DPCs via 
RecBDC-dependent HR.326 Accumulation of RAD51, a pivotal protein in HR, in 
mammalian cells treated with DPC-inducing agents further suggests that HR is 
responsible for the removal of the majority of DPCs in vivo.327 
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1.7 REPLICATION BYPASS OF DNA-PROTEIN CROSS-LINKS 
Hydrolytically stable DPCs,253,295,296 if not repaired, can interfere with DNA 
replication.4,5 These super bulky lesions are likely to block high fidelity replicative 
polymerases.132 Cellular DNA damage response mechanisms will then initiate translesion 
synthesis (TLS)130,133,134 or HR.5 During TLS, low fidelity bypass polymerases can 
potentially accommodate these bulky DPC lesions in their large and flexible active sites 
to replicate past the adducted DNA (Scheme 1-4). As mentioned in section 1.4.1, the 
replication bypass by TLS polymerases can be inefficient and error-prone.149,150 
Structural features such as site of cross-linking on DNA and protein, size of CLP, and 
identity of CLP as well as the polymerase can influence the ability of DPCs to be 
bypassed, and also the fidelity of replication.132,164,219,326,327,334-338 However, only a 
handful of studies have directly examined the effects of DPCs on DNA replication. 
In vitro replication studies conducted using histone H1 cross-linked to DNA via 
cisplatin or transplatin have revealed that histone DPCs completely blocked the Klenow 
fragment of E. coli DNA polymerase I (KF-) and HIV-1 reverse transcriptase               
(RT HIV-1).219,334 The main termination site was one nucleotide prior to the DPCs.219,334 
Ide and coworkers transformed wild-type and uvrA E. coli strains with pGL3-CMV 
plasmids containing FA-induced histone H1 DPCs.326 With both wild-type and uvrA 
cells, the transformation efficiency of plasmids containing histone H1 DPCs was <10% 
compared to that of undamaged plasmids.326 However, the transformation efficiency of 
plasmids containing partially digested histone H1 increased up to 58% with wild-type 
cells.326 These results imply that histone DPCs hinder in vivo replication. Kuo et al. 
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investigated the in vivo replication of pBR322 plasmids in E. coli in the presence of 
azaC.132 AzaC induces DPCs by cross-linking DNA cytosine-C5 methyltransferase 
(MTase).132 Two-dimensional agarose gel electrophoresis has revealed the accumulation 
of bubble and Y molecules in wild-type plasmids, but not in EcoRII methylation site 
mutant.132 These results suggest that azaC-induced DPCs block DNA replication. 
Another study reported that UV-induced DPCs containing T4-pdg blocks plasmid 
replication in cells.339 T4-pdg was trapped at UV-induced cyclobutane pyrimidine dimers 
on double-stranded pMS2 plasmids, and wild-type and ΔuvrD cells were transformed.339 
The relative transformation efficiency of DPC containing plasmids was ~5%, while that 
of UV-irradiated plasmids was ~50% in ΔuvrD strain suggesting replication inhibition by 
UV-induced DPCs.339 
A few studies have also been reported in literature on in vitro replication of DNA-
peptide cross-links. It is known that DNA-peptide cross-links are formed in vivo,305,340 
while natural and synthetic peptides have been cross-linked to DNA in vitro.197,341-343 
Further, the hypothesis that DPCs get proteolytically degraded to a peptide in cells prior 
to their repair,297,331 hence the possibility of these lesion to encounter cellular replication 
machinery also warrants the efforts to investigate the replication of DNA-peptide     
cross-links. Lloyd and coworkers conducted replication bypass studies with DNA 
templates containing tetra- and dodecylpeptides cross-linked to N2 position of guanine via 
a trimethylene linker, i.e., acrolein-induced DNA-peptide cross-links.335 DinB family 
polymerases, hPol κ and its E. coli orthologue, Pol IV were able to catalyze replication 
past these DNA-peptide adducts with varying efficiencies.335 Both enzymes exclusively 
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incorporated the correct nucleotide, dC opposite the peptide cross-links, suggesting error-
free replication.335 In contrast, E. coli replicative polymerase, Pol III or damage inducible 
polymerases, Pol II and Pol V could not bypass the peptide adducts.335 Interestingly,       
A family polymerase ν was capable of bypassing both 4-mer and 12-mer peptides    
cross-linked to N6 of adenine via a trimethylene linkage, while similar adducts at the N2 
of guanine completely blocked replication in both standing and running start 
experiments.336 Replication bypass of N6-dA-peptide cross-links by Pol ν was also highly 
accurate, and only the correct base, dT was inserted opposite the adduct.336 These 
observations suggest that major groove DPC adducts, but not the corresponding minor 
groove adducts, can be bypassed by Pol ν.  The authors proposed that small major groove 
DPC adducts have sufficient conformational flexibility to be accommodated within the 
active site of the polymerase without disturbing primer-template-enzyme interactions.336 
Further, it is reported that E. coli high-fidelity DNA repair polymerase, Pol I can also 
efficiently and accurately bypass a dodecylpeptide cross-linked to N6 of adenine in 
DNA.337 The extent of primer extension was comparable to that of the undamaged 
template.337 In contrast, E. coli DNA damage-inducible polymerases, Pol II, Pol IV and 
Pol V replicated past the peptide adducts with very low efficiency, although the process 
was still highly accurate. E. coli Pol III and hPol κ were completely blocked by this 
adduct.337 Guengerich and coworkers employed a glutathione-DNA adduct of DEB,       
S-[4-(N6-deoxyadenosinyl)-2,3-dihydroxybutylglutathione (N6-dA-(OH)2butyl-GSH) to 
investigate the efficiency and fidelity of replication bypass.338 The highest primer 
extension efficiency was observed with Pol T7 and hPol η, with full extension under their 
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experimental conditions.338 Human TLS polymerases κ and ι, as well as the bacterial 
polymerases Pol T7 and DPO4, preferentially incorporated the correct base, dT opposite 
the adducted site, with misincorporation of dC at varying efficiencies.338 HPLC-MS/MS 
analysis of replication products revealed that 40–55% of replication products of hPol κ 
and Pol T7 were substitution products.338 Further, replication by hPol η was highly 
erroneous, and all four dNTPs were incorporated opposite the adducted DNA, suggesting 
the possibility for both transition and transversion mutations during bypass.338 
Amidst the paucity of systematic studies to evaluate the effects of DPCs on DNA 
replication, structures of DPCs employed in previous studies do not necessarily represent 
the major DPCs formed in vivo. For example, N7 of guanine is the most common site of 
DNA that participates in DPC formation mediated by environmental carcinogens and 
antitumor drugs.85,158,159,294 Yet, replication of N7-G cross-linked DPCs has not been 
previously investigated. Further, hardly any studies have been reported on in vivo 
replication of DPCs, and none have been conducted using eukaryotic systems. 
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1.8 SYNTHETIC METHODLOGIES TO PREPARE SITE-SPECIFIC 
DNA-PROTEIN CROSS-LINKS 
The paucity of site-specific DNA substrates containing biologically relevant, 
hydrolytically stable DNA-protein conjugates is a major obstacle to fully comprehend the 
biological consequences of DPCs. Schiff base formation between an aldehyde-
functionalized DNA and amine groups within proteins/peptides followed by reduction of 
the imine linkage to a stable amine has been the most widely used approach to generate 
DPCs. A semi-synthetic reductive amination methodology has been used to cross-link 
bifunctional glycosylases to DNA (Scheme 1-7A). A nitrogen nucleophile on the enzyme 
displaces the modified DNA base by forming a covalent linkage to C1'.344 This 
intermediate rearranges to a Schiff base, prior to strand cleavage that can be irreversibly 
trapped using a reducing agent.344 T4 pyrimidine dimer glycosylase/AP lyase              
(T4-pdg),169,325,330 Endonuclease VIII (Nei),345 formamidopyrimidine DNA glycosylase 
(Fpg),346 8-oxoguanine DNA glycosylase (Ogg and its bacterial ortholog, MutM)347,348 
have been trapped on abasic sites within DNA to generate site-specific DPCs. Lloyd, and 
Marnett and coworkers have used the reductive amination approach to prepare acrolein-
induced DNA-polypeptide cross-links (Scheme 1-7B). The protein (T4-pdg, histones or 
EcoRI)246,349 or Lys-rich tetra- and dodecyl-peptides197,325,330,335-337 have been cross-
linked to the ring open form of the –hydroxy-1,N2-propano-dG or –hydroxy-          
1,N6-propano-dA to form a Schiff base and subsequent reduction to yield DPCs 
conjugated to N2 of guanine and N6 of adenine via a trimethylene linkage. Another 
approach involved the trapping of DNA methyltransferase (Dnmt) on 
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oligodeoxynucleotide containing 5-fluoro-2'-deoxycytosine (5F-dC) (Scheme 1-7C).331 A 
cysteine residue of the enzyme attacks the C6 of 5F-dC forming a covalent intermediate, 
and the resulting enamine undergoes methylation at C5.344 Fluoro substitution at C5 
prevents enzyme elimination resulting in a DPC.344 Ide and coworkers have employed the 
spontaneous reaction of oxanine (Oxa), a NO-induced oxidative lesion of Gua, with 
amino groups of proteins to prepare site-specific DPCs containing a pyrimidine ring-open 
structure (Scheme 1-7D).164,326,327 Disulfide cross-linking is another strategy used to 
generate site-specific DPCs (Scheme 1-7E). A disulfide tether-appended nucleobase has 
been incorporated site-specifically to DNA allowing the Cys residues within proteins to 
participate in cross-linking.344 HIV reverse transcriptase (HIV-RT), a peptide derived 
from yeast transcription activator, GCN4, and Ogg have been cross-linked via alkyl 
linkers to N2 of Gua,350 N6 of Ade351 and C4 of Cyt,347 respectively. Distefano and 
coworkers have developed an alkyne-azide cycloaddition reaction (click reaction)-based 
methodology to prepare DPCs using alkyne containing DNA and azide-functionalized 
proteins (Scheme 1-7F). Green fluorescent protein (6×His-eGFP) and mCherry 
containing an azide were cross-linked to the 5'-ends of alkyne-functionalized 
oligodeoxynucleotides via the Cu-catalyzed click reaction352 or the Cu-free variation.353 
However, these previous methodologies have several limitations such as poor reaction 
efficiency and low yields,164 limited choices of protein reagents (e.g. specific DNA 
modifying proteins),331,344 and insufficient site specificity with respect to the             
cross-linking site within the protein,164,246,354 requiring novel synthetic methodologies to 
prepare site-specific, structurally defined DPCs. 
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Scheme 1-7 Synthetic methodologies available in the literature to prepare site-specific 
DNA-protein cross-links. (A) glycosylase trapping, (B) acrolein-mediated cross-linking, 
(C) DNA methyltransferase trapping, (D) oxanine-mediated cross-linking, (E) disulfide 
cross-linking, and (F) azide-alkyne cycloaddition. 
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1.9 THESIS GOALS 
As described above (section 1.2), BD is a known human carcinogen and its 
epoxide metabolites can induce DNA damage in cells. However, the repair mechanisms 
responsible for the removal of BD-induced DNA lesions are not well understood. One of 
the goals of this thesis was to investigate the repair mechanisms responsible for the 
removal of three 2'-deoxyadenosine (dA) adducts of BD: a monoadduct formed by      
3,4-epoxy-1-butene (EB), N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine (N6-HB-dA) 
and two exocyclic lesions formed by 1,2,3,4-diepoxybutane (DEB), 1,N6-(2-hydroxy-    
3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (1,N6-HMHP-dA) and N6,N6-(2,3-
dihydroxybutan-1,4-diyl)-2'-deoxyadenosine (N6,N6-DHB-dA). We prepared site- and 
stereospecific BD-dA adducted synthetic oligodeoxynucleotides by a post-
oligomerization methodology, and in vitro repair by human nuclear extracts and 
recombinant proteins was examined using gel electrophoresis and liquid 
chromatography-tandem mass spectrometry-based methodologies (Chapter 2). 
DNA-protein cross-links (DPCs) are ubiquitous, structurally diverse DNA 
adducts formed in cells upon exposure to a variety of physical and chemical DNA 
damaging agents.4,5 These super bulky, helix-distorting DNA adducts interfere with DNA 
metabolism, and elicit adverse biological effects in vivo.4,5 The majority of                   
bis-electrophile-induced DPCs formed in vivo involves the N7 of guanine within 
DNA.85,158,159,294 Moreover, it is hypothesized that cross-linked protein of DPCs is 
proteolytically processed to generate DNA-peptide conjugates prior to repair or 
replication.297,330,331 Nonetheless, the biological consequences of DPCs are not fully 
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understood, partly due to the synthetic challenge in generating site-specific DPC 
substrates that are biologically relevant. Therefore, the second goal of this thesis was to 
develop synthetic strategies to generate hydrolytically stable, site-specific DPCs. In this 
regard, we used a post-synthetic reductive amination strategy to prepare structural mimics 
of nitrogen mustard-mediated DPCs (Chapter 3). Further, we employed copper-catalyzed 
[3+2] Huisgen cycloaddition reaction to generate site-specific DPCs to the C5 of 
thymidine in DNA (Chapter 5). 
The final goal of this thesis was to investigate the replication bypass of DPCs. We 
employed gel electrophoresis and HPLC-ESI--HRMS and MS/MS methods to evaluate 
the efficiency and fidelity of polymerase bypass of model DPC substrates by human 
translesion synthesis (TLS) polymerases. Primer extension assays were conducted using 
the model DPCs prepared in Chapter 3 and 5 to investigate the effects of DPCs of varying 
size on DNA replication, while steady state kinetic studies were performed to assess the 
fidelity and efficiency of replication bypass (Chapters 4, 5 and 6). Further, we employed 
an affinity capture-HPLC-ESI--HRMS and MS/MS-based methodology to quantify and 
sequence the replication products of DPCs (Chapter 6) to examine the fidelity of        
post-lesion synthesis and to detect any insertion/deletion mutations caused by human 
TLS polymerases upon replication of DPCs. 
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BASE EXCISION REPAIR OF 
EXOCYCLIC 2'-DEOXYADENOSINE 
ADDUCTS OF 1,3-BUTADIENE 
2 BASE EXCISION REPAIR OF EXOCYCLIC 2'-DEOXYADENOSINE ADDUCTS OF 1,3-BUTADIENE 
2.1 INTRODUCTION 
1,3-butadiene (BD) is an important industrial and environmental chemical widely 
used in synthetic rubber and plastic industry and present in automobile exhaust, urban air, 
and cigarette smoke.25,45,49 Based on the results of epidemiological and toxicological 
studies, BD  is classified as a human carcinogen.62,88,355,356 BD is metabolically activated 
to DNA-reactive epoxides, 3,4-epoxy-1-butene (EB), 3,4-epoxybutan-1,2-diol (EBD) and 
1,2,3,4-diepoxybutane (DEB),70,81,95,97 which form an array of DNA lesions including 
DNA monoadducts,73-75 exocyclic lesions,78,79 DNA-DNA cross-links,80-82,84 and DNA-
protein cross-links.85,86 
Although the bulk of BD-DNA adducts are formed at the N7 position of 
guanine,357 BD lesions formed at adenine bases are of special interest because of the 
tendency of BD and its metabolites to cause a large number of AT and AG 
mutations.70,90,358-360. Multiple BD-adenine adducts have been identified.73,75,82,84 Among 
these are N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine (N6-HB-dA), 1,N6-(2-hydroxy-
3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (1,N6-HMHP-dA) and N6,N6-(2,3-
dihydroxybutan-1,4-diyl)-2'-deoxyadenosine (N6,N6-DHB-dA) (Scheme 2-1).75,78 N6-HB-
dA is formed upon alkylation of the N6 position of adenine in DNA by 3,4-epoxy-1-
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butene,75 while 1,N6-HMHP-dA and N6,N6-DHB-dA are induced by double alkylation of 
N6-adenine by 1,2,3,4-diepoxybutane.78   
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Scheme 2-1 Proposed mechanism for the formation of 1,3-butadiene-induced                
2'-deoxyadenosine adducts. 1,3-Butadiene (BD) is metabolized by cytochrome P450 
enzymes to 3,4-epoxy-3-butene (EB) and 1,2,3,4-diepoxybutane (DEB). N6 alkylation of 
2'-deoxyadenosine (dA) in DNA by EB generates N6-(2-hydroxy-3-buten-1-yl)-2'-
deoxyadenosine (N6-HB-dA), while N6 alkylation of dA by DEB produces                    
N6-(2-hydroxy-3,4-epoxybutan-1-yl)-2'-deoxyadenosine (N6-HEB-dA). N6 attack on the 
external carbon of the oxirane ring on N6-HEB-dA generates N6,N6-(2,3-dihydroxy-
butan-1,4-diyl)-2'-deoxyadenosine (N6,N6-DHB-dA). Alternatively, N1 attack on the 
internal carbon of the oxirane generates 1,N6-(2-hydroxy-3-hydroxymethylpropan-      
1,3-diyl)-2'-deoxy-adenosine (1,N6-HMHP-dA). 
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Primer extension studies with site- and stereospecific adducts have revealed that  
(R,S)-1,N6-HMHP-dA completely blocked DNA replication by human polymerase β 
(hPol β), while human translesion synthesis (TLS) polymerases η and κ were able to 
bypass the adduct, introducing T, A, or G opposite the lesion and inducing deletion 
mutations.112 Polymerase bypass of (R,R)-N6,N6-DHB-dA by both hPol β and TLS 
polymerases was extremely inefficient, and all four nucleotides were inserted with similar 
frequencies opposite the modified base.157 In contrast, (S)-N6-HB-dA was readily 
bypassed by all DNA polymerases examined (including hPol β) in an error-free 
fashion.157 Taken together, these results provide evidence for the cytotoxic and mutagenic 
potential of 1,N6-HMHP-dA and N6,N6-DHB-dA adducts. However, in order for BD-dA 
lesions to cause mutations, they have to persist long enough in cells to be replicated in an 
error-prone manner. Therefore, cellular repair of 1,N6-HMHP-dA and N6,N6-DHB-dA 
adducts should be investigated as it can define the biological fate of these adducts in vivo. 
In the present study, we investigated the ability of nuclear protein extracts from 
human cells and recombinant base excision repair (BER) enzymes to recognize and 
cleave site- and stereospecific BD-dA adducts: S-N6-(2-hydroxy-3-buten-1-yl)-2'-
deoxyadenosine (S-N6-HB-dA), R,S-1,N6-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-
2'-deoxyadenosine (R,S-1,N6-HMHP-dA) and R,R-N6,N6-(2,3-dihydroxybutan-1,4-diyl)-
2'-deoxyadenosine (R,R-N6,N6-DHB-dA) (Scheme 2-2A). We found that all three adducts 
were recognized and excised with efficiency comparable to other known BER substrates 
(1,N6-ethenoadenine, guanidinohydantoin and 5-fluorouracil, Scheme 2-2B), although 
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the specific BER enzyme(s) involved in recognition of BD-induced adducts remains to be 
identified. 
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Scheme 2-2 Structures and sequences of DNA lesions used in repair studies.                
(A) structures of novel BD-dA lesions studied in this work, (B) structures of known BER 
substrates used as positive controls in BER assays, (C) the sequences of 18-mer and     
11-mer DNA duplexes employed in gel electrophoresis-based assays, and (D) the 
sequences of adducted 18-mer and 11-mer DNA duplexes and corresponding repair 
products employed in mass spectrometry-based assays. 
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2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Protected 2'-deoxyribonucleoside-3'-phosphoramidites (PAC-dA-CE, Ac-dC-CE, 
p-iPr-PAC-dG-CE, dT-CE), 8-oxo-dG-CE, 1,N6-etheno-dA-CE and 5-fluoro-dC-CE 
phosphoramidites, Ac-dC-CPG ABI and p-iPr-PAC-dG-CPG ABI columns, and all other 
reagents necessary for automated DNA synthesis were purchased from Glen Research 
(Sterling, VA). 5′-O-(4,4′-dimethoxytrityl)-3′-O-(2-cyanoethyl)-N,N-diisopropyl-phosph-
oramidite of 6-chloropurine-2′-deoxyriboside was purchased from ChemGenes Corp. 
(Wilmington, MA). Synthetic DNA oligodeoxynucleotides were synthesized by solid 
phase synthesis using an ABI 394 DNA synthesizer (Applied Biosystems, CA).  E. coli 
mismatch uracil DNA-glycosylase (Mug) and human AP endonuclease were purchased 
from Trevigen (Gaithersburg, MD). T4 polynucleotide kinase (T4-PNK) was obtained 
from New England Biolabs (Beverly, MA), while γ-32P ATP was purchased from Perkin-
Elmer Life Sciences (Boston, MA). 40% 19:1 acrylamide/bis solution and micro bio-spin 
6 columns were purchased from Bio-Rad (Hercules, CA). Illustra NAP-5 desalting 
columns and Sep-Pak C18 SPE cartridges were obtained from GE Healthcare    
(Pittsburg, PA) and Waters (Milford, MA), respectively. All other chemicals and solvents 
were purchased from Sigma-Aldrich (Milwaukee, WI) and used without further 
purification. 
 82 
2.2.2 Preparation of Human Fibrosarcoma Nuclear Extracts 
Nuclear extracts were prepared as previously described.361 In brief, human 
fibrosarcoma cells (HT1080) were grown in Dulbecco’s modified Eagle’s media 
supplemented with 9% fetal bovine serum (Life Technologies, Grand Island, NY) in 150 
mm tissue culture dishes. Cells were cultured in a humidified atmosphere of 5% carbon 
dioxide and 95% air at 37 °C. HT1080 cells (30–50 million cells/dish) 
were collected from 15 confluent 150 mm tissue culture dishes, washed thrice with ice-
cold phosphate buffered saline, and resuspended in 2 mL of buffer A (10 mM Tris       
[pH 7.4] containing 10 mM KCl, 10 mM MgCl2, and 10 mM DTT). Following 15 min 
incubation on ice, phenylmethylsulfonyl fluoride (PMSF) was added to a final 
concentration of 1 mM, and the cells were mechanically disrupted by 20 strokes in a 
Dounce homogenizer (tight pestle). The released nuclei were sedimented and                 
resuspended in 2 mL buffer B (comprised of buffer A supplemented with 350 mM NaCl, 
1mM PMSF, 0.5 μg/ml leupeptin, 1.0 μg/ul aprotinin and 0.7 μg/ml pepstatin) and 
incubated for 60 min on ice. This material was centrifuged at 70,000 rpm in a Beckman 
TL-100.3 rotor at 4 °C for 30 min. Following the addition of glycerol and                       
β-mercaptoethanol to the final concentrations of 10% and 10mM, respectively, the extract 
was stored at -80 °C. The total protein concentration was measured using the Bradford 
assay (2–2.9 mg/mL). 
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2.2.3 Synthesis of Site-Specifically Modified DNA Substrates 
Synthetic oligodeoxynucleotides containing site- and stereospecific (S)-N6-HB-
dA, (R,S)-1,N6-HMHP-dA and (R,R)-N6,N6-DHB-dA lesions at position X (5'-TCA TXG 
AAT CCT TCC CCC-3' and 5'-CGG ACX AGA AG-3') were synthesized by the post-
oligomerization methodology developed by Tretyakova and coworkers.362 Briefly,   
(R,S)-1,N6-HMHP-dA adducted DNA strands were prepared by coupling (R,R)-N-Fmoc-
1-amino-2-hydroxy-3,4-epoxybutane with the oligomers containing site-specific             
6-chloropurine at position X. The resulting (R,R)-N6-(2-hydroxy-3,4-epoxybutan-1-yl)-
adenine containing oligodeoxynucleotides were isolated by HPLC and subjected to 
cyclization in water to afford the corresponding (R,S)-1,N6-HMHP-dA strands. The 
corresponding oligomers containing (S)-N6-HB-dA and (R,R)-N6,N6-DHB-dA adducts 
were prepared by carrying out nucleophilic aromatic substitution of 6-chloropurine 
containing DNA (on solid support) with (S)-N-Fmoc-1-aminobut-3-en-2-ol and         
(R,R)-pyrrolidine-3,4-diol, respectively. The modified oligodeoxynucleotides were 
cleaved off solid support using 0.1 M NaOH for 3 days at room temperature. DNA       
18-mer strands containing 5-flouro-dU, 8-oxo-dG and 1,N6-etheno-dA modifications at 
position X (positive controls for BER experiments) were prepared by solid phase 
synthesis using commercially available phosphoramidites (Glen Research, Sterling, VA). 
The modified base was added using offline manual coupling protocol. The 8-oxo-dG-
containing oligomer was subsequently oxidized with Na2IrCl6 to generate 
guanidinohydantoin.363 All DNA strands were purified by reversed phase high 
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performance liquid chromatography, characterized by liquid chromatography-mass 
spectrometry, and quantified by UV spectrophotometry as reported previously.362  
2.2.4 Preparation of Radiolabeled Double-Stranded Oligodeoxy-
nucleotides 
Single stranded oligodeoxynucleotides containing the modified bases (250 pmol, 
Scheme 2-2C) in water were radiolabeled by incubation with T4 PNK (3 μL) and γ-32P 
ATP (3 μL) at 37 °C for 60 min in PNK buffer (final volume = 20 μL). The reaction 
mixture was heated at 65 °C for 10 min to inactivate the enzyme and filtered through 
Illustra microspin G25 column (GE Healthcare, Pittsburgh, PA) to remove excess γ-32P 
ATP. The 5'-32P-labeled oligomers were mixed with 1–1.2 molar equivalents of the 
complementary strands in an annealing buffer (10 mM Tris [pH 7] containing 50 mM 
NaCl or 20 mM Tris-HCl [pH 7.6], 10 mM EDTA, and 150 mM NaCl), heated at 90 °C 
for 10 min, and allowed to cool slowly overnight to obtain double stranded DNA. 
2.2.5 Base Excision Repair Assays with Human Fibrosarcoma Nuclear 
Extracts 
Radiolabeled DNA duplexes containing site-specific BD-dA adducts (50 nM) 
were incubated at 37 °C in 10 mM HEPES (pH 7.4) buffer containing 100 mM KCl,       
1 mM EDTA, 1 mM EGTA and 0.1 mM DTT. For initial assays examining concentration 
dependence for repair, 0–12 μg of nuclear protein extract from human fibrosarcoma cells 
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were added. The repair reactions were conducted in a total volume of 20 μL and stopped 
after 2 h incubation by heating at 95 °C for 5 min.  
To observe time dependent repair, 25 μg of nuclear extract was added to 50 nM 
32P-endlabled adducted DNA in a total volume of 50 μL. Aliquots (10 μL) were 
withdrawn at 0, 15, 30, 75, 120, and 180 min, and quenched by the addition of 10 μL of 
gel loading buffer (20 mM EDTA in 95% formamide containing 0.05% bromophenol 
blue and 0.05% xylene cyanol).  
To establish a role of base excision repair in adduct removal, DNA duplexes were 
pre-incubated with a known BER inhibitor, methoxyamine (MX, 3 mM) in the reaction 
buffer at room temperature for 60 min prior to the addition of the nuclear extract, 
followed by time dependent repair assay as described above. 
2.2.6 Base Excision Repair Assays Using Recombinant Enzymes 
Glycosylase assays were performed under single-turnover (STO) conditions by 
incubating 10–20 nM 32P-endlabeled double-stranded DNA substrates with 10–200-fold 
excess of the enzyme at 37 °C in a final volume of 20 μL. The assay buffer contained    
20 mM Tris-HCl (pH 7.6), 10 mM EDTA, 100 μg/mL BSA, while the experiments using 
edited or unedited hNEIL1 included 60 mM NaCl. The AAG reaction buffer was 20 mM 
Tris-HCl buffer (pH 7.8) containing 100 mM KCl, 5 mM β-mercaptoethanol, 2 mM 
EDTA, 1 mM EGTA, and 50 μg/mL BSA. Manufacturer provided reaction buffer was 
used for Mug (Trevigen, Gaithersburg, MD). Reactions were allowed to go for 60 min 
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and quenched by the addition of NaOH to a final concentration of 0.2 M. The solutions 
were heated at 90 °C for 5 min and then placed on ice until ready to load on a gel.  
For selected enzymes (AAG, NEIL1 and Mug), strand breaks were initiated using 
AP endonuclease. In these cases, repair reactions were conducted for 60 min, followed by 
heating at 90 °C for 5 min and cooling to room temperature. Human AP endonuclease 
(0.5 units, Trevigen, Gaithersburg, MD) was added, and the mixtures were incubated at 
37 °C in commercial reaction buffer for 60 min, followed by heating at 90 °C for 5 min. 
Samples were placed on ice until analysis.  
2.2.7 Monitoring Base Excision Repair by Gel Electrophoresis 
For gel electrophoresis separations, reaction mixtures were mixed with formamide 
denaturing dye (80% formamide, 0.025% xylene cyanol, 0.025% bromophenol blue in 
TBE running buffer) or gel loading buffer (20 mM EDTA in 95% formamide containing 
0.05% bromophenol blue and 0.05% xylene cyanol) immediately prior to loading on to a 
denaturing PAGE gel. 
Method 1: Samples were loaded onto a 15% denaturing polyacrylamide gel      
pre-ran in TBE running buffer (89 mM Tris, 89 mM boric acid, and 2 mM EDTA) and 
run at 1200 V for 2 hours. Radiolabeled DNA fragments were visualized using 
autoradiography by exposure to a storage phosphor screen overnight.  Gels were imaged 
using storage phosphor autoradiography, and the bands were visualized using GraFit 5.0 
(Erithacus Software Ltd., Horley, Surrey, UK). 
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Method 2: A 20 % denaturing polyacrylamide gel containing 7 M urea was      
pre-run at a constant power of 15 W for 30 min in TBE running buffer. The samples from 
repair experiments in gel loading buffer were loaded onto the gel and ran at a constant 
power of 15 W at ambient temperature. Radiolabeled 18-mer DNA strands and               
5′ excision products were detected on a Typhoon FLA 7000 (GE Healthcare, Pittsburgh, 
PA). The extent of repair was evaluated by volume analysis using ImageQuant TL 8.0 
(GE Healthcare, Pittsburgh, PA). The rate constants were calculated by fitting the percent 
DNA remaining vs. time plots to first order rate equation using Origin 9.1 software 
(OriginLab Corp., Northampton, MA). 
2.2.8 Analysis of Base Excision Repair by Liquid Chromatography-
Tandem Mass Spectrometry 
For mass spectrometry experiments, repair assays were performed using 10 μM 
unlabeled adducted DNA duplexes (Scheme 2-2D) in 10 mM HEPES (pH 7.4) buffer 
containing 100 mM KCl, 1 mM EDTA, 1 mM EGTA and 0.1 mM DTT in a total volume 
of 20 μL. Following the addition of nuclear protein extract (5 μg), the reaction mixtures 
were incubated at 37 °C for 3 h. Samples were subjected to solid phase extraction using 
Sep-Pak C18 cartridges (100 mg/1mL) according to the manufacturer suggested protocol 
(Waters, Milford, MA). SPE fractions containing DNA (70% methanol elutions) were 
dried in vacuo and reconstituted in water (20 μL) prior to HPLC-ESI--MS/MS analysis. 
Capillary HPLC-ESI--MS/MS analysis was performed on an Agilent 1100 
capillary HPLC-ion trap mass spectrometer (Agilent Technologies, Inc., Santa Clara, 
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CA). Liquid chromatography was performed on a Zorbax SB-C18 column (150 mm ×  
0.5 mm, 5 μm, Agilent Technologies, Inc., Santa Clara, CA). The column was eluted at a 
flow rate of 15 μL/min using a gradient of 15 mM ammonium acetate (A) and acetonitrile 
(B). The column temperature was maintained at 25 °C. The solvent composition was 
changed linearly from 0 to 20% B over 20 min, then to 80% B over 2 min, kept at 80% B 
for further 2 min, and decreased to 0% B in 1 min. The mass spectrometer was operated 
in the ESI- mode with target ion abundance value set to 50000, and the maximum 
accumulation time was 300 ms. In a typical experiment, 6–10 average scans were taken 
in the mass range of m/z 200–1600. Nitrogen was used as a nebulizing gas (15 psi) and a 
drying gas (5 L/min, 200 °C), while electrospray ionization was achieved at a spray 
voltage of 3–3.5 kV. The identities of the expected 5' excision products were confirmed 
by comparing their MS/MS spectra to experimental MS/MS spectra of synthetic 
standards (5'-TCA T-3' and 5'-CGG AC-3') and theoretical fragmentation patterns from 
Mongo oligo mass calculator version 2.06 (The RNA Institute, College of Arts and 
Sciences, State University of New York at Albany). 
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2.3 RESULTS  
2.3.1 Synthesis, Purification and Characterization of Adducted DNA 
Oligodeoxynucleotides 
Two DNA sequences were selected for the present study. DNA 11-mer,              
5'-C GGA CXA GAA G-3', was derived from the human N-ras proto-oncogene, with 
BD-dA adducts (X) inserted at the second position of the N-ras codon 61.364 The 
sequence of the DNA 18-mer, 5'-TCA TXG AAT CCT TCC CCC-3' (X = BD-dA 
adduct), was engineered to be used in future in vitro polymerase bypass assays. A post-
oligomerization methodology was used to generate synthetic DNA oligonucleotides 
containing site-specific (S)-N6-HB-dA, (R,R)-N6,N6-DHB-dA, or (R,S)-1,N6-HMHP-dA 
(Scheme 2-3).362 In this approach, which was originally introduced by Harris et al.,365 the 
inherent electrophilic-nucleophilic functionalities of a carcinogen and a DNA nucleobase 
are reversed (Scheme 2-3). Solid phase synthesis with commercial 6-chloropurine-        
2'-deoxyribose phosphoramidite (ChemGenes Corp., Wilmington, MA) was used to site-
specifically incorporate a 6-chloropurine moiety at position X (5'-TCA TXG AAT CCT 
TCC CCC-3' and 5'-C GGA CXA GAA G-3'). Synthons representing 1,3-butadiene 
derived side chains conjugated to an amino group were synthesized by previously 
reported methods [(S)-N-Fmoc-1-aminobut-3-en-2-ol and (R,R)-N-Fmoc-1-amino-         
2-hydroxy-3,4-epoxybutane]78 or hydrogenation of commercially obtained (3R,4R)-       
1-benzyl-3,4-pyrrolidinediol (Sigma-Aldrich, Milwaukee, WI). Nucleophilic aromatic 
substitution (SNAr) reactions were carried out at position X on synthetic DNA to displace 
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the chloro group of 6-chloropurine with the amine-functionalized synthon to generate the 
corresponding regio- and stereospecifically modified oligomers (Scheme 2-3).362 In the 
case of (R,S)-1,N6-HMHP-dA adducts, an additional cyclization step is required 
following SNAr coupling between (R,R)-N-Fmoc-1-amino-2-hydroxy-3,4-epoxybutane 
and 6-chloropurine containing DNA (Scheme 2-3).362 In order to avoid multiple HPLC 
purifications and to maximize the yield, (S)-N-Fmoc-1-amino-3-buten-2-ol and        
(R,R)-pyrrolidine-3,4-diol were coupled to 6-chloropurine containing oligomers on solid 
support to generate site- and stereospecific (S)-N6-HB-dA and (R,R)-N6,N6-DHB-dA 
lesions, respectively (Scheme 2-3). All structurally modified DNA oligomers were 
purified by reversed phase HPLC and characterized by capillary HPLC-ESI--MS,   
HPLC-UV and ESI+-MS3 analyses of enzymatic digests, and MALDI-TOF-MS of 
controlled exonuclease digests to ensure their identity and purity (Figure 2-1). HPLC 
pure oligomers were quantified by UV spectrophotometry. 
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Scheme 2-3 Synthesis of site- and stereospecific oligodeoxynucleotides containing     
1,3-butadiene-induced 2'-deoxyadenosine adducts using a post-oligomerization 
approach.£ 
 
 
 
 
 
 
 
                                                 
£ (a) solid phase synthesis, (b) DIPEA, DMSO, 60 °C, 24 h, (c) i. 0.1 M NaOH, rt, 3 d, ii. DIPEA, DMSO, 37 °C, 24 h, 
(d) DIPEA, DMSO, 37 °C, 72 h, (e) H2O, rt, 3h, (f) 0.1 M NaOH, rt, 3d.	
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Figure 2-1 Mass spectrometry-based characterization of 1,3-butadiene-induced 2'-deoxy-
adenosine adducts: a representative capillary HPLC-ESI--MS spectrum of 18-mer        
(S)-N6-HB-dA (A), ESI+-MS3 spectrum (B) and HPLC-UV trace (C) of enzymatic digests 
of 18-mer (R,R)-N6,N6-DHB-dA, and MALDI-TOF-MS spectra of controlled 
exonuclease digests of 11-mer (R,S)-1,N6-HMHP-dA (D and E). 
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Site-specific 18-mer oligodeoxynucleotides containing 5-flouro-dU, guanidino-
hydantoin, and 1,N6-etheno-dA modifications (Scheme 2-2B) were employed as positive 
controls as they are known substrates of mismatch uracil DNA glycosylase (MUG),366 
NEIL1,367 and alkyl adenine DNA glycosylase (AAG),126 respectively. Synthetic DNA 
containing 5-flouro-dU, 8-oxo-dG and 1,N6-etheno-dA were prepared by solid phase 
synthesis. 8-oxo-dG was oxidized with Na2IrCl6 to generate guanidinohydantoin 
adducted DNA as reported elsewhere.363 All DNA strands were purified by reversed 
phase high performance liquid chromatography, characterized by liquid chromatography-
mass spectrometry (Table 2-1), and quantified by UV spectrophotometry. 
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Table 2-1 Capillary HPLC-ESI--MS characterization of synthetic DNA oligomers. 
Oligodeoxynucleotide sequence 
Molecular weight/kDa 
Calculated Observed 
5'-TCA TXG AAT CCT TCC CCC-3'; X = 6-Cl-Pu 5373.4 5373.5 
5'-TCA TXG AAT CCT TCC CCC-3'; X = S-N6-HB-dA 5424.5 5424.2 
5'-TCA TXG AAT CCT TCC CCC-3'; X = R,S-1,N6-HMHP-dA 5440.5 5440.3 
5'-TCA TXG AAT CCT TCC CCC-3'; X = R,R-1,N6-DHB-dA 5440.5 5440.1 
5'-TCA TXG AAT CCT TCC CCC-3'; X = 1,N6-εdA 5378.5 5378.9 
5'-TCA TYG AAT CCT TCC CCC-3'; Y = 8-oxo-dG 5386.5 5386.1 
5'-TCA TYG AAT CCT TCC CCC-3'; Y = Gh 5376.5 5376.5 
5'-TCA TZG AAT CCT TCC CCC-3'; Z = 5F-dU 5349.4 5349.0 
5'-GGG GGA AGG ATT CTA TGA-3' 5643.7 5643.4 
5'-GGG GGA AGG ATT CCA TGA-3' 5628.7 5628.6 
5'-GGG GGA AGG ATT CAA TGA-3' 5652.8 5652.2 
5'-C GGA CXA GAA G-3'; X = 6-Cl-Pu 3418.2 3418.1 
5'-C GGA CXA GAA G-3'; X = R,S-1,N6-HMHP-dA 3485.2 3485.0 
5'-C TTC TTG TCC G-3' 3274.1 3273.8 
5'-TCA T-3' 1148.2 1148.2 
5'-CGG AC-3' 1487.3 1487.1 
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2.3.2 Base Excision Repair of 1,3-Butadiene-Induced 2'-Deoxyadenosine 
Adducts Using Human Fibrosarcoma Nuclear Extracts 
To determine whether the BD-dA adducts can be recognized by base excision 
repair mechanism, radiolabeled 18-mer duplexes (32P-5'-TCA TXG AAT CCT TCC 
CCC-3') containing site- and stereospecific (R,S)-1,N6-HMHP-dA, (S)-N6-HB-dA and 
(R,R)-N6,N6-DHB-dA at position X were incubated with nuclear protein extracts from 
human fibrosarcoma (HT1080) cells. Repair reactions were resolved on a 20% denaturing 
polyacrylamide gel, and the percentage of the excision product (5'-TCA T-3') was 
calculated by volume analysis. We found that all three BD-dA adducts used in this study 
were excised in a concentration dependent manner, with up to 90% excision observed in 
the presence of 12 μg of the extract (Figure 2-2).  
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Figure 2-2 Concentration dependent repair of 1,3-butadiene-induced 2'-deoxyadenosine 
adducts by human fibrosarcoma nuclear extracts. 50 nM 32P-endlabeled 18-mer DNA  
(5'-TCA TXG AAT CCT TCC CCC-3') duplexes were incubated in 10 mM HEPES    
(pH 7.4), 100 mM KCl, 1 mM EDTA, 1 mM EGTA and 0.1 mM DTT with increasing 
amounts of HT1080 nuclear extracts at 37 °C for 2 h. Samples were resolved on a 20% 
denaturing PAGE gel and visualized by phosphorimaging. (A) A representative PAGE 
gel for concentration dependent incision of 18-mer containing (R,S)-1,N6-HMHP-dA, and 
(B) volume analysis showed increasing amounts of incision products for BD-dA 
adducted dsDNA with increasing amounts of nuclear extract. 
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To investigate the kinetics of repair of BD-dA adducts by human nuclear proteins, 
the same radiolabeled duplexes were incubated with HT1080 nuclear extracts, and the 
reactions were quenched at pre-selected time points. The cleavage products were 
analyzed by phosphorimaging following separation on a denaturing urea PAGE gel 
(Figure 2-3A). The repair assay was conducted in triplicate, and percent repair was 
calculated by volume analysis. We found that all three BD-dA adducts were repaired 
efficiently by human nuclear extracts (Figure 2-3B–D, solid lines). First order rate 
constants (Table 2-2 and Figure 2-4A) revealed that the efficiency of repair decreased in 
the order of (S)-N6-HB-dA > (R,R)-N6,N6-DHB-dA > (R,S)-1,N6-HMHP-dA (0.0208, 
0.0152 and 0.0119 min-1, respectively). The extent and the rate of repair were decreased 
significantly in the presence of a known BER inhibitor, methoxyamine (Figure 2-3B–D, 
dotted lines). First order rate constants were ~3–8-fold smaller in the presence of the 
inhibitor (Table 2-2). Interestingly, the extent of inhibition was greater for                
(R,S)-1,N6-HMHP-dA (~5-fold) and (R,R)-N6,N6-DHB-dA (~8-fold) as compared to    
(S)-N6-HB-dA (~3-fold) (Table 2-2 and Figure 2-3). 
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Figure 2-3 Time dependent repair of 1,3-butadiene-induced 2'-deoxyadenosine adducts 
by human fibrosarcoma nuclear extracts: a representative PAGE gel of incision of 18-mer 
(5'-TCA TXG AAT CCT TCC CCC-3') containing (R,S)-1,N6-HMHP-dA (A), time 
dependent incision of 18-mers containing (S)-N6-HB-dA (B), (R,S)-1,N6-HMHP-dA (C), 
(R,R)-N6,N6-DHB-dA (D) in the presence (dotted lines) and absence (solid lines) of BER 
inhibitor, methoxyamine. 50 nM 32P-endlabeled dsDNA 18-mers were incubated with  
0.5 μg/μL nuclear extract in 10 mM HEPES (pH 7.4), 100 mM KCl, 1 mM EDTA, 1 mM 
EGTA and 0.1 mM DTT at 37 °C. Aliquots of the reaction mixture were quenched at 
preselected time points, samples were resolved on a 20% denaturing PAGE gel and 
visualized by phosphorimaging. Volume analysis showed increasing amounts of incision 
products with increasing incubation time (n = 3). 
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Table 2-2 First order rate constants observed for the repair of 1,3-butadiene-induced     
2'-deoxyadenosine adducts and known BER substrates by human fibrosarcoma nuclear 
extracts.€ 
DNA adduct BER inhibitor (MX) Rate constant ± SE/min-1 
(S)-N6-HB-dA  0.0208±0.0034 
(S)-N6-HB-dA  0.0064±0.0002 
(R,S)-1,N6-HMHP-dA  0.0119±0.0013 
(R,S)-1,N6-HMHP-dA  0.0024±0.0004 
(R,R)-N6,N6-DHB-dA  0.0152±0.0009 
(R,R)-N6,N6-DHB-dA  0.0020±0.0002 
8-oxo-dG  0.0275±0.0061 
5-F-dU  0.0119±0.0004 
 
 
 
 
 
 
 
 
                                                 
€	SE = standard error.	
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Figure 2-4 Repair of 1,3-butadiene-induced 2'-deoxyadenosine adducts and known BER 
substrates by human fibrosarcoma nuclear extracts. Percent DNA remaining was plotted 
against time and data were fitted to the first order rate equation to calculate the rate 
constants. (A) Repair of (R,R)-N6,N6-DHB-dA in the presence and absence of BER 
inhibitor, methoxyamine (MX) and (B) repair of known BER substrates.¥ 
 
 
 
                                                 
¥	dA showed cooperative binding, hence data cannot be fitted to a first order rate equation.	
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To compare the efficiency of BER of the BD-dA adducts by human fibrosarcoma 
nuclear extracts to that of known BER substrates, we have prepared DNA duplexes 
containing  1,N6-etheno-dA (a known AAG substrate),126 5-fluoro-dU (a known MUG 
substrate),366 and 8-oxo-dG (a known OGG1 substrate).368 Repair reactions were 
conducted the same way as for BD-dA adducts. We found that BD-dA adducts were 
repaired with similar efficiency as compared to known BER substrates (Figure 2-5). 
According to the first order rate constants (Table 2-2 and Figure 2-4B), all three BD-dA 
adducts were repaired 1–1.7-fold faster as compared to 5F-dU, while the rates were    
1.3–2.3-fold slower with respect to 8-oxo-dG. Since εdA showed cooperative binding 
(percent DNA remaining vs. time plot yielded a sigmoidal curve),369 it was not 
considered for rate comparisons (Figure 2-4B). 
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Figure 2-5 Comparison of repair rates of 1,3-butadiene-induced 2'-deoxyadenosine 
adducts against known BER substrates in human fibrosarcoma nuclear extracts. 50 nM 
32P-endlabeled dsDNA 18-mers were incubated with 0.5 μg/μL nuclear extract in 10 mM 
HEPES (pH 7.4), 100 mM KCl, 1 mM EDTA, 1 mM EGTA and 0.1 mM DTT at 37 °C. 
Aliquots of the reaction mixture were quenched at preselected time points, the samples 
were resolved on a 20% denaturing PAGE gel and visualized by phosphorimaging. 
Volume analysis showed increasing amounts of incision products with increased 
incubation time (n = 2). 
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2.3.3 Analysis of Base Excision Repair by Liquid Chromatography-
Tandem Mass Spectrometry 
A capillary HPLC-ESI--MS/MS methodology was used to further confirm the 
mechanism of base excision repair of BD-dA lesions. Following incubation of BD-dA 
containing 18-mers (5'-TCA TXG AAT CCT TCC CCC-3') with nuclear extracts from 
HT1080 cells, the reaction mixtures were purified by solid phase extraction and subjected 
to HPLC-ESI--MS/MS analysis. Tandem mass spectrometry employing collision-induced 
dissociation was used to sequence the oligonucleotide products. The expected BER 
excision product, (5'-TCA T-3') was observed for all three BD-dA adducts             
(Figure 2-6A–C). Similar results were obtained for repair reactions of unlabeled 11-mers 
containing (R,S)-1,N6-HMHP-dA (5'-C GGA CXA GAA G-3'). HPLC-MS/MS analysis 
confirmed the generation of the 5' excision product, 5'-CGG AC-3' under the assay 
conditions (Figure 2-6D). These mass spectrometry results corroborate the gel 
electrophoresis data in Figure 2-3, confirming that BD-dA adducts can be efficiently 
recognized by the BER mechanism in human cells. 
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Figure 2-6 Liquid chromatography-tandem mass spectrometry analysis of repair products 
of 1,3-butadiene-induced 2'-deoxyadenosine adducts by human fibrosarcoma nuclear 
extracts. Collision induced dissociation (CID) spectra of the 5' excision products of      
18-mers containing (S)-N6-HB-dA (A), (R,S)-1,N6-HMHP-dA (B), (R,R)-N6,N6-DHB-dA 
(C), and 11-mer containing (R,S)-1,N6-HMHP-dA (D). 
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2.3.4 Activity of Recombinant BER Glycosylases against BD-dA Adducts 
In an attempt to identify specific BER glycosylases involved in repair of BD-dA 
adducts, the glycosylase activity of 12 human and bacterial recombinant BER enzymes 
on site-specifically modified substrates was evaluated under single-turnover conditions 
(STO, enzyme concentration > DNA substrate concentration, Figures 2-7 and 2-8). We 
employed human AAG, Mpg, edited and unedited NEIL1 and OGG1, as well as six       
E. coli enzymes EndoIII, Fpg, Mug, MutY, MutYH and Nei, and Archaeoglobus fulgidus 
glycosylase, UDG. Although these glycosylases were active against their known 
substrates (results not shown), they showed no activity towards (R,S)-1,N6-HMHP-dA, 
(R,R)-N6,N6-DHB-dA, and (S)-N6-HB-dA (Figure 2-7). No cleavage was detected even 
when using 100–200-fold excess of AAG, NEIL1, Fpg and Mug or when incubating the 
reaction mixtures with AP endonuclease to maximize the formation of cleaved products 
(Figure 2-8). These results confirm that the BER enzymes tested here are not responsible 
for repairing BD-dA lesions. 
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Figure 2-7 Base excision repair of 1,3-butadiene-induced 2'-deoxyadenosine adducts by human and bacterial BER enzymes. Repair of 
18-mers containing (R,R)-N6,N6-DHB-dA (A) and (S)-N6-HB-dA (B), and 11-mer containing (R,S)-1,N6-HMHP-dA (C). 20 nM      
32P-endlabeled dsDNA substrates were incubated at 37 °C with 200 nM enzymes in 20 mM Tris-HCl (pH 7.6), 10 mM EDTA,        
100 μg/mL BSA (buffer solution for hNEIL1 included 60 mM NaCl). After 60 min, reactions were quenched by the addition of 
NaOH, samples were resolved on a 20% denaturing PAGE gel and visualized by phosphorimaging. 
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Figure 2-8 Base excision repair of 1,3-butadiene-induced 2'-deoxyadenosine adducts by 
recombinant glycosylases: a representative PAGE gel of the repair assay in the presence 
of human alkyladenine DNA glycosylase (AAG). 10 nM 32P-endlabeled synthetic DNA 
duplexes containing BD-dA adducts were incubated with 2 μM AAG in a buffered 
solution containing 20 mM Tris-HCl buffer (pH 7.8), 100 mM KCl, 5 mM β-mercapto-
ethanol, 2 mM EDTA, 1 mM EGTA and 50 μg/mL BSA at 37 °C for 60 min. The 
reaction mixtures were incubated with human AP endonuclease (0.5 units) for another      
60 min. Samples were resolved on a 20% denaturing PAGE gel and visualized by 
phosphor autoradiography. Although 1,N6-etheno-dA, a known substrate of AAG was 
repaired (lane 1–2), none of the BD-dA adducts were recognized by the enzyme        
(lane 3–8). 
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2.4 DISCUSSION 
The integrity and stability of genomic DNA is essential for life since DNA is the 
repository of hereditary information in cells.1-3 DNA is not chemically inert, but 
possesses multiple reactive sites that can be modified by various chemical and physical 
agents resulting in damaged DNA.1,3,6 Multiple cellular DNA damage response 
mechanisms have evolved to rescue the living cells from DNA modifications.1,135           
A number of DNA repair pathways operate in eukaryotic systems including direct repair,1 
mismatch repair (MMR),1,7,121 base excision repair (BER),1,6,121 nucleotide excision repair 
(NER),1,116,118,121 homologous recombination (HR)1,119 and non-homologous end joining 
(NHEJ) (see section 1.3.1).1,120 Adduct size and shape, the extent of helix distortion and 
thermodynamic destabilization can influence the mechanisms of repair.1,121 
In the present study, we have focused on the ability of human cells to recognize 
and repair three deoxyadenosine adducts induced by 1,3-butadiene: the monoadduct, N6-
(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine (N6-HB-dA)370 and two exocyclic adducts, 
1,N6-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (1,N6-HMHP-dA) 
and N6,N6-(2,3-dihydroxybutan-1,4-diyl)-2'-deoxyadenosine (N6,N6-DHB-dA).362 Our 
previous circular dichroism (CD) studies suggested that DNA duplexes containing the 
three adducts maintain B-type DNA conformation.362 NMR studies of (R,R)- and (S,S)-
N6,N6-DHB-dA-containing DNA duplexes have revealed that the adduct is 
accommodated in the major groove of DNA. The modified nucleotide exists in the     
anti-conformation around the glycosidic bond, and with an out-of-plane rotation around 
the C6-N6 bond to accommodate the bulky 3,4-dihydroxypyrrolidine moiety.371 This 
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orientation of the adducted adenine disrupts the stacking interactions of both the adduct 
and its base pair with the neighboring 5' and 3' nucleotides.371 Further, bis-alkylation of 
N6 of adenine prevents hydrogen bonding with the thymidine in the opposite strand.371 
The (S)-N6-HB-dA adduct was also positioned in the major groove such that the             
2-hydroxy-3-butenyl moiety is oriented in the 3' direction with the anti-conformation 
around the glycosidic bond.372 Only minor perturbations in stacking or hydrogen bonding 
interactions were observed.372 These structural data suggests that NER mechanism, which 
recognizes bulky and helix distorting lesions may not be the major repair pathway 
responsible for recognizing these BD-dA adducts. However, the significant lowering of 
the melting temperatures of the BD-dA adducts placed opposite the correct base, 
thymidine suggests that the adducted DNA duplexes are thermodynamically destabilized. 
In addition, when these adducts were mispaired with adenine, the melting studies showed 
considerable stability in comparison to A:d mismatch.362,370 This can possibly mean that 
these adducts can be repaired or replicated in an error-prone manner leading to mutations. 
Moreover, relatively mild effects of these adducts on DNA structure as revealed by NMR 
studies and their ability to destabilize DNA duplex observed in thermal melting studies 
suggest that BER can be responsible for the removal of these lesions. 
Herein, we investigated the ability of BER to recognize and excise three BD-dA 
adducts: (S)-N6-HB-dA, (R,S)-1,N6-HMHP-dA and (R,R)-N6,N6-DHB-dA. We 
incorporated the 2'-deoxyadenosine adducts of interest site- and stereospecifically into 
synthetic DNA oligomers using solid phase DNA synthesis and post-oligomerization 
approach. Gel electrophoresis-based repair assays conducted using human fibrosarcoma 
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(HT1080) nuclear extracts have revealed that all three adducts were efficiently 
recognized and processed by BER pathway (Figure 2-3). The assay was designed such 
that the initial cleavage of the modified nucleobase by a BER glycosylase, and 
subsequent excision of the apurinic/apyrimidinic (AP) site by AP endonuclease (APE) 
can be detected using 5'-radiolabeled DNA. Inhibitor assays performed using a known 
BER inhibitor, methoxyamine (MX) have shown 50–75% reduction in repair, when 
compared to the assays conducted in the absence of the inhibitor. MX is a small molecule 
that binds to the AP site generated, when the adducted nucleobase is excised by a BER 
glycosylase, to form a Schiff base.373,374 We also employed a liquid chromatography-
tandem mass spectrometry assay to sequence the 5' excision products (Figure 2-6). We 
were able to detect the excision products under two different DNA sequence contexts, 
confirming that BER is responsible for the repair of these BD-dA adducts. However, our 
efforts to identify the glycosylases involved in removal of these lesions were not fruitful. 
We tested 12 human and bacterial BER glycosylases under single-turnover (STO) 
conditions. Yet, none of them showed any activity towards the adducts of interest 
(Figures 2-7 and 2-8). Currently, a mass spectrometry-based proteomics methodology is 
being developed in our laboratory to identify the individual glycosylases responsible for 
the repair of these BD-dA adducts. 
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SYNTHESIS OF SEQUENCE-SPECIFIC 
DNA-PROTEIN CONJUGATES CROSS-
LINKED TO 7-DEAZAGUANINE VIA A 
REDUCTIVE AMINATION STRATEGY 
3 SYNTHESIS OF SEQUENCE-SPECIFIC DNA-PROTEIN CONJUGATES CROSS-LINKED TO 7-DEAZAGUANINE VIA A REDUCTIVE AMNATION STRATEGY 
Reproduced in part with permission from Susith Wickramaratne, Shivam Mukherjee, Peter W. Villalta, 
Orlando D. Schärer, and Natalia Y. Tretyakova. Bioconjugate Chem., 2013, 24 (9), 1496–1506. ©American 
Chemical Society. 
3.1 INTRODUCTION 
Exposure to common antitumor drugs,158,159,294 environmental toxins,85,86,244 
transition metals, 211,213,214 UV light,259 ionizing radiation,160 and free radical-generating 
systems164,182,184 can result in cellular proteins becoming covalently trapped on DNA.4 
The resulting DNA-protein cross-links (DPCs) are unusually bulky, structurally diverse, 
and highly heterogeneous DNA lesions involving proteins of varying size, 
hydrophobicity, and cellular functions.4,5,85,158 Mass spectrometry-based studies 
performed by Tretyakova and coworkers have revealed that a wide range of proteins can 
become covalently bound to genomic DNA upon treatment of human cells with clinically 
relevant concentrations of chemotherapeutic drugs (cisplatin and mechlorethamine) and 
metabolically activated carcinogens such as 1,2,3,4-diepoxybutane.85,86,158 Some 
examples of the participating proteins include HSP 90, tubulins, DNA helicases, PCNA, 
Fen-1, Ku70, Ku86, Ref-1, PARP, and DNA polymerase δ.85,158 MS/MS sequencing has 
shown that DNA-protein cross-linking is non-random, with specific amino acid side 
chains (cysteine, lysine, histidine, or arginine) participating in covalent conjugate 
3 
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formation to the N7 position of guanine in DNA (Scheme 3-1).85,158,161 DPCs have been 
shown to accumulate in the brain and heart tissues with age.36,37,167,181,198,234,250,251,308 
Recent studies with laboratory mice deficient in the Fanconi Anemia DNA repair 
pathway have implicated DPC formed by formaldehyde in the observed cellular 
toxicity.306,307 
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Scheme 3-1 Structures of DNA-protein cross-links induced by bis-electrophiles.            
N-[2-(guan-7-yl)ethyl]alkylamine adducts formed by mechlorethamine (A); 4-(guan-     
7-yl)-2,3-butanediol adducts formed by 1,2,3,4-diepoxybutane (B), and 1,1-cis-
diammine-2-alkylamino-2-(2'-deoxyguanosine-7-yl)-platinum(II) adducts induced by 
cisplatin (C). 
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Due to their enormous size as compared to other DNA lesions, DPCs are believed 
to compromise genetic stability and cellular viability by interfering with normal DNA-
protein interactions required for DNA replication, transcription, and repair.4 We have 
recently engineered protein monoepoxide agents that specifically induce chromosomal 
DPCs, when electroporated in to cells.304 These DNA-reactive proteins induced 
significant levels of mutations and toxicity when introduced into human cells,304 probably 
because of the ability of the resulting DPCs to block DNA replication, transcription, and 
repair. However, relatively little is known about the influence of DPC adducts on DNA 
and RNA polymerases or their repair mechanisms in mammalian cells. Consequently, 
there is a pressing need to examine DNA replication and transcription using site-specific 
DPC lesions and to identify DNA repair mechanisms responsible for their removal in 
mammalian cells. 
Any mechanistic investigations of the biological effects of DPC lesions in human 
cells require the availability of structurally defined DNA substrates containing DPC 
lesions at a specified site of DNA. However, the access to such DPC substrates has been 
limited due to the synthetic challenge of covalently linking two complex biomolecules 
(DNA and proteins) in a site-specific manner. Previously, model DPCs have been 
generated by covalently trapping various enzymes on their DNA substrates. For example, 
the Schiff base intermediate produced between T4 pyrimidine dimer glycosylase/AP 
lyase (T4-pdg) and apurinic/apyrimidinic site of DNA can be reduced to form a stable 
T4-pdg-DNA conjugate.324 A disulfide trapping strategy was used to attach N149C 
mutant of human 8-oxoguanine DNA glycosylase I (hOGG1) protein to a DNA duplex 
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containing alkanethiol tether at the N4 position of cytosine.347 DNA methyltransferase 
has been cross-linked to C6 position of 5-azacytosine.331 More recently, a reductive 
amination strategy was used to generate DNA-protein/peptide conjugates by the reaction 
of the N2-guanine aldehyde functionality derived from acrolein-induced 3-(2'-deoxyrobo-
1'-syl)-5,6,7,8-tetrahydro-8-hydroxypyrimido[1,2a]purin-10(3H)-one (-HOPdG) with 
proteins and peptides.246,336  
The most common site of DNA involved in DPC formation following treatment 
with bis-electrophiles is the N7 of guanine (Scheme 3-1).85,158,159,294 However, to our 
knowledge, no methods exist in the literature to generate N7 guanine conjugated DPCs. 
One formidable obstacle in accomplishing this goal is that N7 guanine alkylation 
destabilizes the β-glycosidic bond of the modified nucleoside, leading to spontaneous 
depurination.375 In the present study, we have developed a new methodology to create 
hydrolytically stable structural mimics of N7 guanine conjugated DPCs by reductive 
amination reactions between the Lys and Arg side chains of proteins and acetaldehyde 
functionalities of the modified 7-deazaguanine residues within DNA. The resulting model 
DPCs are structurally analogous to N7 guanine adducts generated by antitumor nitrogen 
mustards, 1,2,3,4-diepoxybutane (Scheme 3-1) and chlorooxirane.85,158,161,376 
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3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Synthetic oligodeoxynucleotides containing 7-deaza-7-(2,3-dihydroxypropan-    
1-yl)-2'-deoxyguanosine (deaza-DHP-dG) and deaza-DHP-dG nucleoside were prepared 
as previously described.377 Fluorescein-dT phosphoramidite, protected 2'-deoxyribo-
nucleoside-3'-phosphoramidites (dA-CE, Ac-dC-CE, dmf-dG-CE, dT-CE), Ac-dC-CPG 
ABI, dmf-dG-CPG ABI columns, and all other reagents required for automated DNA 
synthesis were purchased from Glen Research (Sterling, VA). Synthetic DNA 
oligonucleotides were synthesized by solid phase synthesis using an ABI 394 DNA 
synthesizer (Applied Biosystems, CA). All solvents and chemical reagents were obtained 
from commercial sources and used without further purification. 
3.2.2 Preparation of Radiolabeled DNA Duplexes 
Single stranded oligodeoxynucleotides 5'-G TCA CTG GTA deaza-DHP-dGCA 
AGC ATT G-3' and 5'-C AGT GAC CAT Cdeaza-DHP-dGT TCG TAA C-3' (2 nmol in 
12 μL of water) were radiolabeled with γ-32P ATP using standard methods. Following 
heating at 65 °C for 10 min to inactivate the enzyme, excess γ-32P ATP was removed 
using Illustra microspin G25 columns (GE Healthcare, Pittsburgh, PA). To obtain double 
stranded DNA, 5'-32P-endlabeled oligomers were mixed with equimolar amounts of the 
complementary strands in 10 mM Tris buffer (pH 7) containing 50 mM NaCl and heated 
at 90 °C for 10 min, followed by gradual cooling overnight. 
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3.2.3 Reductive Amination to Generate DNA-Protein Cross-Links 
 32P-endlabeled DNA strands (50 pmol in 8 L water) were oxidized in the 
presence of 50 mM NaIO4 (5 L) in 15 mM sodium phosphate buffer (pH 5.4, 5 L) for 
6 h at 4 C in the dark to unmask the aldehyde moiety on deaza-DHP-dG. Excess NaIO4 
was quenched with 55 mM Na2SO3 (5 L). Proteins and peptides of interest               
(0.5–2.5 nmol) were incubated with the aldehyde-containing DNA (50 pmol) in the 
presence of 25 mM NaCNBH3 at 37 C overnight to generate stable DNA-protein    
cross-links. Aliquots of the reaction mixtures were withdrawn and resolved by 12%  
SDS-PAGE with or without proteinase K digestion (6 units, 48 h at 37 C).  
3.2.4 Gel Electrophoretic Analysis of DNA-Protein Cross-Links 
Generated by Reductive Amination 
12% SDS-PAGE gel plates were pre-run at a constant voltage of 150 V for         
30 min in 1×SDS running buffer. DPC reaction mixtures were dissolved in 0.1% TFA or 
10% SDS (2 µL). The samples were reconstituted in SDS loading buffer and heated at 90 
°C for 5 min prior to loading. The gels were run at a constant voltage of 150 V at ambient 
temperature. Radiolabeled DNA strands and DPCs were detected with a Storm 840 
phosphorimager (Amersham Biosciences Corp., Piscataway, NJ) or a Typhoon FLA 7000 
instrument (GE Healthcare, Pittsburgh, PA). Covalent DPCs were observed as slowly 
moving bands on the gel, and the reaction yields were calculated by volume analysis 
using Image Quant TL 8.0 (GE Healthcare, Pittsburgh, PA). 
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To visualize the proteins participating in DPC formation to aldehyde-containing 
DNA, NuPAGE Novex 12% Bis-Tris gels (Life Technologies, Grand Island, NY) were 
pre-run at a constant voltage of 100 V for 30 min in 1×NuPAGE MOPS SDS running 
buffer (Life Technologies, Grand Island, NY). The reaction mixtures obtained from 
DNA-protein cross-linking were dissolved in 10% SDS (2 µL) and reconstituted in 
NuPAGE LDS sample buffer (Life Technologies, Grand Island, NY). The samples were 
heated at 70 °C for 10 min prior to loading onto a gel. The gels were run at a constant 
voltage of 100 V at ambient temperature. The unreacted protein and DPC bands were 
visualized by staining with SimplyBlue SafeStain (Life Technologies, Grand Island, NY). 
3.2.5 Sample Processing for Mass Spectrometry Analysis  
DPCs were generated by reductive amination as described above using unlabeled 
DNA and proteins (15–20-fold excess) and either directly processed for mass 
spectrometric analysis or purified by PAGE as described below. 
In direct processing experiments, the DNA component of DPCs was digested with 
PDE I (120 mU), PDE II (105 mU), DNase (35 U) and alkaline phosphatase (22 U) in   
10 mM Tris-HCl/15 mM MgCl2 (pH 7) buffer at 37 °C overnight. The resulting protein-
nucleoside conjugates were dried in vacuo, reconstituted in 100 mM NH4HCO3 (pH 7.9, 
90 μL), and subjected to trypsin digestion using MS grade Trypsin Gold (2.5 μg, 
Promega, Madison, WI) at 37 °C for 20 h. The digests were dried in vacuo, desalted 
using ZipTip with 0.6 μL C18 resin (Millipore, Billerica, MA), and the resulting peptides 
were reconstituted in 0.1% formic acid (10 μL) prior to MS analysis. 
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Alternatively, DNA-protein conjugates were first purified by 12% SDS-PAGE 
and stained with SimplyBlue SafeStain (Life Technologies, Grand Island, NY). DPC-
containing gel bands were cut into slices and subjected to reduction using 300 mM DTT 
(10 μL) followed by alkylation with iodoacetamide (10 μL in 100 μL of 25 mM 
NH4HCO3, pH 7.9). Gel pieces were dehydrated with acetonitrile, dried under vacuum, 
reconstituted in 25 mM NH4HCO3 (pH 7.9, 75 μL) and incubated with PDE I (120 mU) 
at 37 °C overnight. Next, the samples were subjected to tryptic digestion and ZipTip 
desalting as described above, followed by MS analysis. 
3.2.6 Characterization of DNA-Protein Cross-Links by Mass 
Spectrometry 
All HPLC-ESI+-MS/MS analyses were conducted with a Thermo Scientific LTQ 
Orbitrap Velos mass spectrometer interfaced with an Eksigent NanoLC-Ultra 2D HPLC 
system. Peptide mixtures (5 μL) were loaded onto a nano HPLC column (75 μm ID,      
10 cm packed bed, 15 μm orifice) created by hand packing commercially purchased 
fused-silica emitters (New Objective, Woburn, MA) with Luna C18, 5 μm separation 
media (Phenomenex, Torrance, CA). Liquid chromatography was carried out at an 
ambient temperature at a flow rate 0.3 μL/min using 0.1% formic acid (A) and 
acetonitrile (B). The solvent composition was changed linearly from 2% to 70% B over 
60 min, then to 95% B over 1 min, kept at 95% B for further 5 min, and decreased to   
2% B in 1 min. Finally, the flow rate was increased to 1 μL/min and kept at 2% B for an 
additional 7 min. Mass spectrometry was performed using the FTMS mass analyzer with 
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a resolution of 60,000 ppm and with a scan range of m/z 300–2000. Peptide MS/MS 
spectra were collected using data-dependent scanning in which one full scan mass 
spectrum was followed by eight MS/MS spectra using an isolation width of 2.5 m/z, 
normalized CID collision energy of 35%, 1 repeat count, 20 s exclusion duration, with an 
exclusion mass width of ±5 ppm.  
Spectral data were analyzed using Thermo Proteome Discoverer 1.3 (Thermo 
Scientific, San Jose, CA) that linked raw data extraction, database searching, and 
probability scoring. The raw data were directly uploaded, without any format conversion, 
to search against the protein FASTA database. Search parameters included trypsin 
specificity and up to 2 missed cleavage sites. Protein N-terminus, lysine, or arginine 
residues were specified as possible modification sites by specifying the following 
dynamic modifications: (A) ethan-1,2-diyl cross-link to 7-deaza-7-ethan-1-yl-2'-deoxy-
guanosine, +292.1172 Da (C13H16N4O4); (B) cross-link to 7-deaza-7-ethan-1-yl-guanine, 
+176.0698 Da (C8H8N4O); or (C) cross-link to 7-deaza-7-ethan-1-yl-2'-deoxyguanosine 
5'-monophosphate, +372.0835 Da (C13H17N4O7P). 
3.2.7 Synthesis and Characterization of 7-Deaza-7-(2-(N-acetyllysine) 
ethan-1-yl)-2'-deoxyguanosine and 7-Deaza-7-(2-(N-acetylarginine) 
ethan-1-yl)-2'-deoxyguanosine Conjugates 
Synthetic 7-deaza-7-(2,3-dihydroxypropan-1-yl)-2'-deoxyguanosine377 (10 nmol) 
was oxidized in the presence of 50 mM NaIO4 (4 L) in 1 M sodium phosphate buffer 
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(pH 5.4, 6 L) for 6 h at 4 C in the dark to generate 7-deaza-7-(formylmethan-1-yl)-     
2'-deoxyguanosine. Excess NaIO4 was quenched with 55 mM Na2SO3 (4 L). N-acetyl 
protected Lys or Arg (4 L of 5 mM solution) was added to the reaction mixture 
followed by 0.5 M NaCNBH3 (4 L), and incubated at 37 C overnight to generate amino 
acid-nucleoside conjugates. The amino acid-nucleoside conjugates were isolated by 
HPLC on a Supelcosil-LC-18-DB (4.6 × 250 mm, 5 μm) column (Sigma Aldrich, 
Milwaukee, WI) using a gradient of 0.1% formic acid (A) and acetonitrile (B). The 
solvent composition was changed from 0 to 24% B over 24 min, then to 75% B over       
6 min, and finally to 0% B over 2 min. HPLC fractions containing major components 
were collected, concentrated in vacuo and analyzed by capillary HPLC-ESI+-MSn on an 
Agilent 1100 capillary HPLC-ion trap mass spectrometer (Agilent Technologies, Inc., 
Wilmington, DE). 
3.2.8 Synthesis and Characterization of Nucleoside-Peptide Conjugates 
Synthetic nucleoside-peptide conjugates were prepared using 7-deaza-7-(2,3-
dihydroxypropan-1-yl)-2'-deoxyguanosine and angiotensin I (DRVYIHPFHL) or 
substance P (RPKPQQFFGLMNH2) peptides by reductive amination procedure as 
described above. The reaction mixtures were dried in vacuo and desalted using ZipTip 
with 0.6 μL C18 resin (Millipore, Billerica, MA). The resulting mixtures were 
reconstituted in 0.1% formic acid (10 μL) and analyzed on a Thermo Scientific LTQ 
Orbitrap Velos mass spectrometer interfaced with an Eksigent NanoLC-Ultra 2D HPLC 
system as described below. 
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Desalted reaction mixtures (2 μL) were loaded onto a nano HPLC column (75 μm 
ID, 10 cm packed bed, 15 μm orifice) created by hand packing commercially purchased 
fused-silica emitters (New Objective, Woburn, MA) with Zorbax SB-C18, 5 μm 
separation media (Phenomenex, Torrance, CA). Liquid chromatography was carried out 
using 0.1% formic acid (A) and acetonitrile (B) as solvents at an ambient temperature at 
an initial flow rate of 1 μL/min at 2% B for 5.5 min. The flow rate was reduced to             
0.3 μL/min in 30 s and the solvent composition was changed linearly from 2% to 50% B 
over 20 min, then to 95% B over 1 min, kept at 95% B for further 5 min, and decreased to 
2% B in 1 min. Finally, the HPLC flow rate was increased to 1 μL/min and kept at 2% B 
for an additional 6 min. Mass spectrometry was performed using the FTMS mass 
analyzer with a resolution of 60,000 ppm and with a scan range of m/z 300–2000 in the 
full scan mode. MS2 spectra were collected using the iontrap with an isolation width of 
2.5 m/z, normalized CID collision energy of 35%, while MS3 spectra were collected using 
the orbitrap with an isolation width of 2.5 m/z, and a normalized HCD collision energy of 
35%. 
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3.3 RESULTS 
3.3.1 Experimental Strategy for the Generation of Hydrolytically Stable 
Model DNA-Protein Cross-Links 
 Since N7-guanine alkylation introduces a positive charge on the alkylated base, it 
destabilizes the N-glycosidic bond, leading to spontaneous depurination.378 Therefore, it 
is not practical to employ N7-guanine adducts in DNA replication and repair 
experiments. To avoid spontaneous degradation of our model DPC substrates, we have 
replaced the N7 nitrogen of guanine with a carbon atom (7-deaza-G).377 To create a 
protein reactive group, the 2,3-dihydroxypropyl group was introduced at the same 
position (deaza-DHP-dG, 1 in Scheme 3-2). Treatment with periodate converts the diol 
group to the corresponding aldehyde (2 in Scheme 3-2), which then reacts with free 
amino groups of proteins (e.g., Lys or Arg side chains) to form a Schiff base                   
(3 in Scheme 3-2). The latter can be quantitatively reduced with NaCNBH3 to produce a 
stable amine linkage (4 in Scheme 3-2). The aldehyde substrate (2 in Scheme 3-2) is a 
direct model for N7-(2-oxoethyl)-G, which is the major DNA adduct from exposure to 
chlorooxirane,376  and the resulting model cross-links are structurally analogous to DPCs 
formed by chlorooxirane and antitumor nitrogen mustards in cells (Scheme 3-3). 
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Scheme 3-2 Synthesis of DNA-protein cross-links by a post-synthetic reductive 
amination strategy. (a) Oxidative cleavage to unmask the reactive aldehyde moiety on the 
7-deaza-7-(2,3-dihydroxypropan-1-yl)-guanine of the synthetic oligomer, (b) reaction of 
an amino group on the protein with the aldehyde on the DNA to form a Schiff base,           
and (c) reduction of the imine to form a stable amine linkage. 
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Scheme 3-3 Structural similarity between the model DNA-protein cross-links prepared 
by reductive amination and DNA-protein cross-links formed in vivo. DPCs obtained by 
reductive amination of aldehyde containing DNA and proteins (A) are structurally 
analogous to cellular DPCs formed upon reaction of antitumor nitrogen mustards with  
N7 guanine of DNA and proteins (B).158 Synthetic DPC substrates (A) are also a direct 
model for cross-linking of proteins to N7-(2-oxoethyl)-G, which is the major DNA 
adduct formed upon exposure to vinyl chloride.376 
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3.3.2 Characterization of DNA-Protein Cross-Link Formation by 
Denaturing Gel Electrophoresis 
Our initial experiments were conducted with recombinant E. coli AlkB protein, a 
DNA repair protein that contains multiple nucleophilic lysine and arginine residues and is 
known to bind to DNA.379,380 The formation of covalent AlkB-DNA conjugates was 
monitored by two independent methods. In the first approach, oligodeoxynucleotides 
containing the convertible nucleoside (deaza-DHP-dG) were radiolabeled with 32P-ATP. 
Following the cross-linking reaction, DPC formation was detected as the appearance of a 
new, low mobility band on denaturing PAGE (Figure 3-1). Alternatively, free proteins 
and DNA-protein conjugates were visualized by protein staining, and the presence of a 
cross-link was detected as a new protein band with reduced mobility (Figure 3-2). 
As shown in Figure 3-1, the cross-linking reaction between deaza-DHP-dG 
containing DNA 20-mer and recombinant AlkB protein led to the formation of covalent 
DPC conjugates as revealed by the appearance of a low mobility band on a denaturing 
polyacrylamide gel (Lane 3). This band was not observed in control experiments 
conducted in the absence of protein (Lane 1), and only trace amounts of conjugation were 
observed in the absence of the reducing agent (Lane 2). The DPC band disappeared when 
the reaction mixture was subjected to proteinase K digestion, (Lane 4), confirming that it 
corresponds to covalent DNA-protein conjugates. 
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Figure 3-1 Denaturing PAGE analysis of DNA-protein cross-links generated by post-
synthetic reductive amination. DNA and DNA-protein conjugation products of the 
reaction between E. coli AlkB protein and aldehyde-containing DNA 20-mer, 5'-G TCA 
CTG GTA deaza-DHP-dGCA AGC ATT G-3', were visualized by 32P-end labeling. The 
formation of covalent DPC was revealed as a low mobility band on the gel. Lane 1: 
aldehyde containing oligonucleotide in the presence of a reducing agent (negative 
control); Lane 2: aldehyde containing oligonucleotide and AlkB protein in the absence of 
a reducing agent; Lane 3: reaction mixture of aldehyde containing oligonucleotide and 
the protein in the presence of a reducing agent; Lane 4: reaction mixture from lane 3 
subjected to proteinase K digestion. 
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Figure 3-2 SDS-PAGE analysis of reductive amination-mediated DNA-protein        
cross-linking. DPC formation between aldehyde-containing DNA 20-mer (5'-G TCA 
CTG GTA deaza-DHP-dGCA AGC ATT G-3') and E. coli AlkB protein was visualized 
via SimplyBlue protein staining. Lane 1: protein size markers; Lane 2: AlkB protein 
(negative control); Lane 3: DPCs generated using 1:2 ratio of DNA to protein; Lane 4: 
proteinase K digested reaction mixture from lane 3; Lane 5: DPCs generated using 4:1 
molar ratio of DNA to protein; Lane 6: DPCs generated using 1:10 ratio of DNA to 
protein. Multiple bands were observed in the region >40 kDa due to protein aggregation. 
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These results were further confirmed using protein staining to visualize the 
protein and the DPCs (Figure 3-2). Following reductive amination reaction between 
AlkB protein and deaza-DHP-dG containing 20-mer, a new band was observed with an 
increased molecular weight as compared to unreacted AlkB protein (22.9 kDa) (Lane 3). 
The size of the newly formed conjugate (~29 kDa) was consistent with the addition of 
18-mer oligodeoxynucleotide (6.2 kDa) to the protein, and the cross-linking yield was 
dependent on DNA:protein ratio (Lanes 3, 5 and 6).  In addition, several higher molecular 
weight bands (>40 kDa) were observed due to the propensity of the AlkB protein to 
oligomerize when present at a high concentration.  
3.3.3 Effects of Reaction Conditions on DNA-Protein Cross-Link Yields 
The experimental conditions for each of the reaction steps (Scheme 3-2) were 
optimized by varying the reaction temperature, reaction time, and molar ratios. We found 
that the highest DPC yields were observed when the NaIO4-mediated oxidative cleavage 
(step a in Scheme 3-2) was conducted at 4 °C, and the optimal temperature for reductive 
amination reaction (steps b and c in Scheme 3-2) was 37 °C (Figure 3-3A). 
When the effect of reaction times on DPC yields was assessed, the best results 
were achieved when the time of periodate-mediated oxidative cleavage (step a                
in Scheme 3-2) was limited to 2–6 h (Figure 3-3B). This can be explained by a limited 
stability of aldehydes under oxidizing conditions. In contrast, the best yields of reductive 
amination reaction (steps b and c in Scheme 3-2) were achieved at extended reaction 
times (12–24 h, Figure 3-3B). 
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Figure 3-3 Effects of reaction conditions on the yields of DNA-protein cross-links. Reductive amination-mediated cross-linking 
between deaza-DHP-dG containing DNA and the AlkB protein was performed, DPCs were visualized by phosphorimaging and 
quantified by volume analysis. (A) Influence of reaction temperature on DPC yields. Oxidative cleavage was most efficient at 4 °C 
and cross-linking reaction gave the highest yields at 37 °C. (B) Influence of reaction time on DPC yields. Oxidative cleavage was high 
yielding at shorter reaction times (2–6 h), while cross-linking reaction gave the highest yields of DPCs when incubated for longer 
reaction times (12–24 h). (C) Variation of DPC yields with increased protein:DNA molar ratio. Cross-linking reaction was carried out 
by varying the molar equivalents of AlkB protein to DNA between 0.5:1 to 5:1. The production of covalent conjugates was increased 
in the presence of excess protein. 
  131
The influence of DNA:protein molar ratios on reaction yields was examined by 
keeping the concentration of one of the reagents (protein or DNA) constant while varying 
the molar equivalents of the other. When protein amounts were varied with respect to 
constant amounts of radiolabeled DNA, the highest DPC yields (~85%) were achieved 
when using an excess of the protein (Figure 3-3C). When protein amounts were held 
constant and protein staining was employed to follow the reaction, increasing DNA 
concentrations similarly has led to increased DPC yields (Figure 3-2). These results 
suggest that the reversible Schiff base formation between the aldehyde functionality 
within DNA and the basic amino acid side chains of the protein can be driven forward 
towards product formation by employing a large molar excess of the other reagent. In a 
practical sense, generation of DNA substrates for replication and repair studies requires 
an excess of the protein in order to maximize the yields of DPC-containing DNA. 
3.3.4 Influence of Protein Identity on DNA-Protein Cross-Link 
Formation  
In theory, any protein containing lysine or arginine side chains can be cross-
linked to deaza-DHP-dG containing DNA using the reductive amination strategy 
(Scheme 3-2). However, the reactivity and the accessibility of basic residues may vary 
depending on the protein identity. Therefore, the general applicability of our approach 
was examined using a range of proteins of different sizes and structures (Table 3-1 and 
Figure 3-4A). We found that while some proteins (AlkB, NEIL1, Histone H4, GAPDH) 
formed DPCs in a high yield (75–95%), significantly lower DPC yields (<20%) were 
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observed for others (trypsin, carboxypeptidase, myoglobin, Table 3-1). In general, DNA 
binding proteins such as those involved in chromatin condensation and DNA repair 
produced DPCs in a higher yield than proteins that do not have an affinity for DNA. 
These results suggest that the formation of DPCs by reductive amination is facilitated by 
reversible DNA-protein interactions, which brings the two biomolecules into a close 
proximity to each other. Additional low mobility bands were observed for some proteins 
due to their dimerization (e.g. histone H4 and myoglobin, Figure 3-4A). 
To gain insight into the identities of the amino acid residues participating in DPC 
formation, the cross-linking reactions were carried out with peptides of differing amino 
acid composition. High abundance DPC bands were observed for Tat and Substance P, 
which are rich in lysine and arginine residues (Figure 3-4B, lanes 2 and 4) suggesting 
that amino groups of Lys and Arg may be involved in crosslinking to DNA. In contrast, 
no covalent conjugates were detected for pepstatin, which has no Lys or Arg residues 
(Figure 3-4B, lane 5). A single DPC band was observed for hypertensin I, which has 
only one Arg residue and no Lys (Figure 3-4B, lane 3). Taken together, these results 
suggest that amino side chains of Lys and Arg within proteins can participate in reductive 
amination reactions with deaza-DHP-dG containing DNA. 
 
 
 
  133
Table 3-1 Proteins and peptides used to generate DNA-protein cross-links using the 
reductive amination reactions with deaza-DHP-dG containing DNA.ǂ 
Protein/peptide Molecular weight/kDa 
No. of Lys per 
monomer 
No. of Arg per 
monomer 
% Yield of 
DPC 
Histones 11-15 14 9 99 
Substance P 1.3 1 1 94 
Tat 1.8 2 6 92 
Ribonuclease A 14.7 8 4 89 
Histone H4 11.5 11 14 89 
GAPDH 38 26 11 74 
Aprotinin 6.5 4 7 73 
NEIL1 44.5 23 42 64 
Apomyoglobin 17.3 19 2 63 
Insulin 5.8 2 5 63 
AlkB 22.9 8 13 59 
RNase 14.7 8 4 56 
Hypertensin I 0.9 0 1 43 
Pepsin 34.6 11 4 25 
AGT 21.9 12 6 20 
Myoglobin 17.6 19 2 19 
T4 PNK 132 29 19 18 
Carboxypeptidase A 34 18 17 17 
Proteinase K 28.9 14 17 9 
Trypsin 23.3 8 3 4 
Pepstatin 0.7 0 0 0 
Leupeptin 0.5 0 1 <1 
 
                                                 
ǂ	The reactions were carried out under optimized conditions using a 20-fold excess of protein/peptide with respect to the 
starting oligodeoxynucleotide.	
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Figure 3-4 Influence of protein identity on DPC yield for reductive amination. (A) SDS-
PAGE analysis of DPCs visualized via protein staining. Lane 1 and 10: protein size 
markers; Lanes 2–9: DPC formation between aldehyde-containing DNA and AlkB, 
histone H4, ribonuclease A, and myoglobin. Lanes 2, 4, 6, and 8 correspond to reactions 
conducted in the absence of DNA and NaCNBH3 (negative controls). The cross-linking 
reactions were conducted using the 2:1 protein:DNA molar ratio. (B) Denaturing PAGE 
analysis of DPCs prepared using a set of different peptides that were visualized via      
32P-endlabeling of DNA. Lane 1: Aldehyde containing oligonucleotide in the presence of 
the reducing agent (negative control), Lanes 2–6: DPC formation between aldehyde-
containing DNA and Substance P, Hypertensin I, Tat, pepstatin and leupeptin. 
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3.3.5 Mass Spectrometry Characterization of DNA-Protein Cross-Links 
 A mass spectrometry-based approach was employed to further characterize the 
structures of DNA-protein conjugates created by reductive amination and to identify the 
amino acids participating in reactions. The DNA components of DPCs to selected 
proteins (AlkB, RNase A, histone H4 and myoglobin) were digested with PDE I, PDE II, 
DNAse, and alkaline phosphatase. The resulting protein-nucleoside conjugates were 
cleaved with trypsin, and the peptides were analyzed by nano HPLC-ESI+-MS/MS on an 
Orbitrap Velos mass spectrometer. Tryptic peptides containing cross-links to deaza-dG 
were identified, and the cross-linking sites were determined by MS/MS sequencing     
(see an example in Figure 3-5). The mass spectral data were processed using Thermo 
Proteome Discoverer 1.3 (ThermoScientific, San Jose, CA) to identify the cross-linking 
sites. We found that for all four proteins examined, multiple lysine and arginine residues 
were engaged in the cross-linking reaction to aldehyde-containing DNA under reducing 
conditions (Tables 3-2 and 3-3). 
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Figure 3-5 Mass spectrometry chracaterization of AlkB-DNA cross-links. MS/MS spectra of AlkB tryptic peptides NDPLK*         
(m/z 439.7, doubly charged) and R*NDPLK (m/z 557.8, doubly charged), where K* and R* contain an ethyl cross-link to 7-deaza-   
2'-deoxyguanosine and 7-deaza-2'-deoxyguanosine 5'-monophosphate, respectively.  
 
  137
Table 3-2 Sites of reductive amination-mediated cross-linking between deaza-DHP-dG 
containing DNA and recombinant AlkB protein as identified by nano HPLC-ESI+-
MS/MS of tryptic digests. 
Amino acid 
positions Amino acid sequence Site of modification 
Location within the 
protein 
25–35 FAFNAAEQLIR R35 - 
122–127 CVPGAK K127 DNA binding groove 
122–134 CVPGAKLSLHQDK K127 DNA binding groove 
161–166 RNDPLK R161 DNA binding groove 
162–166 NDPLK K166 DNA binding groove 
162–167 NDPLKR K166 DNA binding groove 
162–183 RLLLEHGDVVVWGGESR R167 DNA binding groove 
194–204 VGVHPLTTDCR R204 active site 
194–210 VGVHPLTTDCRYNLTFR R204 active site 
194–210 VGVHPLTTDCRYNLTFR R210 active site 
205–215 YNLTFRQAGKK R210 active site 
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Table 3-3 Sites of reductive amination-mediated cross-linking between deaza-DHP-dG 
containing DNA and proteins as identified by nano HPLC-ESI+-MS/MS of tryptic 
digests. 
Amino acid positions Amino acid sequence Site of modification 
A. Histone H4 
1–6 MSGRGK R4 
1–9 MSGRGKGGK R4 
10–17 GLGKGGAK K13 
10–18 GLGKGGAKR K13 
21–24 KVLR R24 
21–24 KVLR K21 
46–56 RISGLIYEETR R46 
B. Myoglobin 
46–56 FKHLKTEAEMK K50 
134–145 ALELFRNDIAAK R139 
134–145 ALELFRNDIAAK K145 
140–145 NDIAAK K145 
140–147 NDIAAKYK K145 
C. RNase I 
1–7 KETAAAK K1 
40–61 CKPVNTFVHESLADVQAVCSQK K41 
40–61 CKPVNTFVHESLADVQAVCSQK K61 
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Nano HPLC-ESI+-MS/MS analysis of AlkB-DNA conjugates was repeated 
several times, yielding reproducible results. Peptide sequencing by HPLC-ESI+-MS/MS 
has revealed that two lysine residues (K127, K166) and five arginine residues of AlkB 
(R35, R161, R167, R204, R210) can participate in the AlkB-DNA cross-linking via 
reductive amination (Figure 3-6 and Table 3-2). Examination of published crystal 
structures suggests that K134, R204, and R210 are located in the active site of AlkB, 
while K127, K166, and R167 reside in the DNA binding groove of the protein.379,380 
These results suggest that specific AlkB-DNA binding facilitates covalent DPC 
formation. However, some of the residues participating in cross-linking (e.g. R35) are 
located outside of the DNA-binding domain. This can be explained by partial 
denaturation of the protein under strongly reducing conditions used in our experiments.  
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Figure 3-6 Crystal structure of AlkB protein bound to double stranded DNA (PDB ID: 
3BI3) showing the amino acids participating in DNA-protein cross-linking. 
 
 
 
  141
3.3.6 Synthesis and Structural Characterization of 7-Deaza-7-(2-(N-acetyl 
lysine)ethan-1-yl)-2'-deoxyguanosine and 7-Deaza-7-(2-(N-acetyl 
arginine)ethan-1-yl)-2'-deoxyguanosine Conjugates 
To confirm the exact chemical structure of the DNA-protein cross-links generated 
via reductive amination (Scheme 3-2), synthetic 7-deaza-7-(2,3-dihydroxypropan-1-yl)-
2'-deoxyguanosine (deaza-DHP-dG) was allowed to react with N-acetyl protected Lys 
and Arg, and the resulting nucleoside-amino acid conjugates were isolated by HPLC and 
characterized by mass spectrometry. In the case of N-acetyllysine, the major conjugation 
product was observed at m/z 503.2, corresponding to the [M+Na]+ ions of 7-deaza-         
7-(2-(N-acetyllysine)ethan-1-yl)-2'-deoxyguanosine. MS/MS fragmentation pathway of 
this conjugate (Figure 3-7A) was dominated by the product ions at m/z 387.1 and        
m/z 485.2, which correspond to the loss of deoxyribose, and a water molecule, 
respectively (Figure 3-7A). Similar results were observed for N-acetylarginine. MS2 
fragmentation of protonated 7-deaza-7-(2-(N-acetylarginine)ethan-1-yl)-2'-deoxy-
guanosine, [M+H]+, has revealed the loss of water ([M+H-H2O]+), acetylamine            
([M+H-MeCONH2]+) and deoxyribose ([M+H-dR]+, Figure 3-7B). Further, 
fragmentation at the guanidinium moiety of Arg (m/z 174.1) and ethylene linker of  
deaza-dG (m/z 280.3) were also observed (Figure 3-7B). Taken together, these results are 
consistent with the cross-linking mechanism shown in Scheme 3-2, e.g. Schiff base 
formation between the lysine amino side chain and the aldehyde functionality within 
oxidized deaza-DHP-dG, followed by imine reduction to generate a stable amino linkage. 
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Figure 3-7 HPLC-ESI+-MS/MS characterization of 7-deaza-7-(2-(N-acetyllysine)ethan-
1-yl)-2'-deoxyguanosine (A) and 7-deaza-7-(2-(N-acetylarginine)ethan-1-yl)-2'-deoxy-
guanosine (B). 
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3.3.7 Synthesis and Characterization of Nucleoside-Peptide Conjugates 
To further confirm the chemical structure and site of cross-linking of DPCs 
formed by reductive amination strategy, nucleoside-peptide conjugates of 7-deaza-         
7-(2,3-dihydroxypropan-1-yl)-2'-deoxyguanosine (deaza-DHP-dG) to angiotensin I and 
substance P were characterized by mass spectrometry. MS2 spectrum of angiotensin I 
conjugate has revealed that the site of cross-linking is side chain amino group of arginine 
(Figure 3-8A). The MS2 spectrum has further revealed that 7-deaza-7-(1-aminoethan-   
2-yl)-2'-deoxyguanosine is lost upon fragmentation of the doubly charged parent ion,   
[M+2H]+ = 794.9 m/z. The resulting singly charged daughter ion, [M+H]+ = 1279.8 m/z 
was further fragmented to observe additional b- and y-ions of the modified peptide that 
confirmed the site of cross-linking (Figure 3-8B). 
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Figure 3-8 NanoLC-nanospary-MS2 (A) and MS3 (B) spectra of the peptide, Angiotensin I (DRVYIHPFHL) cross-linked to 7-deaza-
7-(ethan-1-yl)-2'-deoxyguanosine. 
 
  145
3.4 DISCUSSION 
Dynamic DNA-protein interactions are crucial for many cellular functions 
including chromatin packaging, cell division, DNA replication, gene expression, DNA 
damage response, and DNA repair.4,5,381 Proteins reversibly interact with DNA by a 
combination of electrostatic forces, hydrogen bonding, and stacking interactions, and 
their ability to dissociate from DNA is critical for their cellular functions. However, 
exposure to common antitumor drugs, environmental toxins, transition metals, UV light, 
ionizing radiation, and free radical-generating systems can result in proteins becoming 
covalently trapped on DNA.4,5 This generates super bulky, highly heterogeneous DNA-
protein cross-links (DPCs) that can block DNA and RNA polymerases, causing toxicity 
and/or mutations in affected cells.36,38,85,158,192,308,315,316   
Our previous mass spectrometry-based proteomics studies have revealed that 
covalent DNA-protein cross-links (DPCs) involving the N7 position of guanine are 
readily formed in human cells treated with clinically relevant concentrations of 
chemotherapeutic drugs (e.g., platinum compounds and nitrogen mustards)158,294 and 
metabolically activated carcinogens (e.g., 1,2,3,4-diepoxybutane).85 Additionally, 
covalent DPCs have been shown to accumulate in an age-dependent fashion in the brain 
and heart tissues, probably a result of exposure to endogenous reactive oxygen species, 
lipid peroxidation products, and transition metals.36 If not repaired, DPCs may contribute 
to the development of cancer, cardiovascular disease, and age-related 
neurodegeneration.34,36-38,164,382,383 
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Conflicting data exist in the literature regarding the mechanisms of cellular repair 
of DPC lesions. Reardon et al. examined the ability of reconstituted bacterial and 
mammalian excision nuclease systems to recognize the ring-open T4 pyrimidine DNA 
glycosylase-DNA cross-links.169 While the excision of DNA-protein conjugates was not 
detected, DPCs to short polypeptides were recognized and cleaved by mammalian protein 
extracts, leading to the hypothesis that DPCs are proteolytically degraded prior to their 
repair via the NER pathway.169 Similar conclusions were drawn by the Lloyd group when 
using a bacterial UvrABC system324 and by Baker et al. who examined model DPCs 
containing bacterial DNA methyltransferase-DPC (37 kDa) attached to the C6 position of 
cytosine.331 Quievryn et al. observed reduced rates of repair of formaldehyde-induced 
DPCs in the presence of a protease inhibitor.297 In contrast, Nakano et al. reported that 
cytosolic ATP-dependent proteases are not involved in DPC removal.326,327 These authors 
proposed that homologous recombination repair is responsible for removing the majority 
of DPCs generated via oxanine, while only DPCs involving small proteins (<12 kDa in 
bacteria and <8 – 10 kDa in mammalian cells) are repaired by NER.326,327  
Structural factors such as protein size, identity and lesion structures (e.g. major or 
minor groove of DNA) are also likely to affect the DPC lesion's ability to be bypassed by 
DNA and RNA polymerases.4,260 For example, E. coli polymerase I and HIV-1 reverse 
transcriptase were completely blocked by cis-[diamminedichloroplatinum(II)] (cisplatin) 
cross-linked to histone H1.219 The A family human polymerase ν was blocked by DNA-
peptide cross-links located in the minor groove via N2-dG.336 In contrast, chemically and 
structurally similar lesions located in the major groove of DNA via N6-dA were 
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efficiently and accurately bypassed by both human polymerase ν and E. coli 
polymerase I.336,337  
It is likely that the discrepancies between the mechanisms of DPC repair and 
bypass reported by different groups reflect structural differences between the model 
DPCs examined. Indeed, these previous studies have employed DNA-conjugates of 
diverse structure and size, including those where the protein was directly attached to ring 
open abasic sites in DNA.5,325,327 This underlines the need to re-examine the replication 
and repair of DPC-containing DNA using substrates resembling the lesions formed in 
cells. The most common site of DNA involved in DPC formation is the N7 of 
guanine.5,158,161 However, to our knowledge, no methods have been previously reported in 
the literature to generate N7 guanine conjugated DPCs.  
As mentioned before, currently available synthetic strategies to generate site-
specific DPCs are limited to several main strategies. Lloyd et al.324 and Sancar et al.330 
employed a semi-enzymatic approach to trap T4 pyrimidine dimer glycosylase/AP lyase 
(T4-pdg) on abasic sites of DNA in the presence of sodium borohydride. A similar 
methodology has been used to attach oxoguanine glycosylase (Ogg) to DNA strands 
containing 8-oxo-dG. DNA methyltransferase (Dnmt) has been trapped on DNA 
containing 5-fluorocytosine.331 Another approach involves the use of oxanine (Oxa) in 
DNA that spontaneously reacts with amino groups of proteins to give a pyrimidine ring-
open structure,164 and this strategy, which is specific to nitric oxide-induced Oxa lesion, 
requires a large excess of the protein (425 to 3000-fold), as well as long incubation times 
(up to 48 h).164,326 Finally, Schiff base formation between acrolein-induced γ-HOPdG 
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adducts and lysine residues of proteins and peptides can be stabilized in the presence of 
NaCNBH3.198,246,336 Either the N2 guanine or N6 adenine aldehyde functionality derived 
from acrolein-induced 3-(2'-deoxyribos-1'-yl)-5,6,7,8-tetrahydro-8-hydroxypyrimido 
[1,2a]purin-10(3H)-one (-HOPdG) can be reacted with proteins and peptides to produce 
a Schiff base, which was subsequently reduced to the corresponding amine with sodium 
cyanoborohydride.246,336 To our knowledge, no synthetic methodologies are available to 
generate N7-guanine DPCs such as those formed in vivo upon exposure to environmental 
carcinogens and antitumor agents.85,158 
In the present study, a post-synthetic reductive amination strategy was employed 
to create hydrolytically stable structural mimics of N7 guanine conjugated DPCs by 
reductive amination reactions between Lys and Arg side chains of proteins and 
acetaldehyde functionalities of modified 7-deazaguanine residues of DNA (Scheme 3-2). 
The main advantage of this approach is that it generates sequence specific DPC lesions 
structurally analogous to the lesions formed in vivo. Reductive amination methodology is 
highly versatile, as it can be used to generate DPCs to most proteins and peptides 
containing Lys and/or Arg residues (Table 3-1). The resulting structurally defined and 
hydrolytically stable DPCs can be used to study the biological fate of DPCs in vitro to 
better understand the effects of these lesions in cells. Furthermore, experimental methods 
are being developed in our laboratory to incorporate these substrates into plasmid DNA 
and study their repair in cells to identify the mechanisms responsible for the removal of 
these lesions in vivo.  
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Model DPC lesions generated in this work resemble the adducts induced by 
antitumor nitrogen mustards (Scheme 3-3).158,161 We have previously identified 39 
proteins that form covalent DPCs in human fibrosarcoma (HT1080) cells treated with 
mechlorethamine.159 However, it is not known to what extent DPC formation contributes 
to toxicity of nitrogen mustards in cancer cells. The availability of hydrolytically stable 
model DPC substrates will, for the first time, enable structural and biological evaluation 
of these super-bulky lesions. Based on our recent studies with DNA-reactive protein 
reagents that specifically induce DPCs in cells,304 we hypothesize that spontaneous and 
xenobiotic-induced DPCs, if not repaired, will compromise the efficiency and the 
accuracy of DNA replication and are responsible for a major portion of the toxicity and 
mutagenicity induced by bis-alkylating agents, UV light, reactive oxygen species, and    
γ-radiation. 
The model DPC substrates created by reductive amination (Scheme 3-2) are site-
specific with respect to DNA, but may involve multiple possible cross-linking sites 
within the protein (Figure 3-6, Tables 3-2 and 3-3). This limited specificity with respect 
to the protein side chains should not affect the ability to employ these model conjugates 
in biological studies since the “real” DPC lesions formed in cells are also heterogeneous 
in nature. However, it may not be practical to use this approach to generate DNA-protein 
conjugates for structural studies by NMR or X-ray crystallography, especially in the case 
of proteins that contain multiple basic residues available for reaction with DNA. Other 
types of conjugations that employ bioorthogonal reactive groups in each biomolecule 
(protein and DNA) may be more appropriate for this purpose. To this end, we have 
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employed a copper-catalyzed [3+2] Huisgen cycloaddition (click reaction) between 
azide-functionalized proteins352 and alkyne-containing DNA to generate site specific 
DPC conjugates (Chapter 5). 
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4 REPLICATION BYPASS OF MODEL DNA-PROTEIN CROSS-LINKS CONJUGATED TO THE 7-DEAZAGUANINE OF DNA 
4.1 INTRODUCTION 
DNA-protein cross-linking in drug-treated cells appears to be as prominent as the 
formation of “traditional” DNA adducts. Isotope dilution HPLC-ESI-MS/MS studies of 
DNA hydrolysates from human fibrosarcoma (HT1080) cells treated with 0–100 µM 
mechlorethamine for 3 h have detected 1–5 DPC lesions per 106 nucleotides, depending 
on drug concentration.159 Our more recent studies have revealed significant numbers of 
DPC lesions in peripheral blood lymphocyte DNA from patients undergoing treatment 
with cyclophosphamide, representing a possible novel mechanism of target and off-target 
toxicity of this useful drug (Teshome Gherezghiher and Natalia Tretyakova, unpublished 
data).  
To our knowledge, no reports available in literature on replication bypass of     
N7-guanine adducts, probably because of their transient nature. Recently, we developed a 
post-synthetic reductive amination strategy to generate hydrolytically stable, site-specific 
DPCs that are structurally analogous to N7-G adducts formed in vivo (Chapter 3).354 In 
the present work, primer extension experiments with human lesion bypass DNA 
polymerases were conducted to examine replication bypass of model DPCs of varying 
size. In vitro DNA replication assays have revealed that large protein (AlkB, histone H4 
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and 6×His-eGFP) and polypeptide (23-mer peptide) cross-links completely block human 
translesion synthesis polymerases η and κ, while smaller 10-mer peptide cross-links were 
bypassed. Steady-state kinetics experiments provided evidence for the error-free bypass 
of the 10-mer peptide cross-link by hPol κ. hPol η incorporated primarily the correct 
base, dC opposite the adduct, while the incorporation of dT was much less efficient. Our 
results suggest the requirement of proteolytic degradation of proteins cross-linked to 
DNA prior to replication and the ability of human TLS polymerases to catalyze accurate 
replication in the presence of proteolytically cleaved DPC lesions.  
 
 
 
 
 
 
 
  153
4.2 MATERIALS AND METHODS 
4.2.1 Materials  
Fluorescein-dT phosphoramidite, protected 2'-deoxyribonucleoside-3'-phosphor-
amidites (dA-CE, Ac-dC-CE, dmf-dG-CE, dT-CE), Ac-dC-CPG ABI, dmf-dG-CPG ABI 
columns, and all other reagents required for automated DNA synthesis were purchased 
from Glen Research (Sterling, VA). Recombinant human polymerases hPol η, κ and ι 
were expressed and purified as described elsewhere.384-386 Recombinant AlkB protein 
was a generous donation by Dr. Chuan He (Department of Chemistry, University of 
Chicago). Expression of 6×His-eGFP protein387 and synthesis of 23-mer and 10-mer 
peptides388 were carried out according to previously reported protocols.                        
T4 polynucleotide kinase (T4-PNK) and recombinant histone H4 were obtained from 
New England Biolabs (Beverly, MA), while γ-32P ATP was purchased from Perkin-
Elmer Life Sciences (Boston, MA). 40% 19:1 Acrylamide/bis solution and micro bio-
spin 6 columns were purchased from Bio-Rad (Hercules, CA). The unlabeled dNTPs 
were obtained from Omega Bio-Tek (Norcross, GA). Size exclusion columns (NAP-5 
and Microspin G25) and Sep-Pak C18 SPE cartridges were purchased from GE 
Healthcare (Pittsburg, PA) and Waters (Milford, MA), respectively. All other chemicals 
and solvents were purchased from Sigma-Aldrich (Milwaukee, WI) and were of the 
highest grade available. 
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4.2.2  Synthesis and Characterization of Oligodeoxynucleotides  
Synthetic DNA strands containing site-specific 7-deaza-7-(2,3-dihydroxypropan-
1-yl)-2'-deoxyguanosine (5'-G TCA CTG GTA deaza-DHP-dGCA AGC ATT G-3' and 
5'-GAA AGA AGdeaza-DHP-dG ACA GAA GAG GGT ACC ATC ATA GAG TCA 
GTG-3') were prepared as previously described.377 Primers internally labeled with          
5-[N-((fluoresceinyl)-aminohexyl)-3-acrylimido]-2'-deoxyuridine (5'-CAA FAMdTGC 
TTG-3' and 5'-CTA TGA FAMdTGG TAC C-3') and unmodified DNA strands (5'-G 
TCA CTG GTA GCA AGC ATT G-3', 5'-GAA AGA AGG ACA GAA GAG GGT ACC 
ATC ATA GAG TCA GTG-3', and 5'-CAA TGC TTG-3') were synthesized by standard 
solid phase synthesis using an ABI 394 DNA synthesizer (Applied Biosystems, CA). All 
oligodeoxynucleotides were purified by semi-preparative HPLC, desalted by Illustra 
NAP-5 columns, characterized by HPLC-ESI--MS, and quantified by UV 
spectrophotometry. 
4.2.3 Synthesis and Characterization of DNA-Protein and DNA-Peptide 
Cross-Links 
Site-specific DNA-protein and DNA-peptide cross-links were generated by a 
post-synthetic reductive amination strategy developed in our laboratory.354 Briefly, 
synthetic 20-mer (5'-G TCA CTG GTA deaza-DHP-dGCA AGC ATT G-3') or 39-mer 
(5'-GAA AGA AGdeaza-DHP-dG ACA GAA GAG GGT ACC ATC ATA GAG TCA 
GTG-3', 1 nmol in 36 L water) were oxidized in the presence of 50 mM NaIO4 (70 L) 
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in 15 mM sodium phosphate buffer (pH 5.4, 70 L) for 6 h at 4 C in the dark to unmask 
the aldehyde moiety on deaza-DHP-dG (Scheme 4-1). Excess NaIO4 was quenched with 
55 mM Na2SO3 (70 L), and the resulting aldehyde-functionalized DNA was incubated 
with the protein of interest (AlkB, Histone H4 and 6×His-eGFP, 2–10-fold molar excess) 
in the presence of 25 mM NaCNBH3 at 37 C overnight to generate DNA-protein    
cross-links (Scheme 4-1). Site-specific DPCs were isolated using 20% (w/v) denaturing 
polyacrylamide gels containing 7 M urea followed by gel-elution.  
DNA-peptide conjugates were prepared analogously (Scheme 4-1), except that 
10–100-fold molar excess of the peptide was used, and the pH was adjusted to 7 prior to 
peptide addition. DNA-peptide conjugates were isolated using 15% (w/v) denaturing 
polyacrylamide gels containing 7 M urea followed by gel-elution. DNA-protein and 
DNA-peptide cross-links were desalted by micro bio-spin 6 columns and Sep-Pak C18 
SPE, respectively. The purified conjugates were characterized by HPLC-ESI+-MS/MS as 
described elsewhere.354 An aliquot of the purified sample was radiolabeled with γ-32P, 
and resolved on a 20% (w/v) denaturing polyacrylamide gel containing 7 M urea, 
followed by visualization using a Typhoon FLA 7000 phosphorimager (GE Healthcare, 
Pittsburgh, PA) to assess the purity of the conjugates. Depending on the purity of the 
cross-links obtained, additional gel purifications were carried out to obtain >98% pure 
conjugates. 
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Scheme 4-1 Synthesis of DNA-protein and DNA-peptide cross-links by post-synthetic 
reductive amination.354 
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4.2.4 Preparation of Primer-Template Duplexes  
For primer extension assays, the fluorescein labeled primers (5'-CAA FAMdTGC 
TTG-3' or 5'-CTA TGA FAMdTGG TAC C-3', 50 pmol) were mixed with 2 eq. of 
template strands containing dG, deaza-DHP-dG or DPC in 10 mM Tris buffer (pH 8) 
containing 50 mM NaCl. The mixtures were heated at 95 °C for 10 min and allowed to 
cool slowly overnight to afford the corresponding primer-template duplexes.  
For steady-state experiments to determine the kinetics of single nucleotide 
insertion opposite the cross-links, 9-mer DNA primer (5'-CAA TGC TTG-3', 1 nmol) 
was radiolabeled with T4 PNK (20 U) and γ-32P ATP (25 μCi) in the presence of T4 PNK 
reaction buffer (total volume = 20 μL) at 37 °C for 1 h. The mixture was heated at 65 °C 
for 10 min to inactivate the enzyme and passed through Illustra Microspin G25 columns 
(GE Healthcare, Pittsburgh, PA) to remove excess γ-32P ATP. The 5'-32P-labeled primers 
(50 pmol) were mixed with 2 eq. of template strands (5'-G TCA CTG GTA XCA AGC 
ATT G-3') containing either dG or 10-mer peptide in 10 mM Tris buffer (pH 8) 
containing 50 mM NaCl and annealed as described above. 
4.2.5 Primer Extension Assays 
For standing start experiments, the 9-mer FAMdT primer-20-mer template 
duplexes (0.15 μM, Scheme 4-2B) were incubated with human DNA polymerase hPol η, 
 or ι (0.30 μM) at room temperature in the presence of a buffered solution containing   
50 mM Tris (pH 7.5), 50 mM NaCl, 5 mM DTT, 100 μg/μL BSA, 10% glycerol (v/v) and 
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5 mM MgCl2. Primer extension reactions were initiated by adding 0.5 mM solution 
containing all four dNTPs. Aliquots of the reaction mixture (4 μL) were withdrawn at 
preselected time intervals (0, 5, 30, 60, 90 and 180 min) and quenched by the addition of 
95% formamide (v/v) containing 10 mM EDTA (8 μL). Samples were loaded on to a 
20% denaturing polyacrylamide gel and ran at 75 W for 3 h. The products were 
visualized using a Typhoon FLA 7000 (GE Healthcare, Pittsburgh, PA) in the 
fluorescence imaging mode. The running start experiments were conducted in a similar 
manner using 13-mer FAMdT primer-39-mer template DNA duplexes (Scheme 4-2C). 
4.2.6 Single Nucleotide Incorporation Assays 
To determine which nucleotides are incorporated opposite the DNA-peptide 
cross-links, 32P-endlabeled primer-template duplexes containing either dG or 10-mer 
peptide conjugate (50 nM) at position X (Scheme 4-2D) were incubated with human TLS 
polymerases (50 nM hPol η and 150 nM hPol κ) in 50 mM Tris-HCl (pH 7.5) buffer 
containing 50 mM NaCl, 5 mM DTT, 5 mM MgCl2, 100 µg/mL BSA and 10% glycerol 
(v/v) at room temperature. Reactions were initiated by the addition of individual dNTPs 
(100 μM) in a final volume of 20 μL. Aliquots (4 μL) were withdrawn at pre-selected 
time points, and the reaction was quenched by the addition of the quench solution 
containing 10 mM EDTA, 0.03% bromophenol blue (w/v) and 0.03% xylene cyanol 
(w/v) in 95% (v/v) formamide (8 μL). The extension products were resolved by 20% 
(w/v) denaturing PAGE containing 7 M urea and visualized using Typhoon FLA 7000 
phosphorimager (GE Healthcare, Pittsburgh, PA). 
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Scheme 4-2 Sequences of DNA oligomers employed in in vitro replication experiments. 
(A) DNA strands used for DPC synthesis, (B) 9-mer FAMdT primer-20-mer template 
duplex used in standing start assays, (C) 13-mer FAMdT primer-39-mer template DNA 
duplex used in running start assays, (D) 9-mer primer-20-mer template duplex used for 
the single nucleotide incorporation and steady-state kinetic assays. 
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4.2.7 Steady-State Kinetic Analyses 
Steady-state kinetics for incorporation of individual nucleotides opposite the 
unadducted dG and 10-mer peptide cross-link were investigated by performing single 
nucleotide incorporation assays with 0.5–50 nM hPol η or 3–55 nM hPol κ in the 
presence of increasing concentrations of individual dNTPs (0–500 µM) and reactions 
were quenched at preselected time points (0–60 min). The product bands were visualized 
using Typhoon FLA 7000 phosphorimager (GE Healthcare, Pittsburgh, PA), and 
quantified by volume analysis using the Image Quant TL 8.0 software (GE Healthcare, 
Pittsburgh, PA). The steady-state kinetic parameters were calculated by nonlinear 
regression analysis using one-site hyperbolic fits in Prism 4.0 (GraphPad Software,       
La Jolla, CA). 
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4.3 RESULTS 
4.3.1 Synthesis and Characterization of DNA-Protein and DNA-Peptide 
Cross-Links 
Model DNA-protein and DNA-peptide cross-links were prepared by covalent 
linkage of 7-(oxoethyl)-7-deazaguanine within DNA and side chain amino group of Lys 
or Arg on proteins and peptides under reducing conditions (Scheme 4-1).354 Synthetic  
20-mer (5'-G TCA CTG GTA deaza-DHP-dGCA AGC ATT G-3') was previously used 
for the generation of DPCs in high yields,354 while the 39-mer (5'-GAA AGA AGdeaza-
DHP-dG ACA GAA GAG GGT ACC ATC ATA GAG TCA GTG-3') has been 
employed in replication studies of DNA interstrand cross-links.389 Biological relevance of 
histones and DNA repair enzymes in DNA-protein cross-linking86,158,159,294 warrants the 
use of histone H4 and E. coli repair protein, AlkB, as model proteins for in vitro 
replication studies. We recently reported the replication bypass of 6×His-eGFP protein 
and the peptides (23-mer and 10-mer) cross-linked to C5 of thymidine.388 The same 
polypeptides were used in this study to assess the effect of cross-linking site within DNA 
on replication bypass of DPCs. Structurally modified DNA strands were isolated using 
denaturing gel electrophoresis, and the purity of the conjugates was tested by sequencing 
PAGE to ensure >98% purity. Synthetic DNA-protein and DNA-peptide cross-links were 
structurally characterized by nanoHPLC-nanspray-MS/MS.354 In the resulting model 
cross-links, the Lys and Arg side chains of proteins are conjugated to the 7-deazaguanine 
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residues of DNA via a two carbon linker, creating a structure that is analogous to DPC 
lesions induced by antitumor nitrogen mustards.158 
4.3.2 Replication Bypass of DNA-Protein Cross-Links 
To examine the influence of model DNA-protein cross-links on DNA replication, 
template-primer complexes containing site-specific 7-deaza-G cross-links to histone H4 
(11.5 kDa), AlkB (22.9 kDa), 6×His-eGFP (28.4 kDa) were subjected to primer extension 
in the presence of human TLS polymerases η,  and ι (Figures 4-1 and 4-2). Templates 
containing unconjugated deaza-DHP-dG and native G served as negative controls, and 
primer extension assays were conducted under both standing start and running start 
conditions.  
Our standing start assays employed a 9-mer primer (5'-CAA FAMdTGC TTG-3') 
extending to the penultimate position of the modified site (-1 primer) on the 20-mer 
template 5'-G TCA CTG GTA XCA AGC ATT G-3', where X = unmodified dG, deaza-
DHP-dG or DPC adduct (Scheme 4-2B). A complete extension to a 20-mer product was 
observed for unmodified and deaza-DHP-dG-containing template strands upon primer 
extension by hPol  and  (Figure 4-1A, B, F and G), although the extension across from 
deaza-DHP-dG was relatively inefficient. In contrast, all three DPCs completely blocked 
DNA synthesis, producing no extension products (Figure 4-1C–E, H and I). hPol ι 
incorporated 1–4 nucleotides opposite unmodified dG template to give 10–13-mer  
products, however deaza-DHP-dG and DPC lesions completely blocked replication 
(Figure 4-1J–M). 
  163
Figure 4-1 Standing start assays for replication bypass of DNA-protein cross-links by 
hPol η, κ and ι. 9-mer FAMdT primers were annealed with 20-mers containing 
unmodified dG, deaza-DHP-dG or covalent cross-links to AlkB, histone H4, or       
6×His-eGFP. The resulting primer-template duplexes (0.15 μM) were incubated in the 
presence of hPol η (0.30 μM, A–E), κ (0.30 μM, F–I) or ι (0.30 μM, J–M). Reactions 
were initiated by the addition of a mixture of dNTPs (500 μM), and quenched at the 
indicated time points. Extension products were separated by 20% denaturing PAGE, and 
visualized by fluorescence imaging.  
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Running start experiments were conducted using a 13-mer primer (5'-CTA TGA 
FAMdTGG TAC C-3') annealed to a 39-mer template 5'-GAA AGA AGX ACA GAA 
GAG GGT ACC ATC ATA GAG TCA GTG-3', where X = unmodified dG, deaza-DHP-
dG or DPC. In this primer-template complex, the 3'-end of the primer is placed ten 
nucleotides upstream from the adducted site (-10 primer) (Scheme 4-2B). We found that 
hPol  and  copied the templates containing unmodified dG and deaza-DHP-dG to 
generate full length 39-mer products (Figure 4-2A, B, E and F). DNA synthesis using 
deaza-DHP-dG-containing template was less efficient as compared to the dG control, 
with pause sites observed at the adducted site and 1–2 nucleotides upstream from the 
adduct (Figure 4-2B and F). As observed in standing start experiments, the DPC lesions 
completely blocked DNA replication (Figure 4-2C, D and G). 
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Figure 4-2 Running start assays for replication bypass of DNA-protein cross-links by 
hPol η, κ and ι. 13-mer FAMdT primers were annealed with 39-mers containing 
unmodified dG, deaza-DHP-dG or covalent cross-links to protein. The resulting primer-
template complexes (0.15 μM) were incubated in the presence of hPol η (0.30 μM, A–D), 
κ (0.30 μM, E–G) or ι (0.30 μM, H–J). Reactions were initiated by the addition of the 
four dNTPs (500 μM), and quenched at the indicated time points. Extension products 
were separated on a 20% denaturing PAGE gel, and visualized by fluorescence imaging. 
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4.3.3 Primer Extension Past DNA-Peptide Cross-links 
It has been hypothesized that the protein component of bulky DPC lesions can be 
proteolytically cleaved to smaller DNA-peptide adducts to facilitate lesion repair and 
polymerase bypass.297,330,331 Therefore, we next addressed the ability of human TLS DNA 
polymerases to bypass smaller lesions containing peptides conjugated to 7-deaza-G in 
DNA (Scheme 4-1). Two biologically relevant peptides were employed: a 10-mer 
peptide derived from c-Myc protein (EQKLISEEDL)390,391 and a 23-mer peptide derived 
from tetanus toxoid (PDAQLVPGINGKAIHLVNNESSE).392 Both peptides were 
conjugated to either 20-mer (5'-G TCA CTG GTA XCA AGC ATT G-3') or 39-mer     
(5'-GAA AGA AGX ACA GAA GAG GGT ACC ATC ATA GAG TCA GTG-3') DNA 
templates, where X = peptide cross-link, for primer extension assays (Scheme 4-2B     
and C). 
In standing start experiments, 9-mer primers annealed to templates containing 
unmodified dG, deaza-DHP-dG, and the 10-mer peptide were fully extended by hPol  
and albeit with varying efficiencies (Figure 4-3A–C and E–G). Interestingly, the     
23-mer peptide cross-link completely blocked both polymerases (Figure 4-3D and H). In 
contrast, both 10-mer and 23-mer peptide conjugates were bypassed by hPol  and 
under running start conditions (Figure 4-4), although a pronounced pausing was 
observed 1–2 nucleotides before the adducted site, and extension beyond the modification 
was very inefficient. In cellular systems, polymerase switching may facilitate the 
translesion bypass of DNA-peptide cross-links. 
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Figure 4-3 Standing start assays for replication bypass of DNA-peptide cross-links by 
hPol η and κ. 9-mer FAMdT primers were annealed with 20-mers containing unmodified 
dG, deaza-DHP-dG or covalent cross-links to 10-mer peptide or 23-mer peptide. The 
resulting primer-template duplexes (0.15 μM) were incubated in the presence of hPol η 
(0.30 μM, A–D) or κ (0.30 μM, E–H). Reactions were initiated by the addition of the four 
dNTPs (500 μM), and quenched at the indicated time points. Extension products were 
separated on a 20% denaturing PAGE gel, and visualized by fluorescence imaging. 
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Figure 4-4 Running start assays for replication bypass of DNA-peptide cross-links by 
hPol η and κ. 9-mer FAMdT primers were annealed with 20-mers containing unmodified 
dG, deaza-DHP-dG or covalent cross-links to 10-mer peptide or 23-mer peptide. The 
resulting primer-template duplexes (0.15 μM) were incubated in the presence of hPol η 
(0.30 μM, A–D) or κ (0.30 μM, E–H). Reactions were initiated by the addition of the four 
dNTPs (500 μM), and quenched at the indicated time points. Extension products were 
separated on a 20% denaturing PAGE gel, and visualized by fluorescence imaging. 
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4.3.4 Single Nucleotide Incorporation Opposite a 10-mer Peptide Cross-
Link 
Single nucleotide insertion assays were conducted to examine the fidelity of 
nucleotide insertion opposite the adducted site by TLS polymerases. The 20-mer 
templates (5'-G TCA CTG GTA XCA AGC ATT G-3') containing unadducted dG or   
10-mer peptide cross-link were annealed to 9-mer primers (5'-CAA TGC TTG-3') 
radiolabeled with 32P (Scheme 4-2D). The resulting primer-template complexes were 
incubated with human bypass polymerase  or  in the presence of individual dNTPs 
(100 μM) for 0–60 min. Denaturing PAGE-phosphorimaging analysis has revealed that 
both polymerases preferentially incorporated the correct base (dC) opposite G,               
as expected (Figure 4-5). Interestingly, single nucleotide insertion by hPol opposite the 
10-mer peptide cross-link was essentially error-free, even with 3-fold excess of the 
enzyme with respect to the primer-template duplex (Figure 4-5A). Furthermore, hPol  
also favored the incorporation of the correct base, dC, although small amount of dT was 
also incorporated (Figure 4-5B). Further, it was evident from these experiments that the 
nucleotide insertion efficiency opposite small DPCs is higher for hPol  as compared to 
hPol  (Figure 4-5). 
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Figure 4-5 Single nucleotide insertion opposite unmodified guanine (dG) and the 10mer 
peptide cross-linked to C7 of 7-deaza-guanine (10-mer pep) by TLS polymerase hPol η 
and κ. 50 nM primer-template duplexes were incubated with hPol η (50 nM, A) and        
κ (150 nM, B) in the presence 100 μM individual dNTPs. The reactions were quenched at 
predetermined time points (0–60 min), the products were separated on a 20% denaturing 
PAGE gel, and visualized by phosphorimaging. 
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4.3.5 Steady-State Kinetic Analyses of Nucleotide Incorporation Opposite 
the 10-mer Peptide Cross-Link 
Steady-state kinetic studies were performed to determine the catalytic efficiency 
and to calculate the misinsertion frequency for incorporation of individual dNTPs 
opposite the 10-mer peptide cross-link by TLS polymerases. Primer-template duplexes 
containing unmodified dG or 10-mer peptide cross-link were incubated with hPol  or  
in the presence of increasing concentrations of individual dNTPs (0–500 μM), and the 
reactions were quenched at preselected time points (0–60 min). Polymerase concentration 
and the time points were selected such that the extent of product formation was <35% of 
the starting substrate concentration. The specificity constant (kcat/Km), a measure of the 
catalytic efficiency of incorporation of each dNTP and the misinsertion frequency (f),      
a quantitative measure of incorporating an incorrect vs. correct dNTP opposite the lesion1 
were calculated by plotting the reaction velocity against dNTP concentration (Table 4-1). 
The specificity constants (kcat/Km) for nucleotide insertion by hPol  were          
4–150-fold higher as compared to those of hPol κ, suggesting hPol  is more efficient in 
replication bypass. This was also evident from the qualitative data obtained from single 
nucleotide insertion assays. Moreover, the specificity constants for the insertion of the 
correct base, dCTP opposite the adduct were 0.03 and 0.0002 μM-1 min-1 for hPol  or , 
respectively (Table 4-1). These values were 49 and 1850-fold lower than those obtained 
for dCTP insertion opposite the unmodified dG (1.46 and 0.37 μM-1 min-1, Table 4-1). 
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This is expected, since accommodation of the bulky adduct in the active site and 
nucleotide insertion are unfavorable processes with respect to the unmodified bases. 
Nucleotide insertion opposite the 10-mer peptide conjugate by hPol  was error-
free. Although hpol  can incorporate an incorrect base, dT opposite the adduct, overall 
the nucleotide insertion is mostly error-free. The misinsertion frequency (f) for dTTP was 
500-fold lower compared to the incorporation of the correct nucleotide, dCTP         
(Table 4-1). Hence, our steady-state kinetic data suggests high fidelity nucleotide 
insertion opposite the 10-mer peptide cross-linked to N7 of guanine in DNA. 
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Table 4-1 Steady-state kinetic parameters for single nucleotide insertion opposite the positive control (dG) and the 10mer peptide      
cross-linked to C7 of deazaguanine (10-mer peptide) by human TLS polymerases, hPol  and . 
Polymerase Template Incoming nucleotide 
kcat Km kcat / Km 
f  
min-1 μM μM-1 min-1 
hPol η dG dCTP 3.73 ± 0.23     2.55 ±   1.04 1.46 1 
dTTP 0.70 ± 0.08 120.20 ± 38.39 0.006 0.004 
10-mer peptide dCTP 0.38 ± 0.04   13.11 ±  4.92 0.03 1 
dTTP   0.01 ± 0.001   31.53 ± 11.17 0.00005 0.002 
hPol κ dG dCTP 0.53 ± 0.04     1.46 ±   1.15 0.37 1 
10-mer peptide dCTP  0.02 ± 0.004   62.69 ±  23.98 0.0002 1 
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4.4 DISCUSSION 
Cross-linking drugs such as nitrogen mustards, haloethylnitrosoureas, and 
platinum antitumor agents are commonly used to treat a variety of neoplasms including 
leukemia, lymphoma, ovarian adenocarcinoma, and breast, lung, and testicular 
cancer.269,274,278,286,288 Upon entering the cell nucleus, these drugs form a complex mixture 
of DNA lesions including nucleobase monoadducts, interstrand and intrastrand DNA-
DNA cross-links, and DNA-protein cross-links (DPCs).263 In contrast to the wealth of 
information about interstrand DNA-DNA cross-links, which are thought to induce cancer 
cell death by preventing DNA strand separation,261,393 little is known about how DPC 
lesions contribute to the biological effects of bis-alkylating agents. Because of their 
enormous size as compared to “normal” DNA lesions, DPCs are hypothesized to block 
DNA replication, leading to toxicity.1,4 However, the ability of human DNA polymerases 
to replicate DPC-containing DNA has not been systematically studied. 
The majority of DNA-protein conjugates induced by antitumor nitrogen mustards 
such as mechlorethamine, chlorambucil, platinum compounds, chlorooxirane, and 
diepoxides such as 1,2,3,4-diepoxybutane involve the N7-G position of 
DNA.85,86,158,159,161,294 However, with the exception of platinum adducts, N7-G lesions are 
hydrolytically labile,375 making it unfeasible to synthesize site-specific substrates 
containing such adducts for polymerase bypass assays. We recently developed                 
a reductive amination methodology to prepare hydrolytically stable model DPC 
substrates that resemble DPCs formed by nitrogen mustards and chlorooxirane (Chapter 
  175
3).354 In the present study, this methodology was employed to prepare DNA-peptide and 
DNA-protein substrates of increasing size by systematically varying the size of the 
polypeptide (1.3–28.4 kDa, Scheme 4-1). The resulting template–primer complexes were 
subjected to primer extension experiments to investigate the replication bypass of these 
bulky lesions by human TLS polymerases. 
Lesion bypass is an important mechanism of cellular DNA damage tolerance, 
which allows for DNA replication past bulky DNA adducts that block replicative 
polymerases α, δ and ε.130,131,133-135 Because of the super bulky nature of DPCs, they are 
postulated to completely block these high fidelity polymerases, leading to stalling of the 
replication fork.131,132 A specialized group of polymerases called translesion synthesis 
(TLS) polymerases can be recruited to blocked replication forks.130,133,134 Human            
Y family polymerases hPol η, κ, ι and Rev1, A family polymerase ν, and B family 
polymerase ζ are TLS polymerases that can trade places with replicative polymerases / 
using the PCNA sliding clamp and insert nucleotides opposite bulky nucleobase 
adducts.130,131,136-140,142 TLS polymerases are catalytically less efficient than replicative 
enzymes and are much more error-prone owing to their open and flexible active site that 
accommodate large DNA adducts131,142,144,146 and the lack of intrinsic 3'5' proofreading  
activity.129,130,139,143,149,150 
Our in vitro DNA replication studies employing model DNA-protein cross-links 
at the 7-deazaguanine of DNA (Scheme 4-1) suggest that these super bulky lesions 
represent a complete replication block, even in the presence of human lesion bypass 
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polymerases η, κ and ι (Figures 4-1 and 4-2). In both standing and running start 
experiments, templates containing unmodified dG and deaza-DHP-dG showed full 
extension with varying efficiency for both hPol η and κ. However, primers annealed with 
the C7-G templates cross-linked to histone H4 (11.4 kDa), AlkB (22.9 kDa) and     
6×His-eGFP (28.4 kDa) completely blocked replication, irrespective of the size of the 
protein. Our results are in agreement with previously reported polymerase blockage by 
DPCs in vivo.132,326,339 Kreuzer and coworkers found bubble and Y molecule 
accumulation in wild-type pBR322 plasmids containing MTase (53.5 kDa) cross-linked 
to 5-azacytosine in E. coli, but not in EcoRII methylation site mutant.132 Nakano et al. 
found that transformation efficiency of pGL3-CMV plasmids containing formaldehyde-
mediated histone H1 (21.7 kDa) DPCs was <10% compared to undamaged plasmids.326 
In another study, relative transformation efficiency of pMS2 plasmids containing        
UV-induced T4-pdg (16 kDa) DPCs was found to be <5%, while that of UV-irradiated 
plasmids was ~50%.339 These results suggest that DPCs significantly hinder replication in 
vivo, irrespective of the identity of the protein or the cross-linking agent. Observation that 
transformation efficiency of pGL3-CMV plasmids containing partially digested histone 
H1 DPCs increased to 58% from <10% for undigested DPC containing plasmids suggest 
that size of the cross-linking polypeptide plays an important role in replication bypass.326 
It has been proposed that the protein component of cellular DPCs undergoes 
proteolytic degradation to peptides, generating smaller lesions that can be bypassed in an 
error-free or in an error-prone manner.169,297,324,331 To test this hypothesis, we examined 
the replication bypass of a 23-mer and a 10-mer peptide cross-linked to C7-G. In standing 
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start assays, 23-mer peptide cross-link completely blocked replication, while the 10-mer 
peptide cross-link was bypassed with extremely low efficiency (Figure 4-3). Replication 
blockage by C7-G adducted 23-mer peptide contradicts previous reports that tetra- and 
dodecylpeptides cross-linked to major groove of DNA via N6-A were bypassed by        
Pol ν,336 while same peptides adducted to N2-G were also bypassed by hPol κ and Pol IV 
efficiently.335 This discrepancy may be due to the structural differences of DPCs such as 
site of cross-linking on DNA or peptide size employed. In contrast, TLS polymerases 
were able to replicate past both 10-mer and 23-mer peptide substrates under running start 
conditions (Figure 4-4). Major polymerase pause sites were observed one–two 
nucleotides prior to the adducted site, despite high replication efficiency observed 
initially (Figure 4-4). Nucleotide insertion as well as the extension past the peptide 
adducts were extremely inefficient. Further, the bypass efficiency decreased in the the 
order of dG > deaza-DHP-dG > 10-mer peptide demonstrating the influence of the size of 
the adduct on replication (Figure 4-3). These observations are not surprising, because 
polymerase loading and nucleotide insertion may be unfavorable at the immediate 
vicinity of a bulky lesion. 
To determine what nucleotides are incorporated opposite the adduct upon bypass 
of the 10-mer peptide lesions, we conducted single nucleotide insertion assays       
(Figure 4-5). We found that hPol η is catalytically more efficient than hPol κ in 
bypassing these DPCs. hPol η showed ~80% dCMP insertion within 60 min with 
DNA:enzyme = 1:1 (Figure 4-5B). In contrast, hPol κ only catalyzed the incorporation of 
~20% dCMP after 60 min with DNA:enzyme = 1:3 (Figure 4-5A). These results were 
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confirmed by steady-state kinetic studies. All the specificity constants (kcat/Km), which 
measure the catalytic efficiency of the enzyme, for hPol  were considerably higher 
compared to those of hPol κ (Table 4-1). Higher catalytic efficiency of hPol  over hPol 
κ is consistent with previous reports, which employed either exocyclic DNA 
lesions112,394,395 or DNA-peptide cross-links.338  
Fidelity of replication bypass is crucial in the context of cytotoxicity and 
mutagenicity of DNA lesions. Qualitative data obtained from our single nucleotide 
insertion assays provided evidence for high fidelity replication bypass of model DNA-
peptide cross-links to the major groove of DNA via a purine base. Replication bypass of 
the 10-mer peptide cross-linked to C7-G by hPol κ was error free, while hPol  
preferentially incorporated the correct base, dC (Figure 4-5). According to the 
misinsertion frequencies (f) calculated from steady-state kinetic data, hPol  showed  
500-fold preference to insert the correct base, dC opposite the adduct over the mispair, dT    
(Table 4-1). High fidelity observed with hPol ν and hPol κ in bypassing N6-A and N2-G 
adducted peptides, respectively,335,336 corroborate the high fidelity detected with the        
Y family polymerases in our study.  
The high fidelity of bypass of 10-mer peptide-DNA cross-links observed in the 
present study is in contrast with the highly error-prone bypass and postlesion synthesis 
observed when the same 10-mer peptide was cross-linked to C5 of thymidine (Chapter 6). 
In the latter study, both hPol  and κ incorporated all four dNTPs opposite the C5-T 
peptide cross-links, while hPol  preferentially incorporated the mispair, dG opposite the 
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adduct. These pronounced differences in fidelity can be a result of the different        
cross-linking site on DNA. Unlike 7-deazaguanine DPCs, C5-T cross-links appear to 
interfere with the ability of the DNA polymerases to accurately replicate the adducted 
nucleobase. However, it is interesting that TLS polymerases distinguish an adducted 
purine accurately, but not an adducted pyrimidine. Future X-ray crystallographic or NMR 
structural studies can provide insights into the variability in fidelity of these lesion bypass 
polymerases to purine vs. pyrimidine DNA adducts. 
In summary, we examined the ability of human lesion bypass polymerases to 
catalyze replication past DNA-protein and DNA-peptide cross-links conjugated to the 
major groove of DNA via N7 of guanine. We found that large DNA-protein and DNA-
peptide cross-links represent a complete block to human TLS polymerases, while             
a smaller 10-mer peptide cross-link was bypassed with high fidelity. Our 7-deazaguanine 
DNA substrates are structurally analogous to major DNA-protein cross-links formed      
in vivo when nitrogen mustards and chlorooxirane-mediate DNA-protein cross-
linking.158,159,376 Hence, our results suggest that DPCs formed to N7 of guanine in cells 
get proteolytically degraded to smaller peptide cross-links, which are then bypassed by 
human TLS polymerases with high fidelity. Sequencing of primer extension products 
using a liquid chromatography-tandem mass spectrometry methodology is currently in 
progress. These studies will provide insights into any insertion/deletion mutations caused 
upon replication bypass of these biologically relevant DNA-peptide cross-links. 
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SYNTHESIS OF SITE-SPECIFIC DNA-
PROTEIN CROSS-LINKS CONJUGATED 
TO THE C5 OF THYMIDINE AND THEIR 
EFFECTS ON DNA REPLICATION 
5 SYNTHESIS OF SITE-SPECIFIC DNA-PROTEIN CROSS-LINKS CONJUGATED TO THE C5 OF THYMIDINE AND THEIR EFFECTS ON DNA REPLICATION 
Reproduced in part with permission from Jung-Eun Yeo, Susith Wickramaratne, Santoshkumar Khatwani, 
Yen-Chih Wang, Jeffrey Vervacke, Mark D. Distefano, and Natalia Y. Tretyakova. ACS Chem. Biol. 
(2014) (10.1021/cb5001795). ©American Chemical Society. 
5.1 INTRODUCTION 
DNA-protein cross-linking is non-random, with specific amino acid side chains 
(typically cysteine, lysine, or arginine) participating in cross-linking.86,159,294 In addition, 
acrolein, crotonaldehyde, and 4-hydroxynonenal can form Schiff base cross-links 
between DNA and the N-terminal α-amino groups of proteins.197 Despite their ubiquitous 
nature, the biological consequences of DPC formation have not been fully elucidated, 
probably a result of their inherent structural complexity and the limited availability of 
structurally defined DPC substrates. It has been hypothesized that covalent DNA-protein 
conjugates induced by reactive oxygen species may play a role in the etiology of 
neurodegenerative and cardiovascular diseases due to their deleterious effects on DNA 
replication, transcription, repair, and chromatin remodeling.5,35 Indeed, our recent 
experiments employing epoxide-functionalized protein reagents that selectively induce 
DPCs have provided the first direct evidence for the ability of DNA-protein cross-links to 
induce toxicity and mutations in human cells.304  
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Our laboratory has been developing novel methodologies to generate synthetic 
DPCs structurally analogous to DPC adducts found in cells. We recently reported the use 
of a reductive amination strategy to create a DPC between an C7-deaza-G in DNA and 
basic lysine or arginine side chains of proteins and peptides (Chapter 3).354 The resulting 
model DPC substrates were site-specific within DNA, but involved multiple cross-linking 
sites within the protein.354  
In the present work, a bioorthogonal approach employing copper-catalyzed [3+2] 
Huisgen cycloaddition (click reaction) between azide-functionalized proteins/peptides 
and alkyne-containing DNA was used to generate structurally defined DPC conjugates. 
The azide groups were incorporated via synthetic methods for short peptides and 
enzymatically for a larger protein, while alkyne-containing DNA was generated by solid 
phase synthesis. The resulting cross-links are site specific with regard to both protein and 
DNA. Synthetic DNA-protein conjugates were subjected to in vitro DNA replication 
experiments in order to evaluate the ability of human DNA polymerases to bypass these 
bulky lesions. 
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
C8-alkyne-dT-CE phosphoramidite and all other reagents for DNA synthesis were 
purchased from Glen Research (Sterling, VA). Synthetic DNA oligonucleotides 
containing native DNA bases and nucleobase modifications were prepared by solid phase 
synthesis using an ABI 394 DNA synthesizer (Applied Biosystems, CA), purified by 
HPLC on a Synergi 4u Hydro-RP 80A column, and desalted using NAP-5 columns     
(GE Healthcare, NJ). T4 polynucleotide kinase was obtained from New England Biolabs 
(Beverly, MA). γ-32P ATP was purchased from Perkin-Elmer Life Sciences        
(Waltham, MA). The unlabeled dNTPs were obtained from Omega Bio-Tek       
(Norcross, GA). 40% 19:1 Acrylamide/bis solution and micro biospin-6 size exclusion 
columns were purchased from Bio-Rad (Hercules, CA). Ammonium persulfate, CH3CN, 
and EDTA were obtained from Fisher (Fair Lawn, NJ). Tris[(1-benzyl-1H-1,2,3-triazol-
4-yl)methyl]amine (TBTA) was purchased from AnaSpec Inc. (Fremont, CA). NuPAGE 
Novex 12% Bis-Tris gels (Life Technologies, Grand Island, NY) were run in                 
1× NuPAGE MOPS SDS running buffer (Life Technologies, Grand Island, NY) and 
stained with SimplyBlue SafeStain (Life Technologies, Grand Island, NY). Trypsin was 
obtained from Promega (Madison, WI), and ZipTips for peptide desalting were purchased 
from Millipore (Billerica, MA). Sep-Pak C18 SPE cartridges were from Waters      
(Milford, MA). Recombinant hPol η, hPol κ and hPol ι were obtained from Enzymax 
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(Lexington, KY). All other chemicals and solvents were purchased from Sigma-Aldrich 
(Milwaukee, WI) and were of the highest grade available. 
5.2.2 Oligodeoxyonucleotide Synthesis 
DNA 23-mer (5'-AGG GTT TTC CCA GXC ACG ACG TT-3') and 18-mer      
(5'-TCA TXG AAT CCT TCC CCC-3'), where X = 5-(octa-1,7-diynyl)-uracil             
(C8-alkyne-dT), were prepared by solid phase synthesis on an ABI 394 DNA synthesizer 
using commercial phosphoramidites (Glen Research, Sterling, VA). Manual coupling was 
employed for the incorporation of C8-alkyne-dT. Deprotection of the synthesized 
oligonucleotides was carried out in NH4OH at room temperature for 2 days. The 
corresponding unmodified 18-mer (5'-TCA TTG AAT CCT TCC CCC-3') was prepared 
by standard solid phase methodology. DNA 13-mer (5'-GGG GGA AGG ATT C-3') and 
9-mer (5'-GGG GGA AGG-3') were purchased from Integrated DNA Technologies 
(Coralville, IA). All synthetic DNA oligomers were purified by HPLC on a Synergi 
Hydro-RP 80A (10 × 250 mm, 4 µm) column eluted at a flow rate of 3 mL/min. HPLC 
solvents were 150 mM NH4OAc (A) and 1:1 mixture of 150 mM NH4OAc and      
CH3CN (B). A linear gradient of 10% to 42% B over 60 min was used. HPLC fractions 
containing full length oligomers were collected, concentrated under vacuum, and desalted 
by size exclusion via NAP-5 columns. All synthetic DNA strands were characterized by 
HPLC-ESI--MS and quantified by UV spectrophotometry. 
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5.2.3 Preparation of Radiolabeled Oligodeoxynucleotides  
DNA 23-mers containing C8-alkyne-dT at the 14th position (5'-AGG GTT TTC 
CCA GXC ACG ACG TT-3') or 18-mers containing an C8-alkyne-dT at the 5th position 
(5'-TCA TXG AAT CCT TCC CCC-3', 2 nmol in 17 μL of water) were incubated in   
10× PNK buffer (3 μL) in the presence of T4 PNK (20 U) and γ-32P ATP (30 μCi) at     
37 °C for 1 h. The mixture was heated at 65 °C for 10 min to inactivate the enzyme and 
passed through Illustra Microspin G25 columns (GE Healthcare, Pittsburgh, PA) to 
remove excess γ-32P ATP. DNA primers (5'-GGG GGA AGG ATT C-3' and 5'-GGG 
GGA AGG-3') used in replication assays were also radiolabeled following the same 
protocol. 
5.2.4 Preparation of 6×His-eGFP-N3  
Green fluorescent protein genetically engineered to contain a hexa-histidine tag 
(6×His-eGFP) was expressed and purified as previously described.352 6×His-eGFP was 
enzymatically prenylated on the cysteine of the C-terminal CVIA CaaX box motif using 
yeast farnesyltransferase. Enzymatic reactions (total volume = 10 mL) were carried out 
by incubating a solution of the protein (2 µM) and DTT (5 mM, premixed and incubated 
at room temp. for 1 h) with MgCl2 (10 mM), Tris-HCl (10 µM, pH 7.5), C10 dihydroazide 
(40 µM) and yeast farnesyltransferase (150 nM) at 30 °C for 2 h. The reaction mixture 
was concentrated to ~500 µL by Centricon centrifugal filters (MWCO 10,000), and the 
excess azide was removed by size exclusion with a NAP-5 column eluted with PBS 
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buffer (50 mM NaH2PO4, 0.1 M NaCl, pH 7.3). Concentration of the prenylated protein 
was determined by measuring its absorbance at 488 nm (488 for 6×His-eGFP = 55, 000). 
5.2.5 Preparation of Azide-Containing Peptides 
Peptide synthesis was carried out using an automated solid-phase peptide 
synthesizer (PS3, Protein Technologies Inc., Memphis, TN) employing standard Fmoc 
chemistry and HCTU coupling procedures. The 10-mer peptide N3(CH2)3CO-
EQKLISEEDL-NH2 was synthesized on a Rink-amide-MBHA resin (0.1 mmol scale) by 
coupling each amino acid in DMF containing Fmoc-amino acid (4 eq.), HCTU (4 eq.),   
6-Cl-HOBt (4 eq.) and N-methylmorpholine (8 eq.) for 20 min. Fmoc deprotection of the 
peptide was performed with 20% piperidine in DMF for 5 min twice. N-terminal            
4-azidobutanoic acid was coupled in DMF containing 4-azidobutanoic acid (4 eq.), 
HCTU (4 eq.), 6-Cl-HOBt (4 eq.) and DIPEA (8 eq.) for 2 h. The peptide was 
simultaneously cleaved from the resin and deprotected by the treatment with Reagent K 
(0.5 g phenol, 0.5 mL H2O, 0.5 mL thioanisole, 0.25 mL 1,2-ethanedithiol in 10 mL 
trifluoroacetic acid (TFA)) for 2 h. The solution was concentrated to 2 mL by bubbling 
with N2 and precipitated in Et2O. HPLC purification of the peptide was performed using 
a Luna C18 (10 × 250 mm, 10 µm) column (Phenomenex, Torrance, CA) eluted with a 
gradient of aqueous 0.1% TFA (A) and 0.1% TFA in CH3CN (B). Solvent composition 
was maintained at 0% B for 5 min, followed by a linear gradient of 0 to 70% B over 50 
min at a flow rate of 5 mL/min. Calculated for C55H93N16O21, [M+H]+ = 1313.6696, 
found [M+H]+ = 1313.6436 from ESI+-MS. 
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Synthesis of 23-mer peptide N3(CH2)3CO-PDAQLVPGINGKAIHLVNNESSE 
began on a preloaded Fmoc-Glu(OtBu)-Wang resin (0.10 mmol) and the peptide chain 
was elongated using HCTU/N-Methylmorpholine-catalyzed, single coupling steps with 
protected amino acids (4 eq.) and HCTU (4 eq.) for 30 min. Following complete chain 
elongation, the peptide's N-terminus was deprotected with 10% piperidine in DMF (v/v) 
and the presence of the resulting free amine was confirmed by ninhydrin analysis. The 
resin containing the peptide was washed with CH2Cl2, dried in vacuo overnight, weighed, 
and divided into two portions for further synthesis on a reduced scale. Using 50.0 µmol 
of peptide, the free amino terminus was acylated with the 4-azidobutanoic acid (13.5 mg, 
100 µmol, 2 eq.) catalyzed by DIC (13 mg, 100 µmol, 2 eq.) in the presence of DIEA  
(8.6 µL, 5.0 µmol, 0.1 eq.) in DMF (5 mL) for 10 h. After acylation was judged complete 
by ninhydrin analysis, the resin bound peptide was washed thoroughly with CH2Cl2 and 
dried in vacuo for 4 h. The peptide was cleaved from the resin along with simultaneous 
side chain deprotection by treatment with Reagent K at room temperature for 2 h. The 
released peptide was collected and combined with TFA washes of the resin before 
precipitation of the peptide in chilled Et2O (100 mL). The crude solid peptide was 
collected by centrifugation, the supernatant was removed, and the resulting pellet was 
washed 2 times with cold Et2O (50 mL) repeating the centrifugation and supernatant 
removal steps each time. The crude peptide was purified using a semi-preparative C18 
RP-HPLC column with detection at 220 nm and eluted with a gradient of solvent A 
(H2O/0.1% TFA, v/v) and solvent B (CH3CN/0.1% TFA, v/v). The crude peptide        
(150 mg) was dissolved in a DMF/H2O solution (1:5 v/v, 25 mL), applied to the column 
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equilibrated in Solvent A, and eluted using a linear gradient of 0–70% solvent B over   
1.5 h at a flow rate of 5 mL/min. Fractions were analyzed for purity by an analytical C18 
RP-HPLC column employing a linear gradient of 0–100% solvent B over 60 min at a 
flow rate of 1 mL/min and detected at 220 nm. Fractions containing peptide product of   
at least 90% purity were pooled and concentrated by lyophilization to yield 35 mg (25% 
yield) of a white solid. A small amount (<1mg) of the resulting purified peptide was 
dissolved in 10 µl of 0.1% TFA/CH3CN and diluted 1:50 in a mixture of CH3CN/H2O 
(1:1 v/v) prior to MS analysis. MS analysis was performed using a 50 µL injection and 
collecting 3000 scans. Calculated for C109H178N34O38, [M+2H]2+ = 1258.1345, found 
[M+2H]2+ = 1258.1406 from ESI+-MS. 
5.2.6 Copper-Catalyzed Cycloaddition Reaction between 6×His-eGFP-N3 
and Alkyne-Containing DNA  
HPLC pure DNA oligodeoxynucleotides (5'-AGG GTT TTC CCA GXC ACG 
ACG TT-3' or 5'-TCA TXG AAT CCT TCC CCC-3', 1 nmol), where X = C8-alkyne-dT, 
were mixed with 6×His-eGFP-N3 (6 nmol), 2 µL of Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) 
methyl]amine (TBTA, 5 mM stock in DMSO:tBuOH = 1:4), 20 µL of tris(2-carboxy-
ethyl)phosphine (TCEP, 5 mM stock in H2O), and 20 µL of CuSO4 (5 mM stock in H2O) 
in 50 mM phosphate buffer (pH 7.5), in a final reaction volume of 100 µL. The reaction 
was allowed to proceed for 1.5–2 h at room temperature upon mixing with a rotatory 
shaker. Following desalting on Micro biospin-6 columns, aliquots of the reaction 
mixtures were withdrawn and resolved by 12% SDS-PAGE. To visualize DPC formation, 
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NuPAGE Novex 12% Bis-Tris gels (Life Technologies, Grand Island, NY) were run at a 
constant voltage of 130 V for 1 h in 1× NuPAGE MOPS SDS running buffer. The 
reaction mixtures obtained from DNA-protein cross-linking reactions were reconstituted 
in NuPAGE SDS sample buffer and heated at 70 °C for 10 min prior to loading on the 
gel. The unreacted protein and DNA-protein conjugates were visualized by staining with 
SimplyBlue SafeStain. Proteinase K digestion (6 units, at 37 °C for 48 h) was conducted 
to confirm the presence of protein in slowly moving DNA bands. The reaction yields 
were quantified by ImageJ software. 
5.2.7 Cross-Linking Reaction between Azide-Functionalized Peptides and 
Alkyne-Containing DNA  
DNA oligodeoxynucleotides (5'-AGG GTT TTC CCA GXC ACG ACG TT-3' or 
5'-TCA TXG AAT CCT TCC CCC-3', 15 pmol), where X = C8-alkyne-dT, were mixed 
with 1.5 nmol of azide-functionalized peptide 10-mer N3(CH2)3CO-EQKLISEEDL-NH2 
or the 23-mer N3(CH2)3CO-PDAQLVPGINGKAIHLVNNESSE, 1 µL of TBTA (5 mM 
stock in DMSO:t-BuOH 1:4), 10 µL of TCEP (5 mM stock in H2O), 10 µL of CuSO4     
(5 mM stock in H2O), and 50 mM phosphate buffer (pH 7.5) in a final reaction volume of 
50 µL. The reaction was mixed using a rotatory shaker at room temperature. After 
allowing the reaction to proceed for 1.5–2 h, it was quenched by adding 0.5 mM EDTA. 
An aliquot was radiolabeled using γ-32P ATP as described previously, loaded onto a 20% 
denaturing PAGE gel, and ran at 15 W for 1.5 h. The products were visualized using a 
Typhoon FLA 7000 phosphorimager (GE Healthcare, Pittsburgh, PA).  
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5.2.8 Gel Electrophoresis Purification of DNA-Protein Cross-Links 
DNA-protein cross-linking reaction mixtures were desalted by Micro biospin-6 
size exclusion columns (BioRad, Hercules, CA), while DNA-peptide reaction mixtures 
were desalted using Sep-Pak C18 SPE cartridges (Waters, Milford, MA). The resulting 
solutions were loaded onto 15% or 20% (w/v) denaturing PAGE gels containing 7 M 
urea. DPC bands were visualized by SimplyBlue SafeStain, excised, and the DPCs were 
extracted using the flextube gel elution system (IBI Scientific, IA) following the 
manufacturer's instructions. DNA-peptide conjugates were extracted from the gel by 
using a freeze-thaw method. Gel pieces were suspended in 1× TE buffer, and subjected to 
10 cycles of subsequent freezing in dry ice-ethanol and allowed to thaw at room temp. 
The gel bands were then incubated at 37 °C for 2 days. Following gel purification, DNA-
protein cross-links were desalted using Micro biospin-6 columns, while DNA-peptide 
conjugates were desalted by SPE on Sep-Pak C18 cartridges. 
5.2.9 Mass Spectrometry Analysis of DNA-Protein Cross-Links 
DNA-protein cross-links containing 6×His-eGFP protein conjugated to synthetic 
23-mer oligodeoxynucleotide (5'-AGG GTT TTC CCA GXC ACG ACG TT-3') at 
position X were purified by 12% SDS-PAGE and stained with SimplyBlue SafeStain. Gel 
bands were cut into slices and subjected to reduction with 300 mM DTT (10 μL), 
followed by alkylation with iodoacetamide (10 μL in 25 mM NH4HCO3, pH 7.9). Gel 
pieces were dehydrated with CH3CN, dried under vacuum, reconstituted in 25 mM 
NH4HCO3 (pH 7.9, 75 μL), and incubated with PDE I (120 mU) at 37 °C overnight to 
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digest the DNA portion of the cross-link. The resulting 6×His-eGFP-nucleotide 
conjugates were subjected to tryptic digestion using MS grade Trypsin Gold at 37 °C for 
20 h and desalted using C18 ZipTips (Millipore, Billerica, MA). Samples were dissolved 
in 0.1% acetic acid (25 μL), and 5–8 μL of this solution was used for MS analysis. 
NanoLC-nanospray-MS/MS analysis was conducted using an LTQ Orbitrap 
Velos mass spectrometer (Thermo Scientific, Waltham, MA) in line with a NanoLC-
Ultra 2D HPLC system (Eksigent, Dublin, CA). Chromatography was performed using a 
hand packed Luna C18 capillary column (75 μm ID, 10 cm packed bed, 15 μm orifice,    
5 μm particle size). The HPLC mobile phases used were 0.1% formic acid in H2O (A) 
and 0.1% formic acid in CH3CN (B). Peptide mixtures (5 μL) were injected using a 5 μL 
loop and loaded onto the column with a 1 µL/min flow of 2% B for 5.5 min, at which 
point the injection valve was switched to the load position, and the flow was reduced to 
0.3 µL/min. The following linear gradient profile was then used: 2% to 70% B over 60 
min, then to 95% B over 1 min, kept at 95% B for a further 5 min, and decreased to 2% B 
in 1 min. Finally, the flow rate was increased to 1 µL/min and kept at 2% B for 4 min. 
Mass spectrometry analyses were performed using an FTMS mass analyzer with a 
resolution of 60,000 and a scan range of 300–2000. Peptide MS/MS spectra were 
collected using data-dependent scanning in which one full scan mass spectrum was 
followed by 8 MS/MS spectra using an isolation width of 2.5 m/z, 35% normalized CID 
collision energy, 1 repeat count and 30 s repeat duration with an exclusion mass width of 
5 ppm. Spectral data were analyzed using Proteome Discoverer 1.3 software (Thermo 
Scientific, San Jose, CA) that linked raw data extraction, database searching, and 
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probability scoring. The raw data were directly uploaded, without any format conversion, 
to search against the protein FASTA database. Search parameters included trypsin 
specificity and up to 2 missed cleavage sites. 
5.2.10 Mass Spectrometry Characterization of Synthetic DNA-Peptide 
Cross-Links  
DNA-peptide conjugates, 5'-AGG GTT TTC CCA GXC ACG ACG TT-3' 
containing a covalent cross-link from C5 position of dT to the N-terminus of the 10-mer 
peptide EQKLISEEDL, were generated by copper-catalyzed click chemistry as described 
above and isolated using 15% or 20% (w/v) denaturing polyacrylamide gels containing   
7 M urea. Following elution from the gel using the freeze-thaw method, the cross-links 
were desalted by SPE on Sep-Pak C18 cartridges. The DNA component of the conjugate 
was digested to nucleosides with PDE I (120 mU), PDE II (105 mU), DNase (35 U), and 
alkaline phosphatase (22 U) at 37 °C overnight in 10 mM Tris-HCl/15 mM MgCl2 (pH 7) 
buffer. The resulting dT-peptide conjugates were dried under vacuum and desalted with 
C18 ZipTips. Samples were dissolved in 0.1% acetic acid (25 μL), and 5–8 μL of this 
solution was used for MS analysis. NanoLC-nanospray-MS/MS analysis was conducted 
using an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Waltham, MA) as 
described above for DNA-protein cross-links, with the exception that HPLC was 
conducted using a gradient of 0.1% formic acid in H2O (A) and CH3CN (B). Mass 
spectrometry analysis of DNA-peptide cross-links was performed using an FTMS mass 
analyzer with a resolution of 30,000 and a scan range of 300–2000 in the full scan mode 
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using an isolation width of 1.0 m/z, 35% normalized CID collision energy. Peptide 
MS/MS spectra were collected using an isolation width of 3.0 m/z, 40% normalized HCD 
collision energy with a resolution of 7500 and a scan range of 50–2000 m/z. 
5.2.11 Polymerase Bypass Assay 
Oligodeoxynucleotide primers (5'-GGG GGA AGG ATT C-3' and 5'-GGG GGA 
AGG-3', 100 pmol) were radiolabeled in the presence of T4 PNK (20 unit) and γ-32P ATP 
(30 μCi) at 37 °C for 60 min in 1× PNK buffer (total volume = 20 μL). The solutions 
were heated at 65 °C for 10 min to inactivate the enzyme and passed through Illustra 
Microspin G25 columns (GE Healthcare, Pittsburgh, PA) to remove excess γ-32P ATP.  
5'-32P-labeled primers (50 pmol) were mixed with 2 eq. of HPLC-pure template strands 
(5'-TCA TXG AAT CCT TCC CCC-3' where X = the click reaction generated covalent 
cross-link from the C5 position of dT to the C-terminus Cys of 6×His-eGFP, and N-
terminus of 23-mer peptide (PDAQLVPGINGKAIHLVNNESSE) or 10-mer peptide 
(EQKLISEEDL)) in 10 mM Tris buffer (pH 7) containing 50 mM NaCl. Control template 
strands contained unmodified dT at position X. The strands were annealed by heating at 
90 °C for 10 min and cooling slowly overnight to afford the desired radiolabeled 
template-primer duplexes. 
Primer-template duplexes (40 nM in the final reaction volume of 40 μL) were 
incubated with human recombinant DNA polymerases (final concentrations: 160 nM 
hPol η, 400 nM hPol κ, 80 nM hPol ι) at 37 °C in the presence of a buffered solution 
containing 50 mM Tris (pH 7.5), 50 mM NaCl, 5 mM DTT, 100 μg/μL BSA,             
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10% glycerol (v/v) and 5 mM MgCl2. Primer extension reactions were initiated by adding 
0.5 mM solutions of all four dNTPs. Aliquots of the reaction mixtures (4 μL) were 
withdrawn at preselected time intervals (0–180 min) and quenched by the addition of     
18 µL of a solution containing 95% formamide (v/v), 10 mM EDTA, 0.03% 
bromophenol blue (w/v) and 0.03% xylene cyanol (w/v). Samples were loaded on to a 
20% denaturing polyacrylamide gel containing 7 M urea and run at 80 W for 2.5 h. The 
extension products were visualized using a Typhoon FLA 7000 instrument in the 
phosophorimaging mode. 
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5.3 RESULTS 
5.3.1 Site-Specific DNA–Protein Cross-Linking Using Alkyne−Azide 
Cycloaddition (Click) Reaction 
Site-specific DPCs were generated via 1,3-dipolar cycloaddition between azide-
containing proteins/peptides and alkyne-functionalized oligodeoxynucleotides in the 
presence of copper ([3+2] Huisgen cycloaddition) to give a 1,2,3-triazole (Schemes 5-1 
and 5-2).352 To prepare azide-functionalized green fluorescent protein (6×His-eGFP-N3), 
a previously described eGFP construct bearing an N-terminal His-tag and a C-terminal 
CVIA sequence was employed.352 The latter sequence allows the cysteine residue within 
CVIA to be enzymatically prenylated by protein farnesyltransferase (PFTase) using an 
azide-containing farnesyl diphosphate substrate analogue (Scheme 5-1).352,396,397 
Synthetic 10-mer and 23-mer peptides were prepared via solid phase peptide synthesis 
and appended with an N-terminal 4-azidobutanoic acid group for subsequent                
Cu-catalyzed click reaction (Scheme 5-2). Synthetic DNA oligomers containing 5-(octa-
1,7-diynyl)-uracil (C8-alkyne-dT) were prepared by solid phase synthesis starting with 
commercial phosphoramidites (Glen Research, Sterling, VA). The resulting biomolecules 
were purified by HPLC and characterized by mass spectrometry. 
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Scheme 5-1 Generation of site-specific DNA-protein conjugates by copper-catalyzed 
[3+2] Huisgen cycloaddition. Click reaction between an alkyne group from 5-(octa-    
1,7-diynyl)-uracil in DNA and an azide group within modified green fluorescent protein 
(6×His-eGFP-N3) in the presence of CuI generates triazole-linked DPCs. 
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Scheme 5-2 Synthesis of site-specific DNA-peptide cross-links by copper-catalyzed 
azide-alkyne cycloaddition reaction. Synthetic 10-mer and 23-mer peptides were 
prepared via solid phase peptide synthesis and appended with an N-terminal                    
4-azidobutanoic acid group, and reacted with the terminal alkyne of 5-(octa-1,7-diynyl)-
uracil in DNA to form site-specific DNA-peptide cross-links. 
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Our initial bioconjugation experiments were conducted using 6×His-eGFP-N3 
protein and a 32P-endlabeled 23-mer oligodeoxynucleotide (5'-AGG GTT TTC CCA 
GXC ACG ACG TT-3') containing site-specific C8-alkyne-dT at X (Scheme 5-3A). 
Following cycloaddition reaction in the presence of CuI, denaturing SDS-PAGE of the 
reaction mixture revealed the appearance of a new slowly moving band (Lane 2 in  
Figure 5-1), which was not present in the DNA control (Lane 1 in Figure 5-1). The high 
molecular weight band disappeared when the reaction mixture was incubated with 
proteinase K, confirming that it corresponds to a covalent DNA-protein conjugate    
(Lane 3 in Figure 5-1). The cross-linking yield was estimated as ~70% based on 
densitometry analysis (Lane 2 in Figure 5-1). 
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Scheme 5-3 Sequences of DNA oligomers used for conjugation reactions with proteins 
and peptides (A) and DNA substrates employed in standing start (B) and running start 
primer extension experiments (C). 
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Figure 5-1 SDS-PAGE analysis of site-specific DNA-protein cross-links generated by 
Cu-catalyzed azide-alkyne cycloaddition. DPCs were generated by using 6×His-eGFP-N3 
protein and 32P-endlabeled DNA 23-mer (5'-AGG GTT TTC CCA GC8-alkyne-dTC 
ACG ACG TT-3', where C8-alkyne-dT is 5-(octa-1,7-diynyl)-uracil). Lane 1: alkyne 
containing DNA; Lane 2: reaction mixture following cycloaddition between C8-alkyne-
dT containing DNA and 6×His-eGFP-N3 protein; Lane 3: proteinase K digested reaction 
from lane 2. 
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In a separate experiment, unlabeled DNA 23-mer (5'-AGG GTT TTC CCA GXC 
ACG ACG TT-3') was conjugated to 6×His-eGFP-N3, and the reaction mixture was 
separated by SDS-PAGE, followed by protein visualization by SimplyBlue SafeStain  
(Figure 5-2A). A new band at ~35 kDa was observed upon analysis of the reaction 
mixtures (Lane 2 in Figure 5-2A), which is consistent with the conjugate of 23-mer 
oligodeoxynucleotide (7.1 kDa) and 6×His-eGFP-N3 (28.4 kDa). This band was not 
observed in protein only control (Lane 1 in Figure 5-2A) or in control reactions 
conducted in the absence of Cu (Lane 3 in Figure 5-2A). To examine the influence of 
DNA-polypeptide molar ratios on the efficiency of DPC formation, the cycloaddition 
reaction was repeated in the presence of increasing molar equivalents of either        
6×His-eGFP-N3 or DNA, followed by gel electrophoretic analysis (Figure 5-2B and C). 
We found that the DPC yields improved with increasing protein concentration, reaching a 
maximum yield of DPCs when a 6-fold molar excess of 6×His-eGFP-N3 was employed 
(Lane 4 in Figure 5-2B). We also observed that the DPC yields improved with increasing 
DNA concentration (Figure 5-2C). These results indicate that site-specific DNA-protein 
cross-links can be generated in good yields using copper mediated 1,3-dipolar 
cycloaddition between azide-containing proteins and alkyne-functionalized DNA. 
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Figure 5-2 SDS-PAGE analysis of site-specific DNA-protein cross-links generated by Cu-catalyzed azide-alkyne cycloaddition 
(CuAAC). (A) DPCs generated by using 6×His-eGFP-N3 protein and unlabeled DNA 23-mer containing C8-alkyne-dT were separated 
by 12% SDS-PAGE and proteins were visualized via SimplyBlue staining. Lane M: protein marker; Lane 1: 6×His-eGFP-N3; Lane 2: 
reaction mixture following CuAAC between 6×His-eGFP-N3 protein and alkyne containing DNA; Lane 3: Reaction mixture following 
cycloaddition in the absence of Cu. (B) The yields of cycloaddition-induced DPCs increased with increasing DNA: protein molar 
ratios. The reaction was conducted as in (A), but the molar ratio of DNA:6×His-eGFP-N3 was varied between 1:1 and 1:6. (C) The 
reaction was conducted as in (A) by increasing the molar equivalents of DNA to protein from 1:1 to 4:1. 
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DNA-peptide cross-links were similarly generated by cycloaddition reactions 
between C8-alkyne-dT containing DNA (7.1 kDa) and synthetic azide-containing 
peptides (N3(CH2)3CO-Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-NH2, 1.3 kDa or 
N3(CH2)3CO-Pro-Asp-Ala-Gln-Leu-Val-Pro-Gly-Ile-Asn-Gly-Lys-Ala-Ile-His-Leu-Val-
Asn-Asn-Glu-Ser-Ser-Glu, 2.5 kDa). As shown for the 10-mer peptide reaction, the 
presence of the DNA-peptide conjugates (8.4 kDa) was detected by denaturing PAGE 
(Figure 5-3A). A new, low mobility band (Lane 2 in Figure 5-3A) corresponding to 
oligonucleotide-polypeptide conjugate was only found when the reaction was conducted 
in the presence of Cu (Lane 3 in Figure 5-3A), and disappeared upon incubation with 
proteinase K (Lane 4 in Figure 5-3A). A 200-fold molar excess of peptide to DNA was 
required to achieve optimal yields of DNA-peptide conjugates (81.5% yield,           
Figure 5-3B). The cycloaddition reaction with 23-mer peptide was conducted 
analogously (78% yield, Figure 5-3C). 
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Figure 5-3 Generation of site-specific DNA-peptide cross-links by Cu-catalyzed azide-alkyne cycloaddition. (A) Denaturing PAGE 
analysis of DNA-peptide conjugates generated using 10-mer peptide (N3(CH2)3COEQKLISEEDLNH2) and 32P-23-mer DNA 
containing C8-alkyne-dT. The reaction mixtures were resolved on a 20% (w/v) denaturing PAGE gel, and visualized by 
phosphorimaging analysis. Lane 1: C8-alkyne-dT containing 23-mer; Lane 2: reaction mixture following CuAAC between alkyne 
containing DNA and peptide-N3; Lane 3: the same reaction as in Lane 2 in the absence of Cu; Lane 4: proteinase K digested reaction 
from Lane 2. (B) The DPC yield increased with increasing amount of the peptide. DPCs were generated as in (A) by increasing the 
molar equivalents of DNA to peptide from 1:1 to 1:200. (C) Denaturing PAGE analysis of CuAAC of 23-mer peptide (N3(CH2)3CO-
PDAQLVPGINGKAIHLVNNESSE) and 5'-32P-23-mer C8-alkyne-dT. Lane 1: alkyne containing DNA; Lane 2: alkyne containing 
DNA and peptide-N3 in the presence of Cu; Lane 3: alkyne containing DNA; Lane 4: gel purified DNA-peptide conjugate from lane 2. 
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5.3.2 Mass Spectrometry Characterization of DNA–Protein and DNA–
Peptide Conjugates 
To confirm the formation of covalent DNA-protein and DNA-peptide cross-links, 
the purified conjugates were characterized by tandem mass spectrometry. In order to 
characterize the conjugates between 23-mer DNA oligomer and 6×His-eGFP-N3 protein 
(Scheme 5-1), DNA was digested to nucleotides, while the protein was cleaved to 
peptides with trypsin. Following SDS-PAGE purification, gel bands containing DPCs 
were excised and subjected to in-gel digestion with phosphodiesterase I (PDE I) and 
trypsin, and the resulting peptide-nucleotide conjugates were analyzed by nanoHPLC-
nanospray-HRMS/MS using an Orbitrap Velos mass spectrometer. The mass spectral 
data were processed using Thermo Proteome Discoverer 1.3 software (ThermoScientific, 
San Jose, CA) to identify the cross-linking site(s). A doubly charged ion at m/z 532.77 
was observed corresponding to the tetrapeptide CVIA containing a covalent cross-link to 
dUMP (theoretical mass = 1064.52, Figure 5-4). MS/MS fragmentation of m/z 532.77 
ions under CID conditions gave rise to a series of b- and y-fragments, including a singly 
charged b2 ion at m/z 862.39 and a doubly charged b3 fragment ion at m/z 488.24   
(Figure 5-4). Since the cysteine residue within the sequence CVIA is known to be the 
site of enzymatic prenylation, these observations are consistent with the predicted site of 
modification. Taken together, these results are consistent with cycloaddition reaction 
taking place at the specific cysteine residue of the protein containing the azido 
modification. 
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Figure 5-4 Mass spectrometry characterization of DNA-protein conjugates. NanoLC-
nanospray-MS/MS spectrum of eGFP tryptic peptide, CVIA, cross-linked to 5-(octa-  
1,7-diynyl)-2'-deoxyuridine monophosphate. DPCs were generated by Cu-catalyzed 
cycloaddition between 6×His-eGFP-N3 and C8-alkyne-dT containing DNA 23-mer, and 
DPCs were isolated by 12% SDS-PAGE as shown in Figure 5-1. DNA component of the 
DPCs was digested with phosphodiesterase I, and the resulting protein-nucleotide 
conjugate (m/z 532.77, doubly charged) was subjected to tryptic digestion followed by 
MS/MS analysis on an Orbitrap Velos mass spectrometer. 
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In order to simplify MS analysis of DNA-peptide cross-links (Scheme 5-2A), the 
DNA component of the cross-link was digested to nucleosides. NanoHPLC-nanospray-
MS/MS analysis allowed for the detection of doubly charged peptide species at            
m/z 823.40, which corresponds to the decapeptide EQKLISEEDL containing a triazole 
cross-link to deoxyuridine (Figure 5-5). The doubly charged peptide was subjected to 
HCD fragmentation within an Orbitrap Velos instrument, and the resulting fragments 
were analyzed in the accurate mass mode. Both b- and y-series fragment ions were 
detected (Figure 5-5), and the MS/MS fragmentation under HCD conditions was 
consistent with the predicted conjugate structure (Scheme 5-2A).  
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Figure 5-5 Mass spectrometry characterization of DNA-peptide cross-links. NanoLC-
nanospray-MS/MS characterization of DNA-peptide conjugates generated using 10-mer 
peptide (N3(CH2)3COEQKLISEEDLNH2) and C8-alkyne-dT containing DNA 23-mer. 
Following gel purification as shown in Figure 5-3, the DNA component of the cross-link 
was digested with phosphodiesterases and alkaline phosphatase, and the resulting 
peptide-nucleoside conjugate (m/z 823.40, doubly charged) was sequenced by nanoLC-
nanospray-MS/MS on an Orbitrap Velos mass spectrometer. 
 
  208
5.3.3 Polymerase Bypass of Synthetic DNA–Protein and DNA–Peptide 
Conjugates 
The model DPC-containing DNA substrates were subjected to several rounds of 
purification prior to their use in biochemical assays. The reaction mixtures were initially 
desalted to remove reagents and salts. DPCs were isolated by SDS-PAGE (DNA-protein 
conjugates) or 15% or 20% (w/v) denaturing polyacrylamide gel containing 7 M urea 
(DNA-peptide conjugates), and extracted from the gel using a gel elution kit or a freeze-
thaw method. DPC purity was confirmed by analysis of purified material via either SDS-
PAGE or denaturing PAGE (Lane 3 in Figure 5-6). To confirm the removal of excess 
protein, purified DPCs were fractionated by SDS-PAGE and stained with SimplyBlue 
SafeStain. Purified DPCs were radiolabeled using 32P-ATP, and the absence of 
unreacted oligonucleotides was verified by denaturing PAGE, followed by 
phosphorimaging. Depending on the purity of DPC substrates obtained from initial 
isolation, additional gel purifications were carried out. Only conjugates whose purity was 
greater than 96% were employed in DNA polymerase assays. 
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Figure 5-6 Purification of DNA-protein cross-links by gel electrophoresis–electroelution. 
DPCs were generated by CuAAC of 6×His-eGFP-N3 and 23-mer oligonucleotide         
(5'-AGG GTT TTC CCA GC8-alkyne-dTC ACG ACG TT-3’). The reaction mixture was 
desalted by micro biospin-6 columns, loaded onto a 12% (w/v) SDS-PAGE gel, and the 
gel band containing the DPC was excised and applied to electroelution. Lane M: protein 
marker; Lane 1: 6×His-eGFP-N3; Lane 2: a CuAAC reaction mixture containing     
6×His-eGFP-N3 and alkyne containing DNA in the presence of Cu; Lane 3: a purified 
sample via electroelution method. 
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To elucidate the influence of DNA-protein and DNA-peptide cross-links on DNA 
replication, template-primer complexes containing site-specific cross-links to          
6×His-eGFP-N3 protein, 23-mer peptide (PDAQLVPGINGKAIHLVNNESSE), 10-mer 
peptide (EQKLISEEDL), and unmodified dT (negative control) were subjected to primer 
extension in the presence of human translesion synthesis (TLS) polymerases κ, η, and ι. 
Two types of experiments were conducted: standing start, with the primer extending to 
the -1 position from the DPC lesion (Scheme 5-3B), and running start, with the primer 
ending four nucleotides upstream from the adduct site on the 18-mer template 5'-TCA 
TXG AAT CCT TCC CCC-3', where X = unmodified dT or synthetic DPC lesion 
(Scheme 5-3C). 
In standing start experiments with control template (X = dT, Figure 5-7), both 
hPol κ (a 10:1 molar ratio of polymerase to primer-template duplex) and hPol η (a 4:1 
ratio of polymerase to primer-template) completely extended the primer opposite the 
control template to form 18-mer products (X = dT, Figure 5-7). hPol ι generated mainly a 
single nucleotide addition product, probably due to its known low processivity as 
compared to other Y-family polymerases (X = dT, Figure 5-7).398-401 The presence of 
6×His-eGFP-dT at position X completely blocked primer extension by all three human 
lesion bypass polymerases (Figure 5-7A, D and G). Similar results were obtained for the 
23-mer peptide conjugate (Figure 5-7B, E and H). In contrast, all three polymerases were 
capable of bypassing the smaller DPC containing a 10-mer peptide, albeit with differing 
efficiency (Figure 5-7C, F and I). Extension products of hPol κ included the complete 
18-mer and multiple incomplete extension products (Figure 5-7C). Interestingly, 
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nucleotide incorporation opposite the lesion was more efficient than the addition of 
subsequent nucleotides, resulting in accumulation of the +1 product (Figure 5-7C). In the 
case of hPol ι, the efficiency of primer extension was significantly lower than the 
substrate bearing a native dT, but nearly complete conversion of a 13-mer to a 14-mer 
product was observed in 180 min (Figure 5-7I). 
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Figure 5-7 Replication bypass of DNA-peptide and DNA-protein conjugates of increased 
size adduct by human lesion bypass polymerases under standing start conditions. The  
32P-labeled 13-mer primers were annealed with 18-mer template containing unmodified 
dT or covalent cross-links to 6×His-eGFP-N3, 23-mer peptide, or 10-mer peptide. The 
resulting primer-template complexes (40 nM) were incubated in the presence of hPol κ 
(400 nM, A–C), hPol η (160 nM, D–F) or hPol ι (80 nM, G–I). The polymerase reactions 
were started by the addition of the four dNTPs (500 µM) and quenched at the indicated 
time points. The extension products were separated by 20% (w/v) denaturing PAGE and 
visualized by phosphorimaging analysis. 
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For running start experiments, the 18-mer template (5'-TCA TXG AAT CCT TCC 
CCC-3', where X = dT or DPC adduct containing 10-mer peptide (EQKLISEEDL),      
23-mer peptide (PDAQLVPGINGKAIHLVNNNESSE), or 6×His-eGFP-N3 was 
annealed to a 9-mer (-4) primer (Scheme 5-3C). Complete primer extension by hpol η 
and hpol κ was observed for the control substrate (X = dT, Figure 5-8), while hpol ι 
produced a +1 (14-mer) product (X = dT, Figure 5-8). As was the case for our standing 
start experiments, hpol κ, η and ι were completely blocked by the cross-links containing 
6×His-eGFP-dT and the 23-mer peptide (Figure 5-8A, B, D, E, G and H), whereas the 
presence of a 10-mer cross-link at position X has led to varied amounts of extended 
products with hpol κ, η and ι (Figure 5-8C, F and I). Low amounts of fully extended 
products (18-mers) were observed in the experiment with hpol η, suggesting that bypass 
of DNA-peptide conjugates by hpol η is inefficient (Figure 5-8F). In contrast, hpol ι has 
shown a robust primer extension activity (Figure 5-8I), suggesting that it may coordinate 
with other human polymerases to allow for efficient bypass of small DNA-peptide cross-
links via polymerase switching.402  
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Figure 5-8 Replication bypass of DNA-peptide and DNA-protein conjugates of increased 
size adduct by human lesion bypass polymerases under running start conditions. The   
32P-endlabeled 9-mer primers were annealed to the 18-mer templates containing 
unmodified dT, 6×His-eGFP-N3, 23-mer peptide, or 10mer peptide. The resulting primer-
template complexes (40 nM) were incubated at 37 °C in the presence of hPol κ (400 nM, 
A–C), hPol η (160 nM, D–F) or hPol ι (80 nM, G–I). Reactions were started by the 
addition of all four dNTPs (500 µM) and quenched at indicated time points. The 
extension products were resolved by 20% (w/v) denaturing PAGE and visualized by 
phosphorimaging analysis. 
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5.4 DISCUSSION 
DNA-protein cross-links (DPCs) are among the most abundant and the least 
understood DNA lesions present in the human genome. Despite their propensity to form 
in tissues and their likely involvement in human disease, little is known about their 
cellular effects. However, because of the structural complexity of DPC lesions and the 
difficulty of generating site specific, chemically defined DPC substrates, there is very 
limited information, and no consensus, on how cells respond to this class of DNA lesions. 
This lack of insight hinders our ability to fully understand the molecular basis of the 
therapeutic and adverse effects associated with a major class of anticancer agents and 
may limit insight into a fundamental cause of age-related disorders. 
As mentioned in Chapter 3, a major limitation in the field is the paucity of DNA 
substrates containing site-specific, homogeneous, and structurally defined DNA-protein 
conjugates. Currently available methodologies have several limitations such as poor 
reaction efficiency and low yields,164 limited choices of protein reagents (e.g. specific 
DNA modifying proteins),331 and insufficient site specificity with respect to the cross-
linking site within the protein.164,246,354 Recently, we have developed a methodology for 
site specific protein labeling using protein farnesyltransferase (PFTase).352 In this 
method, synthetic substrate analogs containing bioorthogonal functional groups including 
azides, alkynes and aldehydes are enzymatically transferred to proteins that are 
engineered to contain a C-terminal CAAX-box.397 Protein farnesyltransferase (PFTase) is 
used to label a substrate protein containing a C-terminal tetrapeptide tag with an azide-
modified isoprenoid diphosphate. The Cu-catalyzed alkyne azide cycloaddition reaction, 
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commonly known as the click reaction, has been used extensively for preparing modified 
forms of DNA.403,404 We have previously used the PFTase method described above to 
prepare azide-modified proteins that were subsequently linked to the 5'-ends of alkyne-
functionalized oligodeoxynucleotides via the Cu-catalyzed click reaction352 or the Cu-
free variation,353 but internal DNA-protein cross-links have not been previously prepared. 
We elected to use the Cu-catalyzed reaction in the present study since it generates a less 
bulky linkage between the protein and DNA. To generate DNA-peptide conjugates, 
synthetic peptides were prepared via solid phase peptide synthesis and appended with an 
N-terminal 4-azidobutanoic acid group for subsequent Cu-catalyzed click reaction. 
The new approach was successfully applied to generate site-specific DPCs to a 
28.4 kDa protein, a 23-mer peptide, and a 10-mer peptide (Schemes 5-1 and 5-2, and 
Figures 5-1–5-6). Our optimized reaction conditions and purification strategy generates 
structurally defined DNA-protein and DNA-peptide conjugates in high yield and with 
excellent purity (Figures 5-1, 5-3 and 5-6).  We have recently employed this strategy to 
engineer plasmid molecules containing site-specific DPCs for in vivo replication studies. 
The model DNA-protein and DNA-peptide conjugates generated by click reaction 
(Schemes 5-1 and 5-2) resemble DNA-protein cross-links induced by bis-alkylating 
agents158 and reactive α,β-unsaturated carbonyls.197 Many bis-electrophiles including 
nitrogen mustards, platinum compounds, and diepoxides form DPCs by alkylating 
cysteine thiols within proteins.85,86,158,159,294 On the other hand, acrolein, crotonaldehyde, 
and 4-hydroxynonenal form Schiff base cross-links between DNA and the N-terminal    
α-amine of the peptide.197 Although the linker length within our model DNA-protein 
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conjugates is longer than that observed for cross-links generated physiologically, we 
anticipate that the linker length will play a relatively minor role in determining the route 
of lesion processing. It is more likely that the nature of the protein/peptide and the 
attachment site within DNA will determine the cellular fate of DNA-protein cross-links. 
Our observation of complete polymerase blockage by DNA-protein conjugates 
(Panels A, D and G of Figures 5-7 and 5-8) is consistent with an earlier finding of Kuo 
and collaborators, who reported that 5-azacytidine-induced methyltransferase-DNA 
adducts block DNA replication in vivo.132 In contrast, our finding that C5–thymine cross-
links to a 23-mer peptide block human lesion bypass polymerases κ and η (Panels B, E 
and H of Figures 5-7 and 5-8) contradict earlier reports that pol κ efficiently bypassed    
γ-HOPdG mediated DNA-peptide cross-links connected to the N2 position of guanine in 
DNA,335 while pol ν was able to catalyze replication past γ-HOPdA mediated DNA-
peptide cross-links to the N6 position of adenine.336 This may be due to structural 
differences between the DPCs examined in these studies and also the differences in 
peptide size, since the previous reports were limited to peptide 4-mers and 12-mers335,336 
and did not examine the effects of larger peptide lesions on DNA replication. Indeed, our 
results indicate that smaller cross-links to a peptide 10-mer can be bypassed by pol κ and 
pol η (Panels C, F and I of Figures 5-7 and 5-8). 
In summary, site-specific cross-links between DNA oligomers and polypeptides 
of increasing size were generated using copper-catalyzed [3+2] Huisgen cycloaddition 
(click reaction) between an alkyne group from C8-alkyne-dT in DNA and an azide group 
within engineered proteins/polypeptides in high yield and with excellent purity. 
  218
Polymerase bypass experiments conducted with model DPC substrates incorporating   
10-mer peptide, 23-mer peptide, and a 28.4 kDa protein have shown that while the two 
larger lesions blocked all human polymerases tested, the DPC to a 10-mer peptide can be 
bypassed by polymerases η, κ, and ι. These results suggest that large DPCs generated in 
cells may require proteolytic processing in order to be tolerated. Our ongoing studies will 
identify the proteolytic mechanisms involved and elucidate the effects of proteasomal 
inhibitors on toxicity of common antitumor drugs that are known to form DPCs. 
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ERROR-PRONE TRANSLESION 
SYNTHESIS PAST DNA-PEPTIDE   
CROSS-LINKS CONJUGATED TO        
THE MAJOR GROOVE OF DNA             
VIA C5 OF THYMIDINE 
6 ERROR-PRONE TRANSLESION SYNTHESIS PAST DNA-PEPTIDE CROSS-LINKS CONJUGATED TO THE MAJOR GROOVE OF DNA VIA C5 OF THYMIDINE 
6.1 INTRODUCTION 
Previous investigations have revealed that the ability of translesion synthesis 
(TLS) polymerases to bypass DNA-peptide cross-links is dependent on the lesion size, 
the attachment site within DNA, and polymerase identity.132,164,219,326,327,334-338 Lloyd and 
coworkers reported that human polymerase, hPol κ and its E. coli orthologue, Pol IV 
were able to catalyze error-free primer extension past DNA templates containing tetra- 
and dodecapeptides cross-linked to the N2 position of guanine via a trimethylene 
linker.335 In a different study, A family polymerase ν was capable of bypassing both       
4-mer and 12-mer peptides cross-linked to N6 of adenine via the same linkage, with only 
the correct base (dT) inserted opposite the adduct,336 while the analogous adducts at N2 of 
guanine completely blocked replication.336 Yamanaka et al. proposed that small major 
groove DPC adducts have sufficient conformational flexibility to be accommodated 
within the active site of Pol ν without disturbing primer-template-enzyme interactions, 
while the corresponding minor groove adducts block replication.336 More recently, 
Guengerich and coworkers reported that human TLS polymerases κ and ι as well as the 
6 
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bacterial polymerases, Pol T7 and DPO4 were capable of replicating DNA containing                   
S-[4-(N6-deoxyadenosinyl)-2,3-dihydroxybutyl]glutathione adducts (N6-dA-(OH)2butyl-
GSH).338 However, none of the previous studies, except for the one reported by 
Guengerich and coworkers,338 have sequenced the primer extension products. Despite the 
accurate nucleotide insertion opposite the lesion, TLS polymerases can cause 
insertion/deletion mutations.394,405-407  To our knowledge, no systematic studies have been 
performed on replication bypass of DPCs cross-linked to pyrimidine bases on DNA, 
despite their significance in vivo. Cytosine methylation by DNA methyltransferases 
involves the covalent cross-linking of an active site Cys to C6 of cytosine, and if 
irreversibly trapped, can have adverse effects on epigenetic mechanisms and gene 
expression.408,409 Free radicals and radiation sources can also induce protein cross-linking 
to pyrimidine bases on DNA.182,211,410-412 
We have recently developed a new methodology using copper-catalyzed azide-
alkyne cycloaddition to generate site-specific DNA-protein and DNA-peptide conjugates 
cross-linked to C5 of thymidine in DNA (Chapter 5).388 Our initial polymerase bypass 
studies with substrates containing site-specific C5-dT cross-links to polypeptides of 
increasing size (10-mer, 23-mer, and 28.4 kDa protein) have revealed that large 
polypeptides completely block replication, whereas 10-mer peptide cross-links were 
bypassed by hPol η and κ.388 This suggests that large DPC lesions may undergo 
proteolytic degradation to peptides, which are subsequently bypassed by translesion DNA 
polymerases.  
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 In the present work, we examined the kinetics and the fidelity of translesion 
synthesis past model DNA-peptide cross-links containing a 10-mer peptide 
(N3(CH2)3CO-EQKLISEEDL-NH2) connected to the C5 position of thymidine in DNA388 
using a combination of gel electrophoresis and mass spectrometry-based methodologies. 
Our results provide evidence for a highly error-prone nature of replication past major 
groove DNA-peptide adducts by hPol η and κ, which give rise to large numbers of base 
substitutions and frameshift mutations. 
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6.2 MATERIALS AND METHODS 
6.2.1 Materials 
C8-alkyne-dT-CE phosphoramidite, protected 2'-deoxyribonucleoside-3'-
phosphoramidites (dA-CE, Ac-dC-CE, dmf-dG-CE, dT-CE), Ac-dC-CPG ABI columns, 
and all other reagents required for automated DNA synthesis were purchased from Glen 
Research (Sterling, VA). Recombinant human polymerases hPol η and κ were either 
purchased from Enzymax (Lexington, KY) or expressed and purified as previously 
described.384,385 T4 polynucleotide kinase (T4-PNK) and E. coli uracil DNA glycosylase 
(UDG) were obtained from New England Biolabs (Beverly, MA), while γ-32P ATP was 
purchased from Perkin-Elmer Life Sciences (Boston, MA). 40% 19:1 Acrylamide/bis 
solution and micro bio-spin 6 columns were purchased from Bio-Rad (Hercules, CA). 
The unlabeled dNTPs were obtained from Omega Bio-Tek (Norcross, GA). Illustra   
NAP-5 desalting columns and Sep-Pak C18 SPE cartridges were purchased from          
GE Healthcare (Pittsburg, PA) and Waters (Milford, MA), respectively. All other 
chemicals and solvents were purchased from Sigma-Aldrich (Milwaukee, WI) and were 
of the highest grade available. 
6.2.2 Synthesis and Characterization of Oligodeoxynucleotides 
Synthetic 18-mer oligodeoxynucleotides (5'-TCA TXG AAT CCT TCC CCC-3') 
containing native thymidine at position X were synthesized by automated solid phase 
synthesis using an ABI 394 DNA synthesizer (Applied Biosystems, CA). 18-mer strands 
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containing a 5-(octa-1,7-diynyl)-uracil (C8-alkyne-dT) modification were prepared by 
solid phase synthesis. The modified nucleotide was added using an offline manual 
coupling protocol. Biotinylated 23-mer primer (Biotin-5'-(T)10 GGG GGA AGG AUT   
C-3') and 13mer primer (5'-GGG GGA AGG ATT C-3') were purchased from Integrated 
DNA Technologies (Carolville, IA). All oligodeoxynucleotides were purified by semi-
preparative HPLC, desalted by Illustra NAP-5 columns, characterized by HPLC-ESI--
MS, and quantified by UV spectrophotometry as previously described.388 
6.2.3 Synthesis and Characterization of DNA-Peptide Conjugates 
Synthetic DNA 18-mer (5'-TCA TXG AAT CCT TCC CCC-3') containing       
C8-dT-alkyne at position X was cross-linked to the 10-mer azide-containing peptide 
(N3(CH2)3CO-Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-NH2) via copper catalyzed 
[3+2] Huisgen cycloaddition (click reaction).388 Site-specific DNA-peptide conjugates 
were isolated using 20% (w/v) denaturing polyacrylamide gels containing 7 M urea 
followed by gel-elution and desalting via Sep-Pak C18 SPE. To assess the purity of the 
isolated conjugates, an aliquot of the purified sample was radiolabeled with γ-32P ATP, 
and resolved on a 20% (w/v) denaturing polyacrylamide gel containing 7 M urea, 
followed by visualization using a Typhoon FLA 7000 phosphorimager (GE Healthcare,       
Pittsburgh, PA). A separate aliquot was subjected to alkaline phosphatase/ 
phosphodiesterase digestion, and the resulting nucleoside-peptide conjugates were 
characterized by nanoLC-nanospray-MS/MS.388 
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6.2.4 Preparation of Primer-Template Duplexes 
For single nucleotide insertion assays, 13-mer DNA primers (5'-GGG GGA AGG 
ATT C-3', 1 nmol) were radiolabeled by incubating with T4 PNK (20 U) and γ-32P ATP 
(20 μCi) in the presence of T4 PNK reaction buffer (total volume = 20 μL) at 37 °C for   
1 h. The mixture was heated at 65 °C for 10 min in order to inactivate the enzyme and 
passed through Illustra Microspin G25 columns (GE Healthcare, Pittsburgh, PA)            
to remove excess γ-32P ATP. The 5'-32P-labeled primers (50 pmol) were mixed with 2 eq. 
of template strands (5'-TCA TXG AAT CCT TCC CCC-3') containing either                 
2'-deoxythymidine (dT) or 10-mer peptide cross-link (dT-peptide) in 10 mM Tris buffer 
(pH 8) containing 50 mM NaCl. The primer and template strands were annealed by 
heating at 95 °C for 10 min and cooled slowly overnight to afford the corresponding end-
labeled primer-template complexes.  
Primer-template duplexes used for the capillary HPLC-ESI--MS/MS sequencing 
experiments were generated analogously by annealing biotinylated 23-mer primer 
(Biotin-5'-(T)10 GGG GGA AGG AUT C-3', 100 pmol) to template strands (5'-TCA TXG 
AAT CCT TCC CCC-3') containing either unmodified dT or dT-peptide cross-link at 
position X (2 eq.). 
6.2.5 Single Nucleotide Incorporation Assays 
Single nucleotide insertion assays were conducted in order to determine which 
nucleotides are incorporated opposite the DNA-peptide cross-links, X. 32P-end-labeled 
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primer-template duplexes containing either dT or dT-peptide (40 nM) were incubated at 
37 °C with human translesion synthesis polymerases (20 nM hPol η or 200 nM hPol κ) in 
50 mM Tris-HCl (pH 7.5) buffer containing 50 mM NaCl, 5 mM DTT, 5 mM MgCl2,  
100 µg/mL BSA and 10% glycerol (v/v). Reactions were initiated by the addition of 
individual dNTPs (50 μM for hPol η and 100 μM for hPol κ) in a final volume of 20 μL. 
Aliquots (4 μL) were withdrawn at pre-selected time points, and the reaction was 
quenched by the addition of 8 μL of the quench solution containing 10 mM EDTA, 
0.03% bromophenol blue (w/v) and 0.03% xylene cyanol (w/v) in 95% (v/v) formamide. 
The extension products were resolved by 20% (w/v) denaturing PAGE containing 7 M 
urea and visualized using a Typhoon FLA 7000 phosphorimager (GE Healthcare, 
Pittsburgh, PA). 
6.2.6 Steady-State Kinetic Analyses 
Steady-state kinetics for incorporation of individual nucleotides opposite the 
unadducted dT and dT-peptide cross-link was investigated by performing single 
nucleotide incorporation assays. Experiments were conducted with 0.25–1.25 nM hPol η 
or 2.5–100 nM hPol κ in the presence of increasing concentrations of individual dNTPs 
(0–800 µM) and for specified time periods (0–180 min). The extension products and the 
unextended 13-mer primers were visualized after electrophoretic fractionation using a 
Typhoon FLA 7000 phosphorimager (GE Healthcare, Pittsburgh, PA), and quantified by 
volume analysis using the Image Quant TL 8.0 software (GE Healthcare, Pittsburgh, PA). 
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The steady-state kinetic parameters were calculated by nonlinear regression analysis 
using one-site hyperbolic fits in Prism 4.0 (GraphPad Software, La Jolla, CA). 
6.2.7 Sequencing and Quantitation of Primer Extension Products by 
Liquid Chromatography-Tandem Mass Spectrometry 
Primer extension assays were conducted by incubating the biotinylated 23-mer 
primer-18-mer template duplexes (100–150 pmol) with hpol κ or η (40–60 pmol) in        
50 mM Tris-HCl (pH 7.5) buffer containing 50 mM NaCl, 5 mM DTT, 5 mM MgCl2,  
100 µg/mL BSA and 1 mM each of the four dNTPs at 37 °C for 6 h. Following the 
polymerase reaction, 400 μL of 20 mM sodium phosphate (pH 7.0) buffer containing  
150 mM NaCl were added to the reaction. Streptavidin sepharose high performance 
beads (0.2 mL, GE Healthcare, Pittsburgh, PA) were prepared by centrifugation and 
washing with 500 μL of 20 mM sodium phosphate (pH 7.0) buffer containing 150 mM 
NaCl. The beads were added to the polymerase reaction, and the resulting suspension was 
incubated at room temperature for 2 h with tapping every 10 min to promote mixing. The 
liquid was removed by centrifugation, and the beads were washed three times with water 
(300 μL). A solution of Tris-HCl buffer (50 mM, pH 7.5) containing uracil DNA 
glycosylase (UDG, 20 units), 1 mM EDTA, and 1 mM DTT (500 μL) was added to the 
streptavidin-coated bead suspension, and the mixture was incubated for 4 h at 37 °C. The 
liquid was removed, and the beads were washed with water (3× 300 μL). An aqueous 
solution of 250 mM piperidine (400 μL) was added to the streptavidin-coated beads, and 
the mixture was heated at 95 °C for 60 min. The liquid from the piperidine cleavage was 
  227
decanted, and the beads were washed with water (3× 200 μL). The piperidine cleavage 
fraction was combined with the water washes and dried in vacuo, and the residue was 
reconstituted in 25 µL of water containing 14-mer internal standard (5'-pCTT CAC GAG 
CCC CC-3', 40 pmol). 
Capillary HPLC-ESI--MS/MS analyses were conducted on an Agilent 1100 
HPLC system (Agilent Technologies, Wilmington, DE) coupled to a Thermo LTQ 
Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Waltham, MA). The 
instrument was operated in the negative ion ESI MS/MS mode. Primer extension 
products were resolved on an Agilent Zorbax 300SB-C18 (0.5 × 150 mm, 5 µm) column 
using a gradient of 15 mM ammonium acetate (buffer A) and acetonitrile (buffer B). The 
column was eluted at a flow rate of 15 μL/min. The solvent composition was linearly 
changed from 1 to 10% B in 24 min, further to 75% B in 1 min, held at 75% B for 3 min, 
and brought back to 1% B in 2 min. 
Electrospray ionization conditions were as follows: ESI source voltage, 3.5 kV; 
source current, 6.7 A; auxiliary gas flow rate setting, 0; sweep gas flow rate setting, 0; 
sheath gas flow setting, 30; capillary temperature, 275 °C; and S-lens RF level, 50%. The 
most abundant ions from the ESI--FTMS spectra were selected and subjected to collision-
induced dissociation (CID) analysis using a linear ion trap. The MS/MS conditions were 
as follows: normalized collision energy, 35%; activation Q, 0.250; activation time, 10 ms; 
product ion scan range, m/z 300–2000. Relative quantitation of primer extension products 
was done by comparing peak areas corresponding to each product in extracted ion 
chromatograms with the peak area of the internal standard. Product sequences were 
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confirmed by comparing the MS/MS fragments to expected CID fragmentation patterns 
of oligodeoxynucleotides obtained using the Mongo Oligo mass calculator version 2.06 
(The RNA Institute, College of Arts and Sciences, State University of New York at 
Albany). 
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6.3 RESULTS 
6.3.1 Synthesis of Primer-Template Duplexes Containing Site-Specific 
DNA-Peptide Conjugates 
Synthetic DNA strands containing site specific DNA-peptide cross-links were 
generated by copper-catalyzed [3+2] Huisgen cycloaddition between the 5-(octa-1,7-
diynyl)-uracil (C8-alkyne-dT) base (X) positioned within DNA 18-mer (5'-TCA TXG 
AAT CCT TCC CCC-3') and the N-terminal azide moiety appended to a 10-mer c-Myc 
peptide (N3(CH2)3CO-EQKLISEEDL-NH2) (Scheme 6-1).388 DNA-peptide cross-links 
(Scheme 6-1) were isolated by denaturing PAGE, and their purity was confirmed by 
sequencing PAGE (Figure 6-1). Only DNA templates that were at least 99% pure were 
employed for primer extension assays. Purified DNA-peptide cross-links were 
characterized by nanoLC-nanospray-MS/MS analysis to confirm the structure of the 
conjugate388 and quantified by UV spectrophotometry assuming ε260 nm (DNA-peptide 
cross-link) = ε260 nm (DNA) + ε260 nm (peptide) = 220.08 mM-1 cm-1. 
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Scheme 6-1 Synthesis of DNA-peptide cross-links by copper-catalyzed [3+2] Huisgen 
cycloaddition (click reaction).388 
 
 
 
 
 
 
 
 
 
 
 
 
  231
Figure 6-1 Denaturing PAGE analysis of DNA-peptide cross-links generated by click 
chemistry. Lane 1: oligodeoxynucleotide containing C8-alkyne-dT; Lane 2: oligodeoxy-
nucleotide containing C8-alkyne-dT and peptide azide in the presence of Cu catalyst; 
Lane 3: oligodeoxynucleotide containing C8-alkyne-dT; Lane 4: gel purified DNA-
peptide cross-links from lane 2. 
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6.3.2 Single Nucleotide Incorporation Assays 
Lesion-containing DNA 18-mers (5'-TCA TXG AAT CCT TCC CCC-3') were 
annealed to a 32P-end-labeled 13-mer primer, 5'-GGG GGA AGG ATT C-3'. In the 
resulting primer-template complexes, the 3'-primer terminus is positioned immediately 
prior to the lesion site (-1 primer, Scheme 6-2A). Initial single nucleotide incorporation 
assays were conducted to determine what nucleotides can be inserted opposite the 
adducted site by human translesion synthesis polymerases, hPol η and κ. Those enzymes 
were selected for the current study because these polymerases are known to catalyze 
replication past other DNA-peptide cross-links.335,338 The resulting primer-template 
duplexes were incubated with recombinant polymerases in the presence of individual 
dNTPs for 0–90 min. Denaturing PAGE followed by phosphorimaging analysis revealed 
that any of the four dNTPs can be incorporated, indicative of error-prone replication of 
DNA containing dT-peptide conjugates (Figure 6-2). Under our experimental conditions 
(substrate:enzyme = 2:1), hPol η showed full incorporation opposite the DPC lesion 
within 5 min (Figure 6-2A). In contrast, hPol κ (substrate:enzyme = 1:5) only showed 
<60% incorporation of all dNTPs even after 90 min (Figure 6-2B). These initial 
experiments suggested that hPol η has a higher efficiency of replication past DPCs as 
compared to hPol κ. 
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Scheme 6-2 Sequences of DNA oligomers employed in in vitro replication studies.      
(A) 13-mer primer-18-mer template duplexes used for the single nucleotide incorporation 
and steady-state kinetic assays. (B) Biotinylated 23-mer primer-18-mer template duplexes 
employed for the liquid chromatography-tandem mass spectrometry analyses of primer 
extension products. 
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Figure 6-2 Single nucleotide insertion opposite DNA-peptide cross-links by human TLS polymerases. (A) 40 nM primer-template 
duplexes containing unmodified thymidine (dT control) and the 10-mer peptide cross-linked to C5 of thymidine (dT-peptide) were 
incubated at 37 °C with 20 nM hPol η in the presence 50 μM individual dNTPs. The reactions were quenched at predetermined time 
points (0–60 min) and analyzed by 20% denaturing PAGE. (B) 40 nM primer-template duplexes containing dT-peptide were 
incubated at 37 °C with 200 nM hPol κ in the presence 100 μM individual dNTPs. The reactions were quenched at predetermined time 
points (0–90 min) and analyzed by 20% denaturing PAGE. 
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6.3.3 Steady-State Kinetic Analyses 
To determine the catalytic efficiency and the misinsertion frequency of individual 
dNTPs by hPol η and κ, steady-state kinetic assays were conducted. Primer-template 
complexes containing unmodified dT (positive control) or dT-peptide conjugate             
(X in Scheme 6-2A) were incubated with hPol η or hPol κ in the presence of increasing 
concentrations of individual dNTPs (0–800 µM), and the reactions were quenched at 
specified time points (0–180 min). Conditions were chosen such that the maximum 
percentage of products was ≤35% of the starting substrate concentration. Kinetic 
parameters (kcat and Km in Table 6-1) were calculated by plotting reaction velocity 
against concentrations of individual dNTP.369 The specificity constant (kcat/Km) is a 
measure of the catalytic efficiency of incorporation of each dNTP, while the misinsertion 
frequency (f) provides a quantitative measure of incorporating an incorrect vs. correct 
dNTP opposite the lesion, hence the fidelity of the polymerase for a specific lesion.1 
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Table 6-1 Steady-state kinetic parameters for single nucleotide insertion opposite the positive control (dT) and the 10-mer peptide     
cross-linked to C5 of thymidine (dT-peptide) by human TLS polymerases, hPol κ and η. 
Polymerase Template Incoming nucleotide 
kcat Km kcat / Km 
f ‡‡ 
min-1 μM μM-1 min-1 
hPol κ dT dATP 2.75 ± 0.18   5.11 ±   1.96 0.54 1 
dCTP 0.19 ± 0.02 145.6 ± 48.55 0.0013 0.002 
dGTP 1.93 ± 0.22 94.84 ± 31.27 0.02 0.04 
dTTP 0.51 ± 0.07 371.8 ± 98.51 0.0014 0.003 
   
dT-peptide dATP 0.67 ± 0.04 16.61 ±   6.51 0.04 1 
dCTP   0.07 ± 0.007 90.81 ± 42.90 0.0007 0.02 
dGTP   0.16 ± 0.008 152.5 ± 25.61 0.001 0.03 
dTTP   0.03 ± 0.003 361.8 ± 84.11 0.00008 0.002 
       
hPol η dT dATP 9.44 ± 0.26   2.85 ±   0.70 3.31 1 
dCTP 2.26 ± 0.52 72.60 ± 54.38 0.031 0.009 
dGTP 9.00 ± 1.67 13.36 ±   8.22 0.67 0.2 
dTTP 1.04 ± 0.16 58.82 ± 27.89 0.018 0.005 
   
dT-peptide dATP 2.81 ± 0.37 31.16 ± 22.91 0.09 1 
dCTP 2.67 ± 0.36 65.85 ± 29.08 0.041 0.45 
dGTP    13.44 ± 1.91 33.42 ± 11.60 0.402 4.5 
dTTP 1.21 ± 0.14 32.60 ± 16.55 0.037 0.41 
              
                                                 
‡‡ f = misinsertion frequency = (kcat/Km)incorrect dNTP/(kcat/Km)correct dNTP 
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According to our steady-state kinetics data (Table 6-1), the specificity constants (kcat/Km) 
for the incorporation of the correct base (dA) opposite the dT-peptide conjugate were 0.04 and 
0.09 μM-1 min-1 for hPol κ and η, respectively. These values were 14–37-fold lower than those 
obtained for dATP insertion opposite the unmodified template (0.54 and 3.31 μM-1 min-1). This 
is not unexpected, since it may be difficult to accommodate the bulky DPC adduct in the 
polymerase active site, and this process is likely to be both kinetically and thermodynamically 
disfavored. The specificity constants for the incorporation of the other three nucleotides by hPol 
κ were also 2–20-fold lower for the adducted template compared to the unmodified template 
(Table 6-1). hPol η also showed higher specificity constants for the incorporation of incorrect 
bases (dCTP and dTTP) opposite the adducted template as compared to hPol κ (1.3- and 2-fold, 
respectively). The calculated kcat/Km values for hPol η were larger than those for hPol κ     
(Table 6-1) suggesting that hPol η is more efficient in the replication bypass of the dT-peptide 
cross-link as compared to hPol κ. 
The misinsertion frequencies (f) calculated from kinetic data (Table 6-1) suggest that 
both hPol κ and η bypass dT-peptide conjugates in an error-prone manner. For hPol κ, the 
frequency of insertion of dCTP opposite the adducted template was 10-fold higher as compared 
to the unmodified template, while f was only 0.7-fold for incorporation of dGTP and dTTP. In 
contrast, hPol η showed 50-fold, 23-fold and 82-fold higher misinsertion frequencies for dCTP, 
dGTP and dTTP, respectively. Further, the order of nucleotide insertion opposite the adducted 
template was A > G > C > T for hPol κ, with 33-fold, 50-fold and 500-fold preference for the 
incorporation of dATP over dGTP, dCTP and dTTP, respectively. The order of misinsertion 
opposite the adducted base by hPol η was G > A > C > T with 4.5-fold, 10-fold and 11-fold 
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preference for the incorporation of dGTP over dATP, dCTP and dTTP. These data suggest that 
replication bypass of the DNA-peptide conjugates by hPol η is much more error-prone as 
compared to bypass of the same adduct by hPol κ. 
6.3.4 Sequencing and Quantitation of Primer Extension Products by Liquid 
Chromatography-Tandem Mass Spectrometry 
A mass spectrometry-based approach (Scheme 6-3), similar to the one developed by 
Christov et al.,413 was employed to sequence the products of translesion synthesis. This 
methodology allows for the detection of insertion and/or deletion products and potential errors at 
the adducted site and the +1 position from the adduct.407 A biotinylated primer (Biotin-5'-(T)10 
GGG GGA AGG AUT C-3') was annealed to the 18-mer template containing the site-specific 
DPC at position X (Scheme 6-2B). The biotin group on the 5'-end of the oligodeoxynucleotide 
was used to purify the extension products via affinity capture prior to LC-MS analysis.413 The 
third nucleotide from the 3'-end of the template was replaced with a uridine to allow for selective 
cleavage of the extended primer using uracil DNA glycosylase (UDG) and hot piperidine. This 
strategy generates short oligodeoxynucleotides (7-mers, if fully extended, or 5- or 6-mers, if 
deletion mutations occured) that are more amenable for sequencing by collision induced 
dissociation-based tandem mass spectrometry.407,414 
As was the case for gel-based assays, primer extension reactions were carried out with 
unmodified and dT-peptide containing templates (Scheme 6-2B). The extended primers were 
captured on streptavidin high performance sepharose beads, and the beads were incubated with 
UDG. The 3'-end fragments containing the extension products of interest were cleaved by 
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treatment with hot piperidine (Scheme 6-3), and the eluates were dried in vacuo and analyzed by 
HPLC-ESI--FTMS and MS/MS on an Orbitrap Velos mass spectrometer. The samples were 
initially analyzed in the full scan mode to detect all extension products. HPLC-ESI--FTMS peak 
areas in extracted ion chromatograms (Figures 6-4 and 6-6) were used to determine the relative 
quantities of each extension product as compared to an internal standard. Each sample was 
subsequently analyzed in the HPLC-ESI--MS/MS mode to allow for nucleotide sequence 
determination (Figures 6-3, 6-5, 6-7 and 6-8). 
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Scheme 6-3 Streptavidin capture in combination with capillary HPLC-ESI--MS/MS method for 
sequencing and quantitation of primer extension products. 
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Capillary HPLC-ESI--FTMS analysis of the hPol κ-catalyzed reactions with unmodified 
template revealed one main peak corresponding to the error-free full extension product            
(5'-pT CAA TGA-3'; m/z 1090.68; [M-2H]2-, Table 6-2, Figures 6-3A and 6-4A). In contrast, 
HPLC-ESI--FTMS of the corresponding primer extension reactions conducted with dT-peptide 
conjugate revealed eight different extension products (Table 6-2 and Figure 6-4B). The main 
peak (89% of total products) corresponded to a single base deletion product (5'-pT C_A TGA-3'; 
m/z 934.15; [M-2H]2-), and only 2% of the primer extension products yielded the error-free 
replication product (5'-pT CAA TGA-3'; m/z 1090.68; [M-2H]2-). Other major MS peaks at m/z 
942.15, 777.62, 1086.17 and 1098.68 corresponded to doubly charged ions of 5'-pT C_G TGA-3' 
(one-base deletion, 5%), 5'-pT C_ _ TGA-3' (two-base deletion, 2%), 5'-pT CTA TGA-3' 
(transversion mutation, 1%) and 5'-pT CGA TGA-3' (transition mutation, 1%). The exact 
sequences were determined using the MS/MS spectra obtained by collision-induced dissociation 
of the corresponding doubly charged ions (Figures 6-3B and 6-5). 
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Table 6-2 Summary of extension products formed by hPol κ and η as identified by liquid 
chromatography-tandem mass spectrometry. 
Biotin-5'-(T)10 GGG GGA AGG AUT C               -3' 
                                                         3'-CC C  C C T  T C C  TA A GXT ACT-5' 
Polymerase X Extension     product 
Percent 
product 
Base 
opposite X Comment 
 
hPol κ  dT T CAA TGA 87 A error-free 
 T CTA TGA 9 T substitution opposite adduct 
 T CGA TGA 3 G substitution opposite adduct 
 T CA _ TGA 1 A one-base deletion 
 T CCA TGA <1 C substitution opposite adduct 
 T C _G TGA <1 G one-base deletion 
 
 dT-peptide T CA _  TGA 89 A one-base deletion 
 T C _ G TGA 5 G one-base deletion 
 T CAA TGA 2 A error-free 
 T C_ _ TGA 2 - two-base deletion 
 T CTA TGA  1 T substitution opposite adduct 
 T CGA TGA 1 G substitution opposite adduct 
 T C _ T TGA <1 T one-base deletion 
 T C _ C TGA <1 C one-base deletion 
 
hPol η  dT T CAG TGA 36 A substitution opposite +1-mer 
  T CAC TGA 36 A substitution opposite +1-mer 
  T CAA TGA 28 A error-free 
      
 dT-peptide T CAG TGA 23 A substitution opposite +1-mer 
  T CAA TGA 19 A error-free 
   T C _G TGA 16 G one-base deletion 
  T CAC TGA 15 A substitution opposite +1-mer 
  T CA _ TGA 15 A one-base deletion 
  T C _ C TGA 12 C one-base deletion 
  T C_ _  TGA <1 - two-base deletion 
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Figure 6-3 Collision-induced dissociation (CID) mass spectra of the major extension 
products of in vitro polymerase bypass by hPol κ. (A) MS/MS spectrum of error-free 
product, 5'-pT CAA TGA-3', observed by replication of the unadducted template.         
(B) Tandem mass spectrum of one-base deletion product, 5'-pT C_A TGA-3', detected 
when the dT-peptide containing template was bypassed. 
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Figure 6-4 HPLC-ESI--FTMS analysis of primer extension by hPol κ. (A) Extracted ion 
chromatograms of replication products observed upon primer extension of the 
unmodified template. The major extension product, 5'-pT CAA TGA-3' detected (87%) 
was the error-free full extension product. (B) Extracted ion chromatograms of bypass 
products observed upon primer extension of the template containing 10-mer peptide 
conjugate. Multiple deletion mutations and point mutations were observed. The major 
extension product, 5'-pT C_A TGA-3' detected (89%) was a frameshift mutation. 
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Figure 6-5 Representative MS/MS spectra of extension products observed following      
in vitro replication past 10-mer peptide cross-linked to C5 of thymidine by hPol κ. CID 
spectra of extension products: (A) 5'-pT CTA TGA-3', a substitution mutation,             
(B) 5'-pT C_G TGA-3' and (C) 5'-pT C_T TGA-3', one-base deletion followed by a 
substitution, and  (D) 5'-pT C_ _ TGA-3', double deletion. 
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HPLC-ESI--FTMS analysis of the primer extension of the undamaged template by 
hPol η revealed three main peaks present in roughly equal amounts at m/z 1090.68 (28%), 
1098.68 (36%) and 1078.67 (36%), which correspond to the doubly charged ions of            
5'-pT CAA TGA-3', 5'-pT CAG TGA-3' and 5'-pT CAC TGA-3', respectively (Table 6-2 
and Figure 6-6A). MS/MS sequencing confirmed that hPol η inserts the correct base, dA 
opposite the unmodified T, but insertion of the succeeding nucleotide is error-prone 
(Figure 6-7). When the primer extension reaction corresponding to the adducted template 
was analyzed, seven different products were observed (Table 6-2 and Figure 6-6B). 19% 
of the total extension products corresponded to the error-free full extension product      
(5'-pT CAA TGA-3'; m/z 1090.68; [M-2H]2-), while 23% and 15% were G and C 
substitutions at the +1 position (5'-pT CAG TGA-3'; m/z 1098.68; [M-2H]2- and 5'-pT 
CAC TGA-3'; m/z 1078.67; [M-2H]2-, respectively, Table 6-2, Figures 6-6B and 6-8). 
Other major MS peaks at m/z 942.15, 934.15 and 922.14 corresponded to the doubly 
charged ions of 5'-pT C_G TGA-3' (one-base deletion, 16%), 5'-pT C_A TGA-3' (one-
base deletion, 15%) and 5'-pT C_C TGA-3' (one-base deletion, 12%, Table 6-2, Figures 
6-6B and 6-8). These results suggest that replication bypass of the dT-peptide cross-link 
by TLS polymerases is highly error-prone and that the extension products vary 
dramatically with the polymerase involved in replication of the adducted template. The 
deletion mutations observed are consistent with the fact that these TLS polymerases can 
skip the adducted site during replication and continue the polymerization reaction one 
base after the bulky adducted site.394,405-407 
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Figure 6-6 HPLC-ESI--FTMS analysis of primer extension by hPol η. (A) Extracted ion 
chromatograms of bypass products observed upon primer extension of the unmodified 
template. Three major peaks of roughly equal peak areas were observed. (B) Extracted 
ion chromatograms of replication products observed upon primer extension of the 
template containing 10-mer peptide conjugate. Multiple substitution and deletion 
products were observed. Error-free extension product, 5'-pT CAA TGA-3', constituted 
only 19% of total products. 
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Figure 6-7 Representative MS/MS spectra of extension products observed following      
in vitro replication past unmodified template by hPol η. CID spectra of extension 
products: (A) 5'-pT CAA TGA-3', error-free product, and (B) 5'-pT CAG TGA-3' and                  
(C) 5'-pT CAC TGA-3', substitutions opposite +1-mer. 
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Figure 6-8 Representative MS/MS spectra of extension products observed following      
in vitro replication past 10-mer peptide cross-linked to C5-T by hPol η. CID spectra of 
extension products: (A) 5'-pT CAA TGA-3', error-free product, (B) 5'-pT CAG TGA-3' 
and (C) 5'-pT CAC TGA-3', substitutions opposite +1-mer, (D) 5'-pT C_A TGA-3',    
one-base deletion, and (E) 5'-pT C_G TGA-3' and (F) 5'-pT C_C TGA-3', one-base 
deletion followed by a substitution. 
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6.4 DISCUSSION 
Because of their large size compared with other DNA lesions, DPCs are likely to 
block DNA replication. It has been proposed that proteins cross-linked to DNA can be 
proteolytically processed to generate less bulky DNA-peptide cross-links, which can be 
subsequently bypassed by TLS polymerases in an error-free or error-prone manner. 
Several studies provide evidence in support of this hypothesis. It is reported that DNA-
peptide cross-links are preferable substrates over DNA-protein cross-links in initiating 
DNA repair.169,324,325,330,331 Further, proteasomal inhibitors have been reported to slow 
down the repair of formaldehyde-induced DPCs in cells297 and intracellular repair of 
DPC-containing plasmids.331 In addition, several in vitro replication studies using site-
specific substrates containing small peptides cross-linked within the major or minor 
groove of DNA have provided direct evidence for the ability of lesion bypass 
polymerases to catalyze nucleotide incorporation opposite the DNA-peptide lesions.335-337 
However, all of the previous studies were conducted with model DPCs containing 
peptides conjugated to various positions within purine nucleobases of DNA (the N6 of 
adenine and the N2 of guanine), and no information is available on polymerase bypass of 
the corresponding lesions involving pyrimidine residues in DNA. Such lesions can be 
generated upon exposure to endogenous free radicals, UV light and ionizing 
radiation.182,211,410-412 Further, irreversible trapping of DNA methyltransferases on 
cytosines in genomic DNA can form DPCs that can adversely affect gene 
expression.408,409 
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Our results reported herein (Tables 6-1 and 6-2) provide the first evidence for 
error-prone bypass of peptides conjugated to the major groove of DNA through                
a pyrimidine nucleobase by human lesion bypass polymerases. Our model lesions 
generated via click chemistry contained a 10-mer peptide (Glu-Gln-Lys-Leu-Ile-Ser-Glu-
Glu-Asp-Leu-NH2) cross-linked to the C5 position of thymidine (Scheme 6-1). We found 
that both hPol κ and η can incorporate any of the four nucleotides opposite the cross-link 
(Figure 6-2) suggesting the possibility of both transition and transversion mutations. 
Furthermore, according to MS quantitation, 96% and 81% of the replication products of 
DNA-peptide cross-links by hPol κ and η were erroneous products (Table 6-2).  
Low fidelity DNA replication by hPol η and κ is well documented.150,415-417 Both 
enzymes catalyze error-prone bypass of 8-oxo-dG,418,419 abasic site,418-420 1,N6-HMHP-
dA,112 1,N6-etheno-dA394 and N2,3-etheno-dG.395 hPol η also replicate past bulky 
benzo[a]pyrene-N2-dG418 in an error-prone manner, while hPol κ erroneously bypasses  
2-acetylaminofluorene-dG.419,420 With respect to DNA-peptide cross-links, these results 
are consistent with highly miscoding potential observed with hPol κ and η in bypassing 
the DNA-peptide conjugate, N6-dA-(OH)2butyl-GSH.338 Extremely low accuracy 
observed with hPol κ in bypassing the dT-peptide cross-link in this work is of great 
interest in that hPol κ is known to exclusively incorporate the correct base, dC opposite 
peptides of comparable size (12-mer) cross-linked to N2 of dG.335 This discrepancy can 
arise from that dT-peptide lesion is cross-linked to the major groove of DNA, while     
N2-dG-peptide is to the minor groove,335 because it is reported that site of cross-linking 
within DNA is important for the ability of polymerase to bypass DNA adducts.336 
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Efficiency of replication bypass of adducted DNA is as important as the fidelity 
of the replication. From single nucleotide insertion assays, we found that hPol η is more 
efficient at bypassing DNA-peptide cross-links as compared to hPol κ (Figure 6-2). 
These results were confirmed by quantitative data obtained from steady-state kinetics 
(Table 6-1). Catalytic efficiencies (kcat/Km) of dNTP incorporation opposite the            
dT-peptide conjugate by hPol η were 2.3–463-fold higher than that of hPol κ. Further, 
misinsertion frequencies (f) for hPol η were 22.5–205-fold higher than those of hPol κ. 
Taken together, these data suggests that hPol η is more efficient than hPol κ in replication 
bypass in the context of the sequence and the adduct studied in this work. The order of 
bypass efficiency, hPol η > hPol κ is in agreement with the previously reported values for 
1,N6-etheno-dA,394 1,N6-HMHP-dA,112 N2,3-etheno-dG395 and N6-dA-(OH)2butyl-
GSH.338 
Additional information was provided from capillary HPLC-ESI--MS/MS 
sequencing of extension products (Table 6-2). We found that hPol κ replicated the 
unadducted template with good accuracy, where 87% of the products correspond to the 
error-free full extension product (Table 6-2, Figures 6-3A and 6-4A). In contrast, 
replication bypass of the dT-peptide conjugate was highly error-prone, inducing a large 
number of one and two-nucleotide deletions (96% of total products, see Table 6-2, 
Figures 6-3B, 6-4B and 6-5). It has been previously reported that hPol κ shows 
particularly high single base insertion/deletion rates in repetitive sequences,136,421 which 
is applicable in this case (5'-TCA TTG AAT CCT TCC CCC-3').  
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HPLC-ESI--MS/MS sequencing of extension products of hPol η using the 
unmodified template has revealed that the replication was surprisingly error prone (Table 
6-2). Specifically, hPol η incorporated the correct base (dA) opposite the first T in         
5'-TCA TTG AAT CCT TCC CCC-3', but the subsequent nucleotide insertion opposite 
the second T was highly error-prone (Table 6-2, Figures 6-6A and 6-7). The relatively 
low fidelity of replication of undamaged DNA by hPol η is well documented.136,150,415,417 
It has been reported that hPol η has the highest error rates amongst Y-family 
polymerases.136 The highest substitution rates for hPol η were observed for templates 
containing undamaged dT and d(TT), and dG and dC were preferred in such 
instances,415,417 as observed with our template (Table 6-2). The presence of dT-peptide 
lesion at the first T led to a large number of one-base deletions (43% of the total 
replication products; Table 6-2, Figures 6-6B and 6-8). In addition, hPol η-catalyzed 
replication gave rise to significant amounts of transition and transversion mutations  
(15% and 23%, respectively; Table 6-2, Figures 6-6B and 6-8).  
These results are consistent with the low fidelity and error-prone replication of 
TLS polymerases due to their large and flexible active sites and lack of 3'5' 
exonuclease activity.149 Mechanisms for the induction of deletions by TLS polymerases 
have been proposed,394,405,406 while X-ray crystallographic intermediates of these 
extension products have also been detected.407 The adducted base or adducted base and 
the base adjacent to it can misalign rendering a slipped or extrahelical conformation.394,407 
Alternatively, slippage event can occur subsequent to nucleotide insertion opposite the 
adduct.394,406,407 Extension of the misaligned primer yields one- and two-base 
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deletions,394,406,407 while realignment after nucleotide insertion and further extension 
cause substitution mutations.394,407 These prominent mutations (96% of total products for 
hPol κ) may also take place upon replication of other DNA-peptide conjugates, but would 
not be detected by electrophoresis methodologies employed in previous studies.335-337  
Furthermore, standard single nucleotide insertion assays opposite the damaged base 
cannot detect mutations occurring downstream from the adduct, as observed in the 
present study using HPLC-ESI--MS/MS sequencing (Table 6-2).  
In summary, we investigated the replication bypass of 10-mer peptides cross-
linked to major grove of DNA via a pyrimidine base (C5 of T) using human lesion bypass 
polymerases η and κ. Our gel electrophoresis and HPLC-ESI--MS/MS results provide 
evidence for highly error-prone replication past these bulky adducts. Specifically, large 
numbers of -1 and -2 deletions were observed for the replication catalyzed by hPol κ    
(Table 6-2). Low fidelity and deletion products observed in bypass of DNA-peptide 
cross-links can eventually contribute to mutagenesis of DPCs.304 To our knowledge, this 
is the first systematic study on replication fidelity of DPCs involving pyrimidine residues 
of DNA. In future studies, it would be interesting to determine how these peptide 
conjugates are accommodated in the active site of TLS polymerases. Furthermore, X-ray 
crystallographic or NMR structural studies of ternary complexes of these adducts in the 
presence of TLS polymerases and dNTPs can provide details on why and how this error-
prone replication occurs, especially the reasons for the large amounts of deletion 
mutations observed. 
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SUMMARY AND CONCLUSIONS 
7 SUMMARY AND CONCLUSIONS 
 
DNA damage is a continuous process by which genomic DNA 
is modified by various endogenous and exogenous physicochemical agents, and can 
potentially threaten the integrity of genetic information and decrease cell viability.1,4,5 
DNA adducts can disrupt DNA transactions triggering apoptosis,422 unless rapidly 
repaired.8,9 Alternatively, the persisting lesions can be replicated in an error-prone 
manner,2,8,9 ultimately causing adverse biological effects.30-39 Mitigation or exacerbation 
of these deleterious effects is determined by the cellular dynamics of DNA repair and 
replication. Hence, systematic investigation of repair and replication of DNA adducts is 
essential to fully understand the biological consequences of DNA damage. 
1,3-Butadiene (BD) is a known human carcinogen and mutagen that has               
a widespread occurrence in the environment, resulting in a high potential for human 
exposure.25,45-50,63-65 Epidemiological and toxicological studies in humans and inhalation 
studies in animals have provided evidence for increased risk of cancer incidence upon 
exposure to BD.46,64,65 Further, chronic exposure to BD has been associated with 
respiratory and cardiovascular diseases.51-62 
The adverse biological effects of BD are attributed to DNA damage mediated by 
its epoxide metabolites. Highly reactive epoxides: 3,4-epoxybut-1-ene (EB),                
3,4-epoxybutan-1,2-diol (EBD) and 1,2,3,4-diepoxybutane (DEB) are formed upon 
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metabolic activation of BD by cytochrome P450 monooxygenases (Scheme 1-1).66,67 
Unless detoxified by epoxide hydrolase (EH) or conjugation with glutathione,68 these 
metabolites can react with multiple sites within DNA and proteins, forming covalent 
adducts (Scheme 1-1).73-77 Among these, DEB is considered the ultimate carcinogenic 
metabolite of BD because of its high genotoxicity, which is attributed to its ability to   
bis-alkylate biomolecules to form exocyclic adducts (Chart 1-5),78,79 DNA-DNA cross-
links (Chart 1-4) 80-84 and DNA-protein cross-links.85,86 
The mutagenic and carcinogenic properties of BD are well documeted.70,90,358-360 
Nonetheless, the mechanisms of  cellular repair of BD-induced DNA lesions have not 
been identified. Since the dynamics of repair and replication of DNA adducts as well as 
the ability of these lesions to cause mispairing can significantly alter the biological 
effects of DNA damage, identifying the repair pathways of BD-DNA adducts is crucially 
important. 
Despite the preferential alkylation of guanine nucleobases by BD-derived 
epoxides,357 BD induces a large number of A  T mutations, suggesting the significant 
contribution of adenine lesions to its biological effects.90-93 In the first part of this thesis, 
we examined the repair mechanisms responsible for the removal of three novel BD-
induced 2'-deoxyadenosine (dA) lesions in human cells (Chapter 2). Synthetic 
oligodeoxynucleotides containing site- and stereospecific S-N6-(2-hydroxy-3-buten-1-yl)-
2'-deoxyadenosine (S-N6-HB-dA) monoadduct and the exocycles, R,S-1,N6-(2-hydroxy-3-
hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (R,S-1,N6-HMHP-dA) and R,R-N6,N6-
(2,3-dihydroxybutan-1,4-diyl)-2'-deoxyadenosine (R,R-N6,N6-DHB-dA) using a post-
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oligomerization strategy (Scheme 2-3).362 The adducted DNA strands were characterized 
by capillary HPLC-ESI--MS, ESI+-MS3 and HPLC-UV analysis of enzymatic digests and 
MALDI-TOF-MS of controlled exonuclease digests (Figure 2-1 and Table 2-1).  
Gel electrophoresis-based in vitro repair assays employing radiolabeled dsDNA 
substrates and nuclear extracts from human fibrosarcoma (HT1080) cells have revealed 
that all three BD-dA adducts were recognized and cleaved by the base excision repair 
(BER) mechanism (Figures 2-2 and 2-3). First order rate constants revealed that the 
efficiency of repair decreased in the order of (S)-N6-HB-dA > (R,R)-N6,N6-DHB-dA > 
(R,S)-1,N6-HMHP-dA, while BD-dA adducts were recognized at comparable rates to 
known BER substrates, 5F-dU and 8-oxo-dG (Table 2-2 and Figure 2-4). We observed 
50–75% inhibition in repair of the adducts in the presence of a known BER inhibitor, 
methoxyamine, confirming that BER is indeed responsible for repair of these adducts 
(Figure 2-4). To further confirm the involvement of BER, we developed an HPLC-ESI--
MS/MS method to characterize the excision products. These experiments have detected 
the expected precursor ions ([M-H]-) and fragmentation patterns for the expected 
oligonucleotide products in two sequence contexts (Figure 2-6). In an effort to identify 
the DNA glycosylases involved in removal of BD-dA lesions, we employed 12 human 
and bacterial glycosylases (AAG, Mpg, edited and unedited NEIL1, OGG1, EndoIII, 
Fpg, Mug, MutY, MutYH, Nei and UDG). However, none of the enzymes were able to 
recognize the adducts of interest (Figures 2-7 and 2-8), suggesting that an alternate 
glycosylase is responsible for the observed repair. To our knowledge, this is the first 
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direct evidence for the active repair of biologically relevant BD-induced DNA adducts in 
human cell-free extracts. 
Covalent entrapment of cellular proteins on genomic DNA upon exposure to 
various endogenous and exogenous chemicals and physical agents in vivo results in the 
production of highly heterogeneous and unusually bulky DNA lesions, DNA-protein 
cross-links (DPCs).4,5 The complexity and diversity of these highly abundant, yet 
understudied DNA adducts mainly arise from the partaking of a wide range of proteins of 
varying sizes, properties and functions,85,158-160 and participation of numerous sites on 
DNA and multiple amino acids on proteins in cross-linking (Chart 1-6).4,85,158,161-168 
Endogenous and exogenous bis-electrophiles are the most common type of chemicals that 
participates in DPC generation in cells.85,86,189,190,195-210  
DPCs can compromise genetic integrity and cell viability due to their unusual 
bulkiness as compared to “standard” DNA lesions.4,85,158-168 The cytotoxic effects of a 
number of DNA damaging agents including formaldehyde have been attributed to DPC 
formation.39,132,216,220,234,251,259,260,299-302 The ability of DPCs to interfere with crucial 
DNA-protein interactions in cellular processes such as DNA replication, transcription and 
repair is thought to lead to cytotoxic and mutagenic outcomes.4,5 These in turn can 
contribute to various diseases including cancer,30-33 cardiovascular disease34-36 and      
age-related neurodegeneration.35-39 
The biological consequences of DPCs are poorly understood because of the 
tendency of many DPC-inducing agents to induce other types of DNA adducts,262 and 
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their highly heterogenic nature. In this regard, novel methodologies are required to induce 
and characterize DPCs selectively in cells and to generate site-specific, biologically 
relevant DPCs to study repair and replication in vitro. Previously reported synthetic 
methodologies have several limitations such as poor reaction efficiency and low yields,164 
limited choice of proteins,331 and insufficient site specificity with respect to the cross-
linking site within the protein.164,246,354 In the second part of this thesis, we have 
developed two novel methodologies to generate hydrolytically stable, sequence specific 
model DPCs and investigated their effects on DNA replication. 
The N7 position of guanine is the most nucleophilic site within DNA and is 
therefore the most common site for nucleobase adduct formation.357 It is also the most 
likely site to be involved in DNA-protein cross-linking in the presence of                     
bis-electrophiles such as environmental carcinogens and antitumor drugs (Schemes 1-5     
and 1-6).85,86,158,159,161,294 Yet, no methods exist in the literature to generate N7-G 
conjugated DPCs because of the tendency of N7 alkylated guanines to undergo 
spontaneous depurination.375 Herein, we developed a new synthetic methodology to 
generate site-specific, hydrolytically stable model DPCs that are structural mimics of N7 
conjugated DPCs such as those formed in vivo (Chapter 3). We developed a strategy 
based on post-synthetic reductive amination to cross-link Lys and Arg residues within 
proteins and peptides to the C7 position of aldehyde-functionalized 7-deaza-guanine via 
an ethylene linkage (Scheme 3-2). The resulting model DPC substrates are direct analogs 
of DPCs generated by antitumor nitrogen mustards and chlorooxirane.158,159,161 We tested 
the applicability of our method to generate DPCs using a range of proteins and peptides 
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(Table 3-1 and Figure 3-4). In general, we observed that DNA binding proteins 
produced DPCs in high yields compared to proteins that do not have an affinity to DNA. 
We employed denaturing gel electrophoresis and a nanoLC-nanospray-MS/MS method to 
characterize the model DPCs. DPCs were visualized as low mobility bands on denaturing 
gels by phosphorimaging of radiolabeled DNA or protein staining (Figures 3-1 and 3-2). 
Mass spectrometry characterization of the peptide-nucleoside conjugates resulting from 
the enzymatic digestion of the DNA component and tryptic digestion of the protein 
revealed that Lys and Arg residues on proteins are involved in cross-linking reactions 
(Table 3-2, and Figures 3-5 and 3-6). We further employed a capillary HPLC-ESI+-MS2 
method and a nanoLC-nanospray-MS3 method to confirm the exact chemical structures 
of the resulting conjugates. MS/MS spectra of 7-deaza-7-(2,3-dihydroxy-propan-1-yl)-  
2'-deoxyguanosine (deaza-DHP-dG) conjugates involving free Arg and Lys (Figure 3-7) 
and two peptide conjugates (involving substance P and Angiotensin I) (Figure 3-8) have 
confirmed that side chain amino groups of Lys/Arg residues participate in cross-linking 
reactions. DPCs generated using this methodology can be employed in repair and 
replication studies to fill the gaps in our understanding of the biological consequences of 
DPCs formed in cells. 
Model DNA-protein and DNA-peptide cross-links conjugated to the major groove 
of DNA via the C7 position of 7-deazaguanine were used as templates in primer 
extension studies to evaluate the effects of DPCs on DNA replication. Gel 
electrophoresis-based primer extension assays have revealed that large DNA-protein 
cross-links (11.4 kDa histone H4, 22.9 kDa AlkB and 28.4 kDa 6xHis-eGFP) represent a 
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complete block to human TLS polymerases η and κ under both standing start and running 
start conditions (Figures 4-1 and 4-2). Although a 23-mer peptide cross-linked to C7-G 
blocked replication in standing start experiments, a smaller 10-mer peptide cross-link was 
bypassed (Figure 4-3). These results suggest that DPCs formed to N7 of guanine in cells 
can get proteolytically degraded to smaller DNA-peptide cross-links to facilitate 
polymerase bypass. The efficiency and fidelity of bypass of the decapeptide cross-linked 
to DNA was evaluated using steady-state kinetic experiments (Table 4-1). We found that 
hPol η incorporated the correct base, dC, opposite the peptide cross-link with high 
efficiency and 500-fold preference over dT. hPol κ catalyzed error-free bypass of the 
peptide cross-link, despite low efficiency. The order of bypass efficiency, hPol η > hPol κ 
is in agreement with the previous reports for other bulky lesions.112,338,394,395  
In Chapters 5 and 6, we described a novel method to generate DPCs conjugated to 
the major groove of DNA via pyrimidine nucleobases and examined their effects on 
replication bypass. Site-specific DPC substrates were prepared by copper-catalyzed [3+2] 
Huisgen cycloaddition between an alkyne-functionalized 5-(octa-1,7-diynyl)-uracil in 
DNA and an azide group within 6×His-eGFP, and 23-mer and 10-mer peptides derived 
from tetanus toxoid423 and c-Myc oncogene,424 respectively (Schemes 5-1 and 5-2). Gel 
electrophoresis and mass spectrometry-based techniques described above were used to 
characterize DNA-protein and DNA-peptide conjugates (Figures 5-1–5-5). The results of 
in vitro primer extension assays were similar to those observed with C7-G cross-linked 
polypeptides. DNA primers annealed to templates containing large 6×His-eGFP and        
a 23-mer cross-links completely blocked lesion bypass polymerases η and κ (Figures 5-7     
  262
and 5-8). In contrary, decapeptide conjugated to C5 of thymidine was bypassed, further 
confirming our hypothesis that cross-linked protein in cellular DPCs gets proteolytically 
processed to generate smaller peptide prior to replication (Figures 5-7 and 5-8). 
Complete replication block by proteins conjugated to pyrimidines has been reported.132 
However, our observation of replication block in the presence of 23-mer peptide 
contradicts previous reports that tetra- and dodecapeptides cross-linked to N2-G and N6-A 
were bypassed by hPol  κ and ν, respectively.335,336 This supports the notion that the 
cross-linking site within DNA can influence the biological consequences of DPC lesions. 
We further examined the fidelity of replication bypass of the decapeptide cross-
linked to major grove of DNA via pyrimidine bases (Chapter 6). Steady-state kinetic 
studies were performed using the purified conjugates to determine the catalytic efficiency 
(kcat/Km) and misinsertion frequency (f) opposite the adducted site. We found that hPol η 
is catalytically more efficient than hPol κ, but nucleotide insertion opposite the adduct 
was more error-prone (Table 6-1). Catalytic efficiencies of dNTP incorporation opposite 
the dT-peptide conjugate by hPol η were 2.3–463-fold higher than that of hPol κ. Further, 
misinsertion frequencies for hPol η were 22.5–205-fold higher than those of hPol κ. 
Although both enzymes can insert any of the four dNMPs opposite the adduct, hPol η 
misincorporated dGMP with 4.5-fold preference over the correct nucleotide, dAMP.       
A methodology involving affinity capture in combination with liquid chromatography-
tandem mass spectrometry was developed to quantify and sequence the replication 
products (Scheme 6-3). Capillary HPLC-ESI--HRMS quantitation and MS/MS 
sequencing of primer extension products of the 10-mer peptide conjugated to C5 of 
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thymidine provided evidence for the highly error-prone replication past these bulky 
adducts by human TLS polymerases η and κ (Table 6-2 and Figures 6-3–6-8). Moreover, 
the majority of the products of hPol κ-catalyzed primer extension (96%) corresponded to 
one- and two-base deletions (Figure 6-4). In addition to the effect of the bulky adduct, 
the local sequence context (5'-TCA TTG AAT CCT TCC CCC-3') may be responsible for 
these deletions, since hPol κ can cause insertion/deletion events in repetitive 
sequences.136 Overall, our results are consistent with the low fidelity and error-prone 
replication of TLS polymerases due to their large and flexible active sites and lack of      
3'  5' exonuclease activity.149 X-ray crystallographic evidence of deletion products 
resulting from translesion synthesis of 1,N2-dG further corroborate our findings.407 
These prominent mutations (96% of total products for hPol κ) may also take place upon 
replication of other DNA-peptide conjugates, but would not be detected by 
electrophoresis methodologies employed in previous studies.335-337 Furthermore, the 
mutations observed downstream from the adduct, such as base substitutions at +1 
position, cannot be detected by standard gel electrophoresis-based assays and were only 
revealed due to the use of HPLC-ESI--MS/MS methodology (Table 6-2). Extremely low 
polymerase fidelity and deletion products observed in bypass of these DNA-peptide 
cross-links can eventually contribute to mutagenesis of DPCs.304 To our knowledge, this 
is the first systematic study on replication fidelity of peptides covalently attached to 
pyrimidines on DNA, and it has provided valuable insights into deleterious effects of 
such bulky DNA lesions formed in vivo. 
  264
In summary, the present study employed a combination of nucleic acid chemistry 
and organic synthetic tools to prepare stereo- and site-specific DNA oligonucleotides 
containing BD-dA lesions and site-specific, hydrolytically stable DPCs that are structural 
mimics of biologically relevant DPCs formed to purine and pyrimidine nucleobases in the 
major groove of DNA. Biochemical tools such as gel electrophoresis and bioanalytical 
methodologies including liquid chromatography-tandem mass spectrometry were used to 
examine the repair of BD-dA lesions and to investigate the effects of DPCs on DNA 
replication. In the first part of this thesis, gel electrophoresis-based assays provided 
evidence that all three BD-dA adducts studied in the current work, S-N6-HB-dA,         
R,S-1,N6-HMHP-dA and R,R-N6,N6-DHB-dA, can be recognized by cellular BER 
pathway and cleaved efficiently in human cells (Chapter 2). Repair inhibition assays and 
5' excision products characterized by capillary HPLC-ESI--MS/MS further confirmed the 
involvement of BER in removal of these lesions.  
In the second part of this thesis, we have developed two synthetic strategies to 
generate site-specific DPCs using reductive amination (Chapter 3) and copper-catalyzed 
[3+2] Huisgen cycloaddition reaction (Chapter 5). Replication bypass of synthetic DPCs 
prepared by both strategies revealed that large proteins and polypeptides conjugated to 
the major groove of DNA completely block replication irrespective of the protein identity 
and site-of cross-linking within DNA (Chapter 4 and 5). However, human TLS 
polymerases were able to replicate past small decapeptides conjugated to DNA with 
varying efficiencies suggesting the proteolytic degradation of the cross-linked protein    
in vivo prior to repair or replication (Chapter 4 and 5). Furthermore, according to the 
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results from single nucleotide insertion assays and steady state kinetic studies, we found 
that the human TLS polymerases catalyze bypass of a decapeptide cross-linked to C7 of 
guanine with high fidelity (Chapter 4). In contrast, bypass of a decapeptide conjugated to 
C5 of thymidine was highly error-prone (Chapter 6). Our Capillary HPLC-ESI--HRMS 
and MS/MS experiments further revealed that replication past peptides conjugated to C5 
of thymidine causes a large number of base substitution and deletion mutations (Chapter 
6). Taken together, our data suggest that efficiency and fidelity of replication bypass of 
DNA-polypeptide cross-links are dependent on size of the cross-linked polypeptide, 
cross-linking site within DNA and the identity of the polymerase. 
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FUTURE DIRECTIONS 
8 FUTURE DIRECTIONS 
8.1 IDENTIFICATION OF DNA GLYCOSYLASES INVOLVED     
IN REPAIR OF N6-2'-DEOXYADENOSINE LESIONS OF             
1,3-BUTADIENE 
As described in Chapter 2, we have shown that base excision repair (BER) is one 
of the repair pathways involved in the removal of S-N6-HB-dA, R,S-1,N6-HMHP-dA and     
R,R-N6,N6-DHB-dA adducts in human cells. However, none of the human and bacterial 
glycosylases tested (human AAG, Mpg, edited and unedited NEIL1 and OGG1, E. coli 
EndoIII, Fpg, Mug, MutY, MutYH and Nei, and A. fulgidus UDG) were able to recognize 
these adducts (Figures 2.3 and 2.4). The use of mispaired DNA duplexes, if significant 
changes in repair rates were observed for mispaired DNA duplexes with nuclear extracts, 
can be a useful strategy to identify the BER glycosylases responsible for the cleavage of 
these adducts. These experiments are currently in progress (in collaboration with          
Dr. Sheila David, University of California, Davis).  
To identify any additional/novel DNA glycosylases that may be involved in repair 
of BD-dA lesions, a mass spectrometry-based proteomics strategy can be employed 
(Scheme 8-1). The adducts-containing DNA oligomers and unadducted controls will be 
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prepared on solid support. Adducted and control DNA duplexes will be preincubated 
with methoxyamine to prevent APE cleavage of abasic sites generated by BER enzymes 
upon removal of the adduct. Following incubation with nuclear protein extracts from 
human cells in the presence of a large excess of carrier DNA to minimize non-specific 
binding, DNA-bound proteins will be eluted using a salt gradient, SDS, and heat. Salts 
and low concentrations of SDS will remove any non-specific binders, while heating with 
SDS will release strongly-bound proteins. Fractionation of DNA-bound proteins by SDS-
PAGE and sensitive nanoLC-nanospray-MS/MS detection on an LTQ Orbitrap Velos 
instrument will increase the chances of discovery of the novel glycosylases using MS-
based proteomics (Scheme 8-1). Elimination of protein hits from salt eluates and 
unmodified DNA controls can aid in revealing the BD-dA adduct-specific glycosylases. 
We have already developed methods to synthesize these adducts on solid support 
(Scheme 8-2 and Figure 8-1). Alternatively, an affinity capture-based approach can also 
be employed using 5'-biotinylated adducted DNA.85,294,425,426 If the glycosylase involved 
is a bifunctional enzyme having both glycosylase and AP lyase activity,6,427,428 reduction 
of the Schiff base formed between the enzyme and the AP site upon incubation of 
adducted DNA with nuclear extracts can be reduced to form a stable amine conjugate. 
Covalently trapped DNA-proteins cross-links on solid support/streptavidin beads can be 
used for nanoLC-MS/MS analysis. 
Isotope labeling-based proteomics approach such as isobaric tag for relative and 
absolute quantitation (iTRAQ) can also be employed.429-432 BD-dA adducted dsDNA   
(on solid support or biotinylated) will be incubated with nuclear extracts. Unmodified 
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dsDNA will be used as controls. Following protein elution, fractionation and in-gel 
digestion, samples will be labeled with iTRAQ reagents (iTRAQ reagents–4plex, Ab 
Sciex, Foster City, CA). Peptide backbone fragment ions from nanoLC-MS/MS analysis 
will be used for protein identification, while relative quantities of iTRAQ reporter ions 
will be used to identify the proteins specifically bound to BD-dA adducts.430,431 A higher 
abundance of reporter ions corresponding to the samples from BD-dA adducted DNA as 
compared to the negative control will indicate any glycosylases responsible for the repair 
of the adducts. 
 
 
 
 
 
 
 
  269
Scheme 8-1 Mass spectrometry-based proteomics approach to identifying the base excision repair glycosylases responsible for         
the repair of 1,3-butadiene-induced 2'-deoxyadenosine adducts. 
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Scheme 8-2 Synthesis of 1,3-butadiene-induced 2'-deoxyadenosine adducts on solid 
support.§§ 
 
 
 
 
 
 
 
 
 
 
 
                                                 
§§	 (a) solid phase synthesis, (b) DIPEA, DMSO, 60 °C, 24 h, (c) DIPEA, DMSO, 37 °C, 24 h, (d) DIPEA, DMSO,     
37 °C, 72 h, (e) H2O, rt, 3h.	
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Figure 8-1 Characterization of 18-mer oligodeoxynucleotides containing site- and stereo-
specific 1,3-butadiene lesions after cleavage from the solid support. Capillary HPLC-ESI-
-MS spectra of 18-mer containing R,R-DHB-dA (A) and R,S-HMHP-dA (B), HPLC-UV 
analysis of enzymatic digests of the 18-mer containing S-HB-dA (C) and ESI+-MS3 
spectrum of S-HB-dA (D). 
 
  272
8.2 IN VITRO AND IN VIVO INVESTIGATION OF REPAIR OF   
1,3-BUTADIENE-INDUCED N6-ADENINE ADDUCTS 
Our in vitro repair studies revealed efficient recognition of BD-dA adducts by 
BER in human cell free extracts (Chapter 2). Nonetheless, it will be interesting to 
examine whether these adducts can be recognized by other cellular repair mechanisms. 
For example, it is reported that guanidinohydantoin (Gh), spiroiminodihydantoin (Sp) and 
hydantoin amine adducts formed upon oxidation of guanine are good substrates for both 
BER and NER.433 
To examine whether NER plays a role in removal of BD-dA lesions, in vitro 
repair experiments can be performed using HeLa nuclear extracts (Scheme 8-3). The site-
specifically adducted 18-mer (5'-TCA TXG AAT CCT TCC CCC-3') 
oligodeoxynucleotides prepared in Chapter 2 will be 5'-endlabeled, ligated with 5' and 3' 
flanking sequences and annealed to the complementary strands to construct longer       
(50 nucleotides or more), linear ds-DNA substrates (Scheme 8-3).128,433,434 Alternatively, 
32P-end-labeled, site-specific BD-dA adducted 18-mer DNA strands will either be 
annealed to single-stranded plasmids followed by primer extension435 or be inserted into 
restriction endonuclease-nicked double-stranded plasmids,436 and ligated to prepare 
double-stranded plasmids containing the adducts (Scheme 8-3). Following incubation 
with cell free protein extracts, samples will be analyzed by denaturing PAGE, and the 
incision products will be visualized by phosphorimaging.128,433-435 Unmodified and 
aminofluorene adducted dG (N-(2'-deoxyguanosin-8-yl)-2-aminofluorene or N-(2'-deoxy-
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guanosin-8-yl)-2-acetylaminofluorene) containing DNA substrates will be used as 
negative and positive controls, respectively.435 
For time course studies of DNA repair, unlabeled dsDNA substrates will be 
incubated with nuclear extracts or human cells will be tranfected with adducted plasmids 
for predetermined time points (0–180 min) and purified using a commercial DNA 
isolation kit. Following enzymatic digestion to nucleosides, BD-dA adducts will be 
isolated by solid phase extraction.111 Isotope dilution liquid chromatography-tandem 
mass spectrometry (HPLC-ESI-MSn) methods similar to those developed by Tretyakova 
and coworkers111 will be used for adduct quantitation. The mass spectrometry-based 
methods can be advantageous over biochemical methods described above due to the 
ability of absolute quantitation. 
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Scheme 8-3 In vitro repair experiments to examine the involvement of nucleotide excision repair in the removal of 2'-deoxyadenosine 
lesions of 1,3-butadiene. 
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8.3 EXAMINATION OF IN VIVO MUTAGENESIS OF 2'-DEOXY-
ADENOSINE LESIONS OF 1,3-BUTADIENE 
In vitro replication studies conducted in our laboratory using human TLS 
polymerases have provided evidence for the mutagenic potential of both exocyclic      
BD-dA adducts.112,157 Yet, the applicability of these mutation spectra in vivo should be 
evaluated as cellular responses to DNA damage is complex: DNA repair and tolerance 
mechanisms that operate prior to or simultaneously with DNA replication can mitigate 
the effects of damaged DNA. Quantitative lesion bypass and mutagenesis experiments of 
BD-dA adducts are currently in progress (in collaboration with Dr. John Essigmann, 
Massachusetts Institute of Technology). Site- and stereo-specific 16-mers, 5'-GAA GAC 
CTX GGC GTC C-3', containing BD-dA adducts prepared in our laboratory were ligated 
to ss-M13 plasmids linearized using EcoRV with the aid of a scaffold DNA, and 
consequently transfected into E. coli.437-439 The effects of BD-dA adducts on DNA 
replication will be assessed by using the competitive replication of adduct bypass 
(CRAB) assay,438,439 while site-specific mutation frequency will be calculated using the 
restriction endonuclease and post-labeling analysis of mutation frequency (REAP) 
assay.437-439 Preliminary data indicates that S-N6-HB-dA and R,R-N6,N6-DHB-dA do not 
block replication, while R,S-1,N6-HMHP-dA strongly blocks replication (~10% bypass in 
non-induced cells). However, none of the lesions were strongly mutagenic in E. coli.  
R,R-N6,N6-DHB-dA induced ~1% A  G and A  T mutations. R,S-1,N6-HMHP-dA 
caused ~2% A  T mutations, while S-N6-HB-dA did not appear to be mutagenic. No 
deletion mutations were observed for any of the three adducts under the assay conditions. 
  276
These in vivo mutagenicity data contradict what has been observed in vitro with human 
TLS polymerases,112,157 suggesting that these adducts are efficiently repaired in cells. 
However, the kinetics of repair and replication of these adducts can be different in 
bacterial and human cells. 
To study mutagenicity of these adducts in human cell cultures, quantitative gap-
filling assay440,441 and single-stranded pMS2-based oligonucleotide hybridization assay442 
can be employed (Scheme 8-4). Gapped plasmids (chloramphenicol resistant, cmR GP20 
and kanamycin resistant, kanR GP21) will be constructed by ligating synthetic gapped 
duplex oligonucleotides (unmodified or BD-dA adducted) to restriction endonuclease 
cleaved plasmids (Scheme 8-4A).441 Human cells (for example, embryonic kidney cells, 
HEK293T) will be co-transfected with gapped plasmids (unmodified and BD-dA lesions) 
and a carrier plasmid.440,441 After allowing for gap filling and replication, filled-in 
progeny plasmids will be isolated using alkali and transformed into E. coli recA strain. 
Progeny cells will be plated in parallel on LB+kan and LB+cm to select for GP21 
plasmids that underwent TLS and GP20 control plasmids (Scheme 8-4A).440,441 Lesion 
bypass is the ratio of kanR/cmR transformants, and mutation analysis will be done by 
sequencing the kanR transformants.440,441 Alternatively, 18-mer DNA strands (5'-TCA 
TXG AAT CCT TCC CCC-3', where X = dA or BD-dA adducts) will be ligated to a 
single-stranded pMS2 vector linearized using EcoRV with the aid of a scaffold DNA 
(Scheme 8-4B).442-445 Human embryonic kidney cells (HEK293T) will be transfected 
with the adducted and control plasmids.442 Following replication and transformation in  
E. coli HD10B strain, progeny plasmids will be analyzed by oligonucleotide 
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hybridization and DNA sequencing (Scheme 8-4B).442-445 In vivo mutagenesis of BD-dA 
adducts, if conducted using biologically more relevant cell types such as human bronchial 
epithelial cells (HBEC), will provide more useful information compared to bacterial 
systems to understand the adverse effects of BD-mediated DNA damage in humans. 
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Scheme 8-4 In vivo mutagenesis studies of 1,3-butadiene-induce 2'-deoxyadenosine adducts. Quantitative gap filling assay (A)440,441 
and single-stranded plasmid-based oligo hybridization assay (B).442 
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8.4 SYNTHESIS OF SITE- AND STEREO-SPECIFIC OLIGO-
DEOXYNUCLEOTIDES CONTAINING 1-(ADEN-N6-YL)-         
4-(GUAN-7-YL)-BUTAN-2,3-DIOL FOR STRUCTURAL AND 
BIOLOGICAL STUDIES 
BD and its epoxide metabolites induce a large number of A  T mutations 
(section 1.2.4).90-93 The exact structures and/or mechanisms responsible for these 
mutagenic effects are not well understood. 1-(Aden-N6-yl)-4-(guan-7-yl)-butan- 2,3-diol 
(N6A-N7G-BD) is a partially hydrolytically stable bulky DNA adducts induced by 
DEB.446 The sequential alkylation of N7G and N6A by DEB forms N6A-N7G-BD adducts 
(Scheme 8-5). The resulting positive charge on alkylated guanine promotes the 
hydrolysis of the N-glycosidic bond to generate a partially depurinated bulky N6A-N7G-
BDdep adducts protruding out of the DNA major groove (Scheme 8-5). Hydrolytically 
stable N6A-N7G-BDdep adducts can have significant effects on DNA structure, stability, 
repair and replication as observed with similar bulky adenine lesions. For example, site-
specifically adducted DNA containing N6-(14R-(+)-trans,anti-((11S,12R,13R)-
trihydroxy-11,12,13,14-tetrahydrodibenzo[a,l]pyrenyl)-dA and N6-(14S-(-)-trans,anti-
((11R,12S,13S)-trihydroxy-11,12,13,14-tetrahydrodibenzo[a,l]pyrenyl)-dA were found to 
intercalate differentially (5'- and 3'-intercalation from the major groove of DNA, 
respectively), leading to significant differences in thermal stabilities.447 However, both 
stereoisomers were resistant to nucleotide excision repair, when subjected to NER dual 
incision assay using HeLa cell free extracts.447 Further, N6-(10-(7,8,9-trihydroxy-
7,8,9,10-tetrahydrobenzo[a]pyrenyl))-dA adducts represented a significant block to 
  280
human bypass polymerases in vitro,448 and produced mutagenic products with 
recombinant polymerases and human cell extracts.448,449 Similarly, N6-[(chrysene-          
5-yl)methyl]-adenine has revealed sequence-specific replication block with E. coli DNA 
polymerase I.450 These results suggest that N6A-N7G-BDdep adducts can alter the DNA 
structure contributing to adverse effects on DNA transactions. 
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Scheme 8-5 Formation of hydrolytically stable 1-(adenosin-N6-yl)-4-(guan-7-yl)-butan-
2,3-diol adduct. 
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We have developed the synthetic methodologies to prepare site-specifically 
modified synthetic DNA containing N6A-N7G-BDdep (Scheme 8-6 and Figure 8-2).          
N-Fmoc-1-amino-3,4-epoxybutan-2-ol (2) was coupled to either 2'-deoxy-N2,3',5'-O-tri-
acetylguanosine (1, R=Ac) or 2'-deoxyguanosine (1, R=H) in an acidic medium to 
generate N-Fmoc-4-(N2-acetylguan-N7-yl)-1-aminobutane-2,3-diol (3, R=Ac) and         
N-Fmoc-4-(guan-N7-yl)-1-amino-butane-2,3-diol (3, R=H), respectively (Scheme 8-6). 
The resulting N7G adduct was coupled with 6-chloropurine containing DNA in the 
presence of Hunig’s base in DMSO to generate the N6A-N7G-BD adducted 
oligodeoxynucleotides (4, Scheme 8-6). This synthetic methodology will be used to 
prepare site-specific DNA strands containing bulky N6A-N7G-BDdep adducts for 
structural studies including solution state NMR, CD spectroscopic and UV melting 
studies to evaluate the effect of this bulky lesion on DNA duplex structure and stability. 
Further, replication bypass and repair experiments will be performed to elucidate its 
consequences on genomic stability and cell viability. 
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Scheme 8-6 Synthesis of oligodeoxynucleotides containing 1-(adenosin-N6-yl)-4-(guan-   
7-yl)-butan-2,3-diol.*** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
*** (a) AcOH, 80 °C, 5 h, (b) 6-Cl-Pu oligodeoxynucleotide, DIPEA, DMSO, rt, 3 d, (c) 0.1 M NaOH, rt, 3 d.	
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Figure 8-2 Capillary HPLC-ESI--MS spectrum of a 11-mer, 5'-CGG ACX AGA AG-3', 
containing 1-(adenosin-N6-yl)-4-(guan-7-yl)-butan-2,3-diol (A) and capillary HPLC-
ESI+-MS (B) and MS/MS spectra (C) of 1-(adenin-N6-yl)-4-(guan-7-yl)-butan-2,3-diol. 
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8.5 FURTHER INVESTIGATION OF IN VITRO REPLICATION OF 
MODEL DNA-PROTEIN CROSS-LINKS 
As discussed in Chapter 4, the decapeptide cross-linked to C7 of 7-deaza-guanine 
in DNA was bypassed with high fidelity by human TLS polymerases η and κ. In contrast, 
the post-lesion bypass of the same peptide conjugated to C5 of thymidine was highly 
mutagenic (Chapter 6). Therefore, it is critical to test the post-lesion bypass of C7-G 
conjugated peptide, since further extension past the damaged site may be mutagenic. To 
this end, quantification and sequencing of the replication products by a similar strategy 
used in Chapter 6 is currently underway to determine the fidelity of replication past N7-G 
adducted DNA (Scheme 8-7). Biotinylated 19-mer primer, Biotin-5'-(T)10 CAA TGC 
UTG-3', containing a uridine at the 3rd position from the 3'-end will be annealed to the 
20-mer, GTT ACG AAC XAT GGT CAC TG-5', where X = dG or deaza-DHP-dG-
decapeptide cross-link. The resulting primer-template complexes will be subjected to 
primer extension using hPol η and κ, subsequently captured on streptavidin beads and 
washed to remove enzymes and buffer solution. Incubation with UDG followed by 
heating in the presence of piperidine will release the extended primer (5'-pTG NNN NNN 
NNN NN-3' and insertion/deletion products, if any), which will be dried in vacuo. The 
samples will be reconstituted in water and a 14-mer will be added as an internal standard, 
immediately prior to analysis. Quantitation and sequencing of primer extension products 
will be performed by separate capillary HPLC-ESI--FTMS and MS/MS analyses. 
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Scheme 8-7 Streptavidin capture in combination with capillary HPLC-ESI--MS/MS 
methodology for sequencing and quantitation of primer extension products. 
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Although it is rare, replicative polymerases can also bypass DNA adducts. For 
example, Lloyd and coworkers reported that E. coli replicative polymerase, Pol III 
catalyzed efficient bypass of N6-(1-hydroxy-3-buten-2-yl)-dA, a regiosiomer of the     
HB-dA adduct studied in this work, and N6-(2,3,4-trihydroxybutan-1-yl)-dA adducts.70 It 
will be interesting to examine whether human replicative polymerases can replicate past 
DNA-protein cross-links. Our pilot experiments using the decapeptide cross-linked to 
C5-T revealed that human replicative polymerase  can partially extend a primer-
template duplex past the peptide cross-link with extremely low efficiency (Figure 8-3). 
We also observed some degradation of the primer, which is typical for hPol  having      
3'  5' exonuclease activity.451 These observations warrant further experiments using 
hPol . Ideally, the enzyme lacking the exonuclease activity should be expressed to 
conduct steady-state kinetic studies.  
It will be interesting to investigate the cooperativity and synergy of replicative 
polymerases and translesion synthesis polymerases. The cooperativity of polymerases 
will be examined by conducting the primer extension assays with an enzyme that catalyze 
partial extension of adducted DNA, followed by the addition of another enzyme after a 
predetermined time.112,157 Full extension products will be observed if the enzymes act 
cooperatively. Alternatively, primer extension assays will be performed in the presence 
of both polymerases to test whether these enzymes can act synergistically. Higher 
amounts of full extension products will be observed with the dual enzyme reaction 
compared to the reactions with individual enzymes or heat inactivation of one enzyme 
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after a preselected time followed by the addition of the other, confirming the synergy of 
the polymerases in replication past the adduct.112,157 
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Figure 8-3 Standing start assay for replication bypass of DNA-peptide cross-links by 
human replicative polymerase . 50 nM primer-template duplexes were incubated at      
37 °C with 5 nM polymerase in the presence 150 μM individual dNTPs. The reactions 
were quenched at predetermined time points (0–60 min) and analyzed by 20% denaturing 
PAGE. 
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8.6 IDENTIFICATION OF REPAIR MECHANISMS RESPONSIBLE 
FOR REMOVAL OF DNA-PROTEIN CROSS-LINKS 
As mentioned in section 1.6, mechanisms responsible for the repair of DPCs in 
cells are not fully understood. Previous studies have yielded contradicting data dependent 
on structure of model DPC substrates. This requires a systematic investigation of in vivo 
repair using biologically relevant, site-specific DPCs. To this end, model DPC substrates 
prepared in the present study (Chapters 3 and 5) can be employed. 
Repair experiments with phosphoramide mustard-induced DPCs in human cells 
has revealed that nucleotide excision repair pathway may be involved in removal of these 
bulky DNA adducts (Arnie Groehler and Natalia Tretyakova, unpublished data). 
Furthermore, the repair rates were slower upon inhibition of the proteasome suggesting 
the involvement of proteolytic processing of DPCs prior to repair (Arnie Groehler and 
Natalia Tretyakova, unpublished data).  
To test whether NER and proteolytic degradation play a role in removing DPC 
lesions, in vitro repair experiments can be carried out using linear dsDNA containing 
cross-linked proteins and peptides of varying sizes (as described in section 8.2 for 
exocyclic N6-dA adducts).  
Further in vivo experiments can be performed using repair proficient and deficient 
human cell culture, and gene knockdown methods452-455 to assess the effects of size and 
identity of cross-linked protein, site of cross-linking within DNA and proteins, and DNA 
sequence context on repair of these super bulky lesions. Host cell reactivation assay can 
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be employed for in vivo repair experiments (Scheme 8-8).456 Proteins or peptides cross-
linked to a 23-mer, 5'-CCA TGG TGG# CT*T TAC CAA CAG TA-3', containing either 
G# = 7-deaza-DHP-dG or T* = C8-dT-alkyne, will be annealed to single-stranded pGL3 
plasmids, followed by primer extension and ligation to generate double-stranded 
plasmids containing site-specific DPCs (Scheme 8-8A). Alternatively, proteins or 
peptides can be cross-linked to double-stranded plasmids containing 7-deaza-DHP-dG or 
C8-dT-alkyne (Scheme 8-8A). The 23-mer sequence, 5'-CCA TGG TGG# CT*T TAC 
CAA CAG TA-3', containing the site-specific DPC lesion is complementary to                
a sequence between the SV40 promoter and the Photinus pyralis (firefly) luciferase gene 
(luc+) on single-stranded pGL3 plasmid. Unmodified pRL-CMV plasmids expressing 
Renilla reniformis (sea pansy) luciferase protein will be used as an internal control. 
Human cells (wild-type and deficient in specific repair pathways) will be co-transfected 
with adducted and unadducted double-stranded plasmids. A dual luciferase assay will be 
used to quantify DPC repair (Scheme 8-8B).457,458 Cell lines deficient in specific repair 
pathways (BER, NER, MMR, HR and NHEJ) can be obtained from Coriell Institute for 
Medical Research (Camden, NJ) or Trevigen (Gaithersburg, MD). These cell lines can be 
used to identify the repair mechanisms involved in the removal of these bulky DNA 
lesions, since relative repair rates will be significantly lower compared to those of wild-
type cells.459,460 Using short interference RNA (siRNA) to knockdown specific genes will 
be beneficial to confirm the repair pathways involved, since repair rates will decrease 
considerably in the presence of appropriate siRNAs.452-455 
 
  292
Scheme 8-8 Preparation of double-stranded pGL3 plasmids containing site-specific 
DNA-protein cross-links (A) and host cell reactivation assay to study repair (B). 
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8.7 INVESTIGATION OF MUTAGENICITY OF DNA-PROTEIN 
CROSS-LINKS IN CELLS 
High fidelity bypass of an C7-G cross-linked peptide (Chapter 4) and highly 
mutagenic replication of the same peptide adducted to C5-T on DNA (Chapter 6) by TLS 
polymerases merit further investigation of the mutagenic potential of these lesions in 
cells. In vivo mutagenesis studies are currently in progress (in collaboration with          
Dr. Ashis Basu, University of Connecticut). A 6×His-eGFP cross-linked 23-mer, 5'-AGG 
GTT TTC CCA GXC ACG ACG TT-3', was ligated to a single-stranded pMS2 vector, 
and human embryonic kidney cells (HEK293T) were transfected with the adducted 
plasmids (Scheme 8-4B).442,443 Following replication and transformation, progeny were 
analyzed by oligonucleotide hybridization and DNA sequencing.442,443 In preliminary 
experiments, we found ~7% of recovered progeny to contain both targeted and          
semi-targeted mutations (Table 8-1). A systematic analysis of in vivo mutagenesis using 
polypeptides of varying sizes cross-linked to N7-G and C5-T prepared in this thesis work 
(Chapters 3 and 5) will enhance the current understanding of the effects of DPCs on 
DNA replication in cells. 
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Table 8-1 Mutation analysis of ss-pMS2 plasmids containing 6×His-eGFP cross-link 
replicated in HEK293T cells.†††  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
†††	X = 6×His-eGFP cross-linked to C5-T.	
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8.8 STRUCTURE ELUCIDATION OF DNA-PROTEIN CROSS-
LINKS  
Replication bypass studies described in this thesis (Chapters 4–6) discovered that 
the size of the cross-linked polypeptide, the cross-linking site within DNA, and the 
identity of the polymerase play an important role in determining the efficiency and 
fidelity of replication past DNA-protein cross-links. It is intriguing that the same peptide 
cross-linked to major groove of DNA via a purine vs. a pyrimidine nucleobase has 
different effect on replication fidelity. It is also unclear how these bulky adducts are 
accommodated in polymerase active site. Therefore, it will be beneficial to obtain 
structures of human TLS polymerases in the presence of DPCs and dNTPs to better 
understand these observations. NMR461 or X-ray crystallographic techniques148 can be 
employed in this regard. Sequences like 5'-pGGC GAA GCC GGG TGC GAA GCA CC-
3'dd for NMR461 and 5'-TTC ATT AGT CCT TCC CCC-3' for X-ray crystallography148 
that have been successfully used to obtain the structures of ternary complexes (the 
enzyme, dducted primer template duplex and the incoming dNTP) can be modified to 
contain either C7-G or C5-T cross-linked decapeptide for these studies. The resulting 
structural data will aid in fully comprehending the biological consequences of DPCs. 
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